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Summary 
 
The rare, but potentially fatal autoimmune disorder pemphigus is considered as a prototypical 
antibody-mediated organ-specific disease, in which immunoglobulin (Ig) G autoantibodies (auto-
ab) mainly target the desmosomal cadherins Desmoglein 3 (Dsg3) and Dsg1 within the epidermis. 
This process, referred to as acantholysis, manifests clinically with the formation of flaccid blisters 
and erosions of the skin and mucous membranes. Still to date, therapeutic intervention is 
predominantly limited to unspecific immunosuppression causing severe side effects and 
comorbidities. Although it has long been recognized that auto-ab crucially contribute to the 
pathology of pemphigus, the exact immunological events leading to the loss of self-tolerance have 
not yet been fully identified. 
Aim of the first part of this doctoral thesis was to investigate antigen-presenting cells (APC) and 
APC-derived cytokines, as well as their relation to T helper (Th) cell subsets and the auto-ab 
response in the pathogenesis of pemphigus. Therefore, blood samples were obtained from 34 
pemphigus patients, of which twelve clinically well characterized patients with no or minimal intake 
of immunosuppressive agents were selected for comprehensive analysis. This study group 
consisted of nine pemphigus vulgaris (PV), as well as three pemphigus foliaceus (PF) patients 
who were categorized according to either active or remittent state of disease. A cohort of twelve 
patients suffering from the autoimmune muscle weakness myasthenia gravis (MG) served as a 
control for a further unrelated auto-ab–mediated organ-specific disorder. 
Concerning the APC compartment, a major finding was reduced circulating frequencies of both 
myeloid and plasmacytoid dendritic cells (mDC and pDC, respectively) in active pemphigus 
patients. In concordance with this observation, augmented surface expression of the C-C 
chemokine receptor 2 (CCR2) of mDC suggest an increased migration activity to inflamed 
peripheral tissues, such as the skin. Similarly, active pemphigus patients displayed an 
upregulation of CCR2 on blood CD14+ monocytes, as well as elevated numbers of circulating 
CD16+ monocytes with expansion of the nonclassical subset. However, functional analysis on the 
cellular level could not confirm an enhanced immunogenicity status of APC in active pemphigus 
patients, yet we found in these patients increased plasma levels of the proinflammatory tumor 
necrosis factor (TNF)-α. Interestingly, plasma concentrations of interleukin (IL)-27 known to exert 
primarily regulatory functions were also elevated in active pemphigus patients, pointing to a rather 
inflammatory role of IL-27 in disease pathogenesis. 
Strikingly, in pemphigus patients, a significant correlation was not only found between serum IgG 
auto-ab titers and plasma levels of both IL-6 and TNF-α, but also between auto-ab titers and 
plasma concentrations of IL-27. Furthermore, similarly augmented plasma levels of IL-21 playing 
a crucial role in B cell activation possibly indicate the mechanism of an IL-27–mediated activation 
of IL-21–producing Tfh cells. 
Finally, as a further major finding, we observed an increase of both Th17 cells and IL-10–secreting 
T cells in active pemphigus patients. 
 
XIV 
 
Aim of the second part of this doctoral thesis was to investigate Dsg3-specific cellular and humoral 
immune responses in a novel human leukocyte antigen (HLA)-DRB1*04:02–transgenic (tg) 
mouse model of PV under the genetic restriction by HLA-DRB1*04:02. Rationale for the 
generation of this model is the high prevalence of distinct HLA class II alleles in PV patients, such 
as HLA-DRB1*04:02, –DRB1*14:01, and –DQB1*05:03. The occurrence of PV being associated 
with the presence of specific HLA class II alleles thereby reflects the high relevance of 
autoreactive CD4+ T cells in disease pathogenesis. 
In summary, this experimental study convincingly confirmed that the PV mouse model reproduces 
the principle mechanisms of HLA-dependent and human Dsg3-specific induction of CD4+ T and 
B cell responses observed in PV patients. Accordingly, the generation of Dsg3-reactive IgG 
antibody responses highly depended on prior activation of Dsg3-reactive CD4+ T cells. In turn, 
APC-mediated activation of T cells critically relied on the recognition of epitopes of the Dsg3 
ectodomain, which displayed strong binding affinity to the PV-linked HLA class II allele HLA-
DRB1*04:02. 
Furthermore, limited cross-reactivity of human Dsg3-specific IgG antibodies with the mouse 
analogue protein explained lack of the clinical phenotype of PV upon immunization of HLA-
DRB1*04:02–tg mice with human Dsg3 protein. Yet, this model accurately reflects that 
polymorphisms of peptide-binding motifs of specific PV-related HLA-class II alleles tightly regulate 
CD4+ T cell-mediated induction of Dsg3-reactive IgG antibodies. Therefore, this novel mouse 
model represents a suitable tool for further investigations of the pathoimmunological mechanisms 
of PV in vivo considering the strong HLA class II association of this disease. 
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Zusammenfassung 
 
Die prototypische antikörpervermittelte und organspezifische Autoimmunerkrankung Pemphigus 
zeichnet sich durch Autoantikörper der Immunglobulinklasse G (IgG) aus, welche vornehmlich 
gegen die desmosomalen Cadherine Desmoglein 3 (Dsg3) und Dsg1 in der Epidermis gerichtet 
sind. Dieser Prozess, der Akantholyse genannt wird, äußert sich klinisch in der Bildung von 
fragilen Blasen und Erosionen auf Haut und Schleimhaut. Therapiemöglichkeiten beschränken 
sich zurzeit überwiegend auf eine unspezifische Immunsuppression, welche mit dem Risiko 
schwerer Nebenwirkungen und Folgeerkrankungen einhergeht. Obwohl lange bekannt ist, dass 
IgG-Autoantikörper wesentlich an der Pathologie des Pemphigus beteiligt sind, ist dennoch 
unklar, welche immunologischen Mechanismen im Einzelnen zum Verlust der Selbsttoleranz 
führen. 
Ziel des ersten Teils dieser Dissertation war es, antigenpräsentierende Zellen (APC) und APC-
assoziierte Zytokine sowie deren Beziehung zu T-Helfer (Th)-Zell-Populationen und zur 
Autoantikörper-Antwort in der Pathogenese des Pemphigus zu untersuchen. Zu diesem Zwecke 
wurden 34 Pemphigus-Patienten Blutproben entnommen und zwölf klinisch detailliert 
charakterisierte Patienten für eine umfassendere Analyse ausgewählt, welche keiner oder einer 
nur minimalen Immunsuppression unterlagen. Diese Kohorte bestand aus neun Pemphigus 
vulgaris (PV)- und drei Pemphigus foliaceus (PF)-Patienten, die entsprechend eines aktiven oder 
remittierenden Krankheitsstatus subgruppiert wurden. Als Kontrollgruppe wurden zwölf Patienten 
der autoimmunen Muskelschwäche Myasthenia gravis (MG) definiert, welche eine unabhängige 
autoantikörpervermittelte und organspezifische Autoimmunerkrankung darstellt. 
Im APC-Kompartiment konnte als wesentliches Ergebnis eine verminderte Anzahl zirkulierender 
myeloider und plasmazytoider dendritischer Zellen (DC) bei aktiven Pemphigus-Patienten 
festgestellt werden. Eine gleichzeitig vermehrte Oberflächenexpression des C-C 
Chemokinrezeptors-2 (CCR2) auf myeloiden DC weist in diesem Zusammenhang auf eine 
erhöhte Migration dieser Zellen in entzündete periphere Gewebe wie der Haut hin. Analog zeigte 
sich eine vermehrte Expression des CCR2 auf CD14+ Monozyten sowie eine erhöhte 
zirkulierende Population an CD16+ Monozyten mit selektiver Expansion der nichtklassischen 
Subpopulation. Eine funktionelle Analyse auf zellulärer Ebene konnte allerdings keinen erhöhten 
Immunstatus der APC bei aktiven Pemphigus-Patienten nachweisen, jedoch zeigten sich bei 
diesen Patienten erhöhte Plasmaspiegel des entzündungsfördernden Tumornekrosefaktors-α 
(TNF-α). Interessanterweise ergaben sich außerdem bei aktiven Pemphigus-Patienten erhöhte 
Plasmaspiegel des überwiegend immunregulatorischen Interleukin-27 (IL-27), das hauptsächlich 
von aktivierten APC produziert wird. Diese Beobachtung deutet auf eine entzündliche Funktion 
des IL-27 beim Pemphigus hin. 
Bemerkenswerterweise ergab sich darüber hinaus bei Pemphigus-Patienten nicht nur eine 
signifikante Korrelation zwischen Serum-Autoantikörpern und den Plasmaspiegeln von IL-6 und 
TNF-α, sondern auch eine signifikante Korrelation zwischen IgG-Autoantikörpern und der 
Plasmakonzentration von IL-27. Die beobachteten, ebenfalls erhöhten Plasmaspiegel des IL-21, 
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welches eine wesentliche Funktion in der B-Zell-Aktivierung innehat, weisen auf eine mögliche 
Aktivierung von IL-21–produzierenden follikulären Th-Zellen in Abhängigkeit von IL-27 hin. 
Schließlich wurde als weiteres auffälliges Ergebnis der Studie bei aktiven Pemphigus-Patienten 
eine deutliche Zunahme an inflammatorischen Th-17-Zellen sowie IL-10–sezernierenden Th-
Zellen festgestellt. 
 
 
Ziel im zweiten Abschnitt dieser Dissertation war es, Dsg3-spezifische zelluläre und humorale 
Immunantworten in einem neuartigen human leukocyte antigen (HLA)-DRB1*04:02–transgenen 
PV-Mausmodell zu untersuchen unter der genetischen Restriktion von HLA-DRB1*04:02. Dieses 
Modell wird definiert durch die hohe Prävalenz bestimmter HLA-Klasse-II-Allele bei PV-Patienten 
wie HLA-DRB1*04:02, –DRB1*14:01, und –DQB1*05:03. Der enge Zusammenhang zwischen 
dem Vorkommen von PV und dem Auftreten spezifischer HLA-Klasse-II-Risikoallele ist ein Indiz 
für die wesentliche Funktion autoreaktiver CD4+ T-Zellen in der Pathogenese der Erkrankung. 
Zusammenfassend geht aus dieser tierexperimentellen Studie schlüssig hervor, dass sich die in 
PV-Patienten identifizierten Mechanismen der HLA-abhängigen und Dsg3-spezifischen Induktion 
von CD4+ T– und B-Zell-Antworten in diesem Modell wiederspiegeln. Entsprechend zeigte sich 
in der Entstehung Dsg3-spezifischer Antikörper eine direkte Abhängigkeit von der Aktivierung 
Dsg3-reaktiver CD4+ T Zellen. Die APC-vermittelte Aktivierung dieser T-Zellen unterlag wiederum 
der Erkennung von Epitopen der Dsg3-Ektodomäne, welche eine hohe Bindungsaffinität zu dem 
PV-assoziierten HLA-DRB1*04:02–Allel aufwiesen. 
Darüber hinaus erklärte eine nur geringe Kreuzreaktivität der Antikörper zwischen humanem und 
murinem Dsg3-Protein das Fehlen eines klinischen Phänotyps bei HLA-DRB1*04:02–transgenen 
Mäusen trotz wiederholter Immunisierung mit humanem Dsg3-Protein. Jedoch gab dieses PV-
Mausmodell konsequent wieder, dass die Peptidbinde-Motive spezifischer PV-assoziierter HLA-
Klasse-II-Allele eine wesentliche Rolle in der CD4+-T-Zell-vermittelten Induktion von Dsg3-
reaktiven Antikörpern spielen. Dieses PV-Mausmodell stellt daher ein geeignetes Instrument dar, 
um zukünftig immunpathologische Mechanismen des PV in vivo unter Berücksichtigung der 
starken HLA-Klasse-II-Assoziation dieser Erkrankung zu untersuchen. 
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1 Introduction 
 
In the state of autoimmunity, aberrant immune responses are directed against endogenous 
structures of the body, disturbing tissue integrity and culminating in the destruction of the whole 
organism. Pathological autoantibodies (auto-ab) are a characteristic feature many severe and still 
to date incurable autoimmune diseases share, such as myasthenia gravis (MG), systemic lupus 
erythematosus (SLE), and rheumatoid arthritis (RA) (Martin and Chan). Despite decade-long 
research into the mechanisms of autoimmune responses, the precise immunological events 
resulting in the breakdown of self-tolerance are not yet completely understood. 
 
This doctoral thesis deals with the prototypical antibody-mediated autoimmune disorder 
pemphigus, in which auto-ab are mainly directed against the desmosomal cadherins Desmoglein 
3 (Dsg3) and Dsg1, causing loss of keratinocyte adhesion in the suprabasilar layer of the 
epidermis. Besides autoreactive B cells, the activation of autoreactive Dsg3- and/or Dsg1-specific 
CD4+ T cells plays a pivotal role in the pathogenesis of pemphigus, which has been demonstrated 
in numerous studies (Amagai 2008; Hertl, Eming, and Veldman 2006). However, not yet well 
characterized is the contribution of antigen-presenting cells (APC), including dendritic cells (DC) 
being the most potent inducers of CD4+ T cell activation, as well as monocytes to disease 
pathogenesis. Aim of the first part of this study was to investigate APC and APC-derived 
cytokines, as well as their relation to CD4+ T cell subpopulations and the auto-ab response in the 
pathogenesis of pemphigus. For this purpose, populations of DC and monocytes were 
qualitatively and quantitatively analyzed in the peripheral blood of pemphigus vulgaris (PV) and 
pemphigus foliaceus (PF) patients using flow cytometry. References comprised both healthy 
controls (HC) and MG patients who served as a control for a further unrelated auto-ab–mediated 
organ-specific disorder. In addition, using flow cytometry and enzyme-linked immunosorbent 
assay (ELISA), APC were functionally characterized concerning their capability to produce and 
secrete cytokines, as well as their capacity to internalize antigen. Moreover, the distribution of 
CD4+ T cell subpopulations was determined by intracellular detection of their respective signature 
cytokines using flow cytometry. Finally, serum immunoglobulin (Ig) G auto-ab titers were 
correlated with the parameters assessed in both the APC and CD4+ T cell compartment to identify 
novel factors involved in the induction of antibodies in pemphigus. 
Aim of the second part of this thesis was to analyze Dsg3-specific CD4+ T and B cell responses 
under the genetic restriction by human leukocyte antigen (HLA)-DRB1*04:02 in experimental PV. 
The respective mouse model of PV was established to consider the strong prevalence of distinct 
HLA class II alleles in PV patients, including HLA-DRB1*04:02. In a cell proliferation assay using 
flow cytometry, Dsg3-reactive CD4+ T cell responses were tested for regulation by HLA-
DRB1*04:02 by stimulation of T cells with APC from HLA-transgenic (tg) mice presenting Dsg3 
peptides that bind to HLA-DRβ1*04:02. In the inverse approach using an enzyme-linked 
immunospot (ELISPOT) assay, mice were immunized with the HLA-DRβ1*04:02-binding Dsg3 
peptides to induce a local CD4+ T cell response that was later challenged with Dsg3 protein ex 
vivo. Dependence of Dsg3-reactive IgG antibody production on HLA-DRB1*04:02 was finally 
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assessed by both ELISA and immunofluorescence microscopy using sera from mice immunized 
with the HLA-DRβ1*04:02-binding Dsg3 peptides. Mice transgenic for HLA-DRB1*04:01 served 
as a control in most assays. 
 
The following section now provides information about the biology of APC, T and B lymphocytes, 
and cytokines, including their role in autoimmunity. The composition of human skin is described, 
as well as the pathogenesis of pemphigus with presentation of its current experimental mouse 
models. 
 
1.1 The immune system 
1.1.1 Innate immunity 
The immune system of vertebrates encompasses two main branches, innate and adaptive 
immunity. The innate immune system is a universal and ancient form of host defense against 
infection (Janeway and Medzhitov 2002) and is composed of a humoral arm, which consists of 
antimicrobial peptides and opsonins, as well as a cellular arm, which mainly involves specialized 
cells known as phagocytes (Auffray, Sieweke, and Geissmann 2009). Its responses rely on timely 
recognition of pathogenic or danger signals by a limited number of germline-encoded receptors 
(Yin et al. 2015; Janeway and Medzhitov 2002). With the help of these receptors, not only 
pathogenic microbes, but also toxic or allergenic substances that enter through mucosal surfaces 
are eliminated. Central to the ability of the immune system to mount a response to invading 
pathogens, toxins, or allergens is its capacity to distinguish self from nonself (Chaplin 2010). 
The major decision to respond or not respond to a particular ligand is primarily taken by the 
genome-encoded receptors of the innate immune response (Janeway and Medzhitov 2002). 
Multiple of these receptors can be found on the cell surface or within the cytoplasm, from where 
they transmit pathogenic or danger signals for proper counteractions using various adaptor and 
effector molecules. Innate immunity comprises four major signaling pathways, including those 
triggered by toll-like receptors (TLR), retinoic acid-inducible gene (RIG)-I-like receptors, 
inflammasoms, or cyclic guanosine monophosphate (GMP)–adenosine monophosphate (AMP) 
synthases (cGAS). Although cellular localization, ligand specificity, and signal relay mechanisms 
differ between each signal transduction pathway, they collectively entail numerous overlapping 
consequences, such as nuclear factor -light-chain-enhancer of activated B cells (NF-B) 
activation, interferon (IFN) response, cytokine maturation, and cell death (Yin et al. 2015). 
Inflammatory responses are initially elicited by foremost macrophages, granulocytes, and mast 
cells using their innate immune receptors that are also expressed by DC and natural killer (NK) 
cells. Besides leukocytes, the skin and the epithelia that line internal organs can also be 
considered as a part of the innate immune system (Janeway and Medzhitov 2002). 
 
1.1.2 Adaptive immunity 
The innate immune system broadly expresses recognition molecules on numerous cells that 
recognize conserved molecular patterns of invading pathogens or toxins. Therefore, the innate 
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immune response constitutes the initial host response and takes effect rapidly. In contrast, the 
adaptive immune system provides specific recognition of antigens by a limited number of 
lymphoid cells that must proliferate upon encounter of the antigen in order to mount an effective 
immune response. Consequently, in host defense, the adaptive immune response generally 
develops temporally after the innate response (Chaplin 2010). Specific recognition of proteins, 
carbohydrates, lipids, nucleic acids, and pathogens is mediated by both Ig and T cell receptors 
(TCR) of the adaptive immune system (Janeway and Medzhitov 2002). The mechanism of 
generating these receptors involves great variability and rearrangement of variable, diversity, and 
joining gene segments (Litman, Rast, and Fugmann 2010). An essential property of the adaptive 
immune response is to induce long-lived cells that persist in an apparently dormant state, but can 
exert effector functions again rapidly after another encounter with their specific antigen. Hence, 
the adaptive immune system is able to establish immune memory, contributing to a more effective 
host response against specific pathogens or toxins that have been encountered before (Chaplin 
2010). Yet, the adaptive immune response can also cause pathological conditions, such as allergy 
and autoimmunity, as well as rejection of tissue grafts (Janeway and Medzhitov 2002). 
 
1.1.3 Linkage between innate and adaptive immunity 
As presented in 1.1.1 and 1.1.2, the immune system of vertebrates is composed of both innate 
(“natural”) and adaptive (“acquired”) immunity. These days, innate control of the adaptive immune 
response is a well-established paradigm first postulated by Charles Janeway Jr. in 1989 (Janeway 
1989). It states that the innate immune system recognizes evolutionary conserved structures of 
microbial pathogens (pathogen-associated molecular patterns, PAMP), such as bacterial and 
fungal cell wall components, as well as viral nucleic acids using pattern-recognition receptors 
(PRR). Detection of PAMP by PRR elicits inflammatory responses and innate host defense 
mechanisms, whereas sensing of microbes by PRR expressed on APC, especially DC, 
additionally induces activation of adaptive immune responses (Iwasaki and Medzhitov 2015). 
The function of antigen presentation is required for effective responses of lymphoid cells to 
antigens and is confined to mononuclear phagocytic APC. Receptor-mediated recognition of 
microbial constituents facilitates the initial uptake and phagocytosis of microbes by APC with both 
scavenger receptors and receptors of the complement system participating in this process. Upon 
concurrent maturation of DC, upregulation of major histocompatibility complex (MHC) class I and 
class II molecules, costimulatory molecules, such as CD40, CD80, and CD86, as well as the 
production of cytokines enables efficient interaction between DC and naïve CD4+ and CD8+ T 
cells in an antigen-specific manner (Hoebe, Janssen, and Beutler 2004). This way, recognition of 
microbes by distinct pathways of the innate immune system is translated into different facets of 
effector immune responses of the adaptive immune system, principally through specialized 
populations of DC (Iwasaki and Medzhitov 2015). 
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1.2 Cellular immunity 
1.2.1 Human dendritic cell subsets 
Discovered by Steinman and Cohn in 1973 (Steinman and Cohn 1973b), DC form a remarkable 
cellular network that is recognized for exerting a pivotal function in regulating innate and adaptive 
immunity (Maldonado and von Andrian 2010). Present throughout the body, DC are sentinels of 
the immune system that constantly survey tissues to instruct the adaptive immune system in 
response to peripheral stimuli. The DC system constitutes a unique hematopoietic branch as it 
originates from a hematopoietic lineage distinct from other leukocytes. Nonlymphoid tissues and 
the spleen marginal zone are the critical locations, at which DC continuously encounter tissue 
and blood antigens. Additionally, DC exhibit not only superior abilities to acquire, process, and 
present antigen to naïve T cells, but also migrate to the T cell zone of lymph nodes (LN) whilst 
loaded with tissue antigens (Merad et al. 2013). 
Characteristically, DC adjust the context of antigen presentation according to inputs that signal 
the presence of pathogens or tissue damage. These signals cause DC maturation, which entails 
migration from peripheral tissues into and within secondary lymphoid organs, in which effector T 
cell responses are efficiently induced and regulated. In contrast, DC maintain immunological 
tolerance by perpetual presentation of innocuous self and nonself antigens, resulting in the 
induction of attenuating T regulatory (Treg) cells (Maldonado and von Andrian 2010). 
As responses to environmental stimuli cause phenotypic alterations, the definition of discrete DC 
subsets is based on developmental specificity and functional specialization (Merad et al. 2013). 
Each DC subset displays distinct cell surface markers and reacts differently to activation by 
secretion of a unique cytokine profile. Abnormalities in both the differentiation and function of DC 
are directly associated with several immune disorders (Kim and Diamond 2015). The typical DC 
phenotype comprises expression of the hematopoietic markers CD45, MHC II, and CD11c, 
whereas T cell, NK cell, B cell, granulocyte, and erythrocyte lineage markers are absent. In 
addition, DC demarcate from other leukocytes, including macrophages by the formation of a 
unique transcriptional entity (Merad et al. 2013). 
In general, DC populations split into two major subsets, myeloid DC (mDC) and plasmacytoid DC 
(pDC). The minor subset of pDC recirculates between the blood stream and lymphoid tissues and 
in the steady state expresses low levels of MHC class II and costimulatory molecules. Upon 
detection of foreign nucleic acids by TLR7 and TLR9, pDC produce vast amounts of type I IFN 
and obtain the ability to present foreign antigens to T cells. DC other than pDC are referred to as 
mDC that constitute a small subset of mainly tissue hematopoietic cells. Unlike pDC, mDC show 
enhanced capacities of antigen capture, procession, and presentation to T cells (Merad et al. 
2013). 
 
Here presented is an overview of circulating human DC subsets that were investigated in 
pemphigus patients and control groups within the framework of this doctoral thesis. 
In humans, four discrete populations of DC are generally acknowledged to be present in blood, 
of which all lack expression of the lineage markers CD3, CD19, CD14, CD20, CD56, and 
glycophorine A, but display surface expression of HLA-DR. Characteristically, human pDC 
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express low levels of the integrin CD11c, lack expression of CD1a, and are positive for CD123, 
blood DC antigen (BDCA)-2 (CD303), and BDCA-4 (CD304) (Kim and Diamond 2015). Besides 
pDC, two mDC subsets expressing the non-overlapping markers BDCA-1 (CD1c) or BDCA-3 
(CD141) are found in the human blood circulation (Merad et al. 2013) and account for 5% of 
monocytic-like cells (Auffray, Sieweke, and Geissmann 2009). DC positive for CD1c represent 
the most frequent mDC subset (Merad et al. 2013), display additional expression of CD11c, and 
are negative and low for CD1a and CD11b, respectively. DC positive for CD141 only constitute a 
minor population and share the surface marker expression profile of the other mDC subset except 
of expression of CD1c (Kim and Diamond 2015). Furthermore, an inflammatory population termed 
6-sulfo LacNAc (slanDC) with expression of Fc receptor-III (FcR-III), HLA-DR, and CD11c, but 
devoid of lineage markers has also been identified in human blood. Yet, in contrast to mDC 
positive for CD1c and CD141, slanDC are mainly absent from tissues and are considered to 
represent a monocyte subset despite their name (Schakel et al. 2002). 
Beside the blood circulation, human DC populations are found in nonlymphoid tissues, of which 
the skin is the affected organ in the pathogenesis of pemphigus. Human skin hosts several distinct 
DC subsets with Langerhans cells (LC) residing in the epidermis, whilst interstitial DC populate 
the dermis (Klechevsky 2013). 
In the dermis, at least three functionally discrete DC subsets are present, including DC positive 
for CD1a and negative for CD14, as well as DC expressing the inverse phenotype. Dermal DC 
with expression of CD1a can be further subdivided according to the presence of CD141. 
Moreover, a further blood-derived subset with expression of CD141 was identified in human 
dermis (Merad et al. 2013). Interesting for pemphigus pathogenesis, DC positive for CD14 were 
shown to impact humoral immune responses, such as the direct activation of B cells by secretion 
of interleukin (IL)-12 (Klechevsky et al. 2008). Despite being weak stimulators of T cells 
(Pasparakis, Haase, and Nestle 2014), dermal CD14+ DC also induce CD4+ T cells with a 
phenotype of T follicular helper (Tfh) cells (Klechevsky et al. 2008) that provide essential 
costimulation to B cells during the development of antibody-producing plasma cells in germinal 
centers (GC) (Crotty 2014). Apart from IL-12, dermal CD14+ DC secrete IL-10 and transforming 
growth factor (TGF)-β that induce the differentiation of B cells into plasma cells and switch of 
isotype towards plasma IgG and mucosal IgA (Klechevsky et al. 2008). 
Identified in 1868 by Paul Langerhans, LC constitute the predominant hematopoietic cells in the 
human epidermis with their dendritic processes extending to the stratum corneum. Based on the 
expression of the hematopoietic markers CD45, HLA-DR, the epithelial cell adhesion molecule, 
and the lectin langerin, human LC are easily detected in the epidermis (Merad et al. 2013). 
Typically, LC display high levels of CD1a, produce IL-15, and are eminently adept at inducing 
primary CD8+ T cell responses. Moreover, LC potently induce T helper (Th) 1, Th2, Th17, and 
Th22 cell responses (Klechevsky et al. 2008). Similarly to dermal DC positive for CD14, LC were 
also demonstrated to be able to efficiently differentiate naïve CD4+ T cells into IL-21–secreting 
cells (Shi and Pamer 2011). 
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Figure 1.1: Human skin dendritic cell subsets and their interaction with T cells. 
Human skin hosts Langerhans cells in the epidermis and at least three interstitial dendritic cell (DC) subsets 
in the dermis with the respective phenotypes indicated. The dermal CD14+ DC secrete interleukin (IL)-12, 
vitamin D (VitD), IL-10, and transforming growth factor (TGF)-β and induce the differentiation of T helper 
(Th) 1, T follicular helper (Tfh), as well as T regulatory (Treg) cells and have limited capacity to prime 
cytotoxic T lymphocytes (CTL) (Klechevsky et al. Eur J Immunol, 2013). 
 
 
Concerning lymphoid tissues, two DC subsets positive for either CD1c or CD141 are located in 
human spleen and tonsils (Kim and Diamond 2015). Beside LN-resident DC, LN cells were also 
shown to comprise migratory LC, migratory dermal CD1a+ DC, and dermal CD14+ DC, 
respectively (Merad et al. 2013). 
 
 
 
Figure 1.2: Phenotype of human dendritic cell subsets. 
Overview of the phenotype, pathogen recognition receptor (PRR) repertoire, and location of human dendritic 
cell (DC) subsets, as well as the supposed mouse subset equivalent. LC, Langerhans cell; ND, not 
determined (Merad et al. Annu. Rev. Immunol., 2013). 
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In addition to the classification of DC according to localization within the organism and phenotype, 
DC can also be categorized according to immunological function. As already mentioned, DC 
represent central regulators of the adaptive immune response, whereby maturation stage and 
functional capacity of DC critically determine the immunological consequence – tolerance or 
immunogenicity. Important factors in this process are also form and place of the encountered 
antigen, as well as the distinct DC subset involved (Kim and Diamond 2015). 
At steady state, tissue-resident immature DC constantly acquire antigens from their environment, 
but are barely immunogenic due to modest expression levels of MHC and costimulatory 
molecules, as well as lack of inflammatory cytokine production (Maldonado and von Andrian 
2010). The capacity of DC to promote peripheral tolerance has been studied in a number of 
different mouse models. Delivery of antigens to DC in vivo using DC-specific antibodies was 
demonstrated to induce robust T cell tolerance in the steady state (Hawiger et al. 2001; Hawiger 
et al. 2004). Although DC apparently facilitate the induction (Yamazaki et al. 2003; Sela et al. 
2011) and/or the maintenance (Bar-On et al. 2011) of peripheral Treg cells, they are neither 
indispensable for Treg cell homeostasis (Birnberg et al. 2008) nor do they preferably regulate 
Treg cells compared to effector T cells (Darrasse-Jeze et al. 2009; Swee et al. 2009; Collins et 
al. 2012). 
In the maintenance of central tolerance, thymic DC can cross-present self-antigens from 
medullary thymic epithelial cells (Gallegos and Bevan 2004; Hubert et al. 2011) that are primarily 
responsible for the negative selection of autoreactive T cells in the thymus. In addition, peripheral 
DC potentially enter the thymus and present peripherally acquired self-antigens to induce clonal 
deletion of T cells or generation of Treg cells (Bonasio et al. 2006; Proietto et al. 2008). 
In contrast to tolerogenic DC, inflammatory DC are transiently induced in the periphery in 
response to microbial infection or inflammatory stimuli. Inflammatory DC not only comprise 
monocyte-derived cells, but also those cells derived from DC precursors emerging under different 
inflammatory conditions (Kim and Diamond 2015). Pathogenic microbes or material associated 
with cellular stress are sensed by the PRR of immature DC, inducing extensive phenotypical and 
functional alterations. DC lose their capacity to take up antigen in exchange for upregulation of 
antigen procession, expression of MHC and costimulatory molecules, as well as production of 
cytokines. Apart from that, DC leave peripheral tissues and migrate to the draining LN by 
increased expression of traffic molecules, including C-C chemokine receptor 7 (CCR7) (Ohl et al. 
2004). In the LN, now fully mature DC instruct circulating lymphocytes according to the antigenic 
status of their source tissue (Maldonado and von Andrian 2010). 
Tolerogenic and immunogenic DC require tight regulation, as altered or prolonged generation of 
these DC subsets is believed to result in immunodeficiency or autoimmune diseases (Kim and 
Diamond 2015). 
 
1.2.2 Human monocyte subsets 
Human monocytes are bone marrow (BM)-derived circulating leukocytes that originate from the 
common macrophage and DC precursor (MDP) (Saha and Geissmann 2011) that also gives rise 
to common DC progenitors (CDP) (Chow, Brown, and Merad 2011). Monocytes have been 
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considered circulating precursors for tissue macrophages and DC (Shi and Pamer 2011), yet 
many DC and macrophage cell types are derived from the MDP independently of monocytes 
(Saha and Geissmann 2011). Together with macrophages and DC, monocytes form the 
mononuclear phagocyte system (MPS) (Chow, Brown, and Merad 2011) and exert crucial 
functions in development and homeostasis of the organism by clearing apoptotic cells and 
scavenging toxic compounds (Auffray, Sieweke, and Geissmann 2009). 
Monocytes represent 10% of leukocytes in human blood (Auffray, Sieweke, and Geissmann 
2009) and act as innate effectors of the inflammatory response to microbes, whereby they 
eliminate pathogens by phagocytosis and the production of reactive oxygen species (ROS), nitric 
oxide (NO), myeloperoxidase, and inflammatory cytokines (Saha and Geissmann 2011). 
Expression of numerous trafficking molecules, including CCR2 enables monocytes to exit the 
blood circulation and enter infected tissues (Shi and Pamer 2011). As accessory cells, monocytes 
can also bridge inflammation and the innate defense against pathogens to adaptive immune 
responses, mostly upon differentiating into DC. Despite their limited capacity of antigen 
presentation (Auffray, Sieweke, and Geissmann 2009), monocytes in some conditions can as well 
induce and polarize T cell responses in infectious and autoimmune diseases (Saha and 
Geissmann 2011). 
Human circulating monocytes are not a homogenous population, but can be discriminated 
according to phenotype and function, including size, expression of trafficking and innate immune 
receptors, as well as their ability to differentiate following stimulation with cytokines and/or 
microbial molecules (Shi and Pamer 2011). To date, three discrete subsets that exert specific 
roles in homeostasis and inflammation have been recognized (Auffray, Sieweke, and Geissmann 
2009). In general, both human and mouse blood monocytes display surface expression of the 
colony-stimulating factor 1 (Csf-1) receptor and the chemokine receptor C-X-C chemokine 
receptor 1 (CXCR1). Monocytes segregate from granulocytes, NK cells, as well as T and B 
lymphocytes by lack of CD335, CD3, CD19, and CD15 expression. In addition, monocytes sense 
lipids and various microorganisms using a large range of scavenger receptors and upon 
stimulation, they produce diverse mediators of inflammation (Auffray, Sieweke, and Geissmann 
2009). 
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Figure 1.3: Dendritic cells commit to differentiate into a monocyte, macrophage, or dendritic cell at 
the stage of the macrophage and dendritic cell precursor. 
Macrophage and dendritic cell (DC) progenitors (MDP) can give rise to common DC progenitors (CDP) or 
monocytes. Being committed to the DC lineage, CDP give rise to both CD8+ and CD8− DC in lymphoid 
tissues and CD103+CD11b− DC in peripheral nonlymphoid tissues. In addition, monocytes can differentiate 
into some CD11b+CD103− DC or macrophages. CMP, common myeloid progenitor; GMP, granulocyte and 
macrophage progenitor; HSC, hematopoietic stem cell (modified from Chow et al. Nat Rev Immunol, 2011). 
 
 
In both humans and mice, the monocyte population comprises two main subsets that are primarily 
located in the circulation, BM, and spleen (Chow, Brown, and Merad 2011). They are segregated 
on the basis of surface CD14 and CD16 expression (Shi and Pamer 2011). Classical monocytes 
being devoid of CD16 account for 80% to 90% of circulating monocytes, exhibit high levels of 
CCR2 and low levels of CX3CR1. Upon stimulation with bacterial lipopolysaccharides (LPS) in 
vitro, they secrete IL-10 rather than tumor necrosis factor (TNF) and IL-1, and carry out high 
phagocytic activity (Ziegler-Heitbrock 2000). 
The minor population of monocytes typically expresses CD16 (Passlick, Flieger, and Ziegler-
Heitbrock 1989) and opposed to the major subset displays high expression levels of CX3CR1, 
but low levels of CCR2. It produces TNF-α in response to LPS stimulation and frequencies were 
reported to be enhanced in the blood of patients with acute inflammation and infectious diseases 
(Auffray, Sieweke, and Geissmann 2009). Important for exclusion of pemphigus and MG patients 
in this study, systemic treatment with glucocorticoids resulted in reduced numbers of circulating 
CD16+ monocytes (Fingerle-Rowson, Auers, et al. 1998). 
 
Monocytes with CD16 expression can be further subdivided into those displaying diminished and 
high levels of CD14, referred to as nonclassical and intermediate monocytes, respectively 
(Ziegler-Heitbrock et al. 2010). 
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The function of CD16+ monocytes considerably differ (Grage-Griebenow, Flad, and Ernst 2001) 
with intermediate CD14+CD16+ monocytes additionally expressing the Fc receptors CD64 and 
CD32, exhibiting phagocytic activity, and robustly releasing TNF-α and IL-1 upon stimulation with 
LPS. In contrast, the nonclassical CD14dimCD16+ monocyte subset is devoid of Fc receptors, 
barely phagocytic, and does not produce TNF-α or IL-1 in response to LPS (Auffray, Sieweke, 
and Geissmann 2009). Its actual function is not yet well characterized, however increased 
frequencies were observed in the blood of septic patients (Fingerle-Rowson, Auers, et al. 1998). 
Apart from that, expression of MHC class II processing and presentation genes was shown to be 
increased in intermediate monocytes, as well as surface molecules partaking in APC–T cell 
interaction, particularly CD40 and CD54 (Wong et al. 2012). 
 
1.2.3 Lymphocytes 
1.2.3.1 CD4+ T lymphocytes 
T lymphocytes are composed of two main classes, cytotoxic T cells that carry CD8 and CD4-
bearing Th cells that are involved in activating, rather than killing the cells they recognize. CD4+ 
T cells support B cells in antibody production, reinforce and maintain CD8+ T cell responses, 
regulate the function of macrophages, and mediate immune responses against a large array of 
pathogenic microbes. In addition, they regulate and suppress immune responses to prevent 
autoimmunity and to adjust the extent and persistence of responses. Importantly, CD4+ T cells 
are critical mediators of immunological memory and contribute to autoimmunity, asthma, and 
allergic responses, as well as to tumor immunity. The differentiation of naïve CD4+ T cells into 
discrete Th cell lineages depends on a distinct cytokine milieu present during APC-mediated 
activation (Zhu, Yamane, and Paul 2010). 
At least four types of Th cells have been identified, Th1, Th2, Th17, and induced Treg (iTreg) 
cells, each with its own individual phenotype and function (Zhu, Yamane, and Paul 2010). While 
Th1, Th2, and Th17 cells play a crucial role in eliminating intracellular pathogens, helminths, and 
extracellular (EC) bacteria or fungi, respectively, both Th1 and Th17 cells are critically involved in 
many types of autoimmune disorders. Th2 cells are important mediators of allergic responses 
(Zhu and Paul 2008), whereas iTreg and natural Treg (nTreg) cells ensure self-tolerance and 
modulate immune responses to infectious pathogens (Belkaid and Tarbell 2009). 
 
Th1 and Th2 cells were the first distinctive populations of differentiated CD4+ T cells identified in 
mice by Mosmann et al. in 1986 (Mosmann et al. 1986). Typically, Th1 cells secrete IFN- as their 
signature cytokine (Kanno et al. 2012) and represent unique producers of lymphotoxin. In 
addition, they have been shown to synthesize both IL-2 and TNF-α (Zhu, Yamane, and Paul 
2010). Induction of Th1 cell differentiation requires the presence of IL-12 and IFN-, and is under 
control of the master transcription factor T-bet. In Th1 cells, T-bet is induced by signal transducer 
and activator of transcription 1 (STAT1) and STAT4 receiving signals from IFN and IL-12, 
respectively (Kanno et al. 2012). Th1 cell development blocks that of Th2 cells, demonstrated by 
overexpression of T-bet rendering Th2 cells able to produce IFN- and lose their capacity to 
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produce IL-4 (Zhu, Yamane, and Paul 2010). Beside Th2 cells, T-bet also inhibits Th17 cell 
differentiation (Kanno et al. 2012). 
The signature cytokines of Th2 cells are IL-4, IL-5, IL-10, and IL-13, whereas they neither produce 
IFN- nor lymphotoxin. Moreover, Th2 cells secrete TNF-α and some produce IL-9, whilst IL-2 is 
synthesized in limited amounts. Under the influence of the cytokines IL-4 and IL-2, naïve CD4+ T 
cells differentiate into Th2 cells upon stimulation by cognate antigen. As T-bet in Th1 cells, GATA3 
propagates the differentiation and growth of Th2 cells and impedes Th1 cell development (Zhu, 
Yamane, and Paul 2010). STAT5 or STAT6 induces GATA3 in Th2 cells, although GATA3 can 
also be induced by Notch signaling in a STAT6-independent fashion. In addition, STAT3 has been 
identified to be involved in Th2 cell differentiation (Kanno et al. 2012). 
 
Apart from Th1 and Th2 cells, Th17 cells, a third major effector population of CD4+ T cells derived 
from naïve CD4+ T cells was initially described in 2003 (Aggarwal et al. 2003; Langrish et al. 
2005). They typically produce IL-17A, IL-17F, and IL-22 as signature cytokines, resulting in a 
massive tissue reaction due to the broad local distribution of IL-17 and IL-22 receptors (Korn et 
al. 2009). In addition, they represent solid producers of IL-21 being also secreted by other Th cell 
types (Zhu, Yamane, and Paul 2010). Th17 cell-specific differentiation factors comprise TGF-β 
combined with IL-6 or IL-21, while IL-23 acts as a growth and stabilization factor (Korn et al. 2009). 
RAR-related orphan receptor (ROR)t is the master regulator of Th17 cell development identified 
in mice (Zhu, Yamane, and Paul 2010) with contribution of the transcription factors STAT3 and 
RORα. Apart from Th17 cells, TGF-β also induces differentiation of peripheral naïve T cells into 
Treg cells, placing the Th17 lineage in close relationship to Treg cells (Korn et al. 2009). 
 
Treg cells play a critical role in controlling immune responses, highlighted by the fact that 
mammals that lack functional Treg cells succumb to fatal autoimmune disease. Based on their 
origin, Treg cells are composed of two major types, thymus-derived nTreg cells that initially 
emerge in the fetal circulation (Maldonado and von Andrian 2010) and additional iTreg cells that 
differentiate from naïve CD4+ T cells in the periphery (Zhu, Yamane, and Paul 2010). Both Treg 
cell types constitutively express the transcription factor forkhead box P3 (FOXP3) that is essential 
for Treg cell development and suppressive activity. Moreover, they display surface expression of 
CD25, the α-chain of the IL-2 receptor, as well as cell surface and intracellular expression of the 
coinhibitory receptor cytotoxic T lymphocyte antigen 4 (CTLA-4) (Sakaguchi et al. 2013). IL-2 is 
central to the maintenance of Treg cell populations by activation of STAT5 that induces 
expression of FOXP3. By binding to RORt, FOXP3 interferes with Th17 cell differentiation 
(Kanno et al. 2012). 
 
Tfh cells are professional providers of T cell help to B cells and are substantial for GC formation, 
affinity maturation, and the development of most high-affinity antibodies and memory B cells. The 
differentiation of Tfh cells is a multistage process that is controlled by the transcription factor B 
cell lymphoma 6 (Bcl6) (Crotty 2014). Bcl6 is required to induce Tfh cell-related molecules, 
including CXCR5, programed cell death-1 (PD-1), as well as IL-6 and IL-21 receptors. 
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Additionally, Bcl6 inhibits production of Th1, Th2, and Th17 cell-related cytokines. CXCR5 permits 
Tfh cells to locate to B cell follicles, where they interact with B cells (Zhu, Yamane, and Paul 
2010). Expression of Bcl6 and IL-21, the signature cytokine of Tfh cells is not a feature unique to 
Tfh cells, but is also shared by other Th cell subsets (Kanno et al. 2012). Interestingly, Tfh cells 
contribute to a range of diseases, especially autoimmune disorders (Crotty 2014). In pemphigus, 
their implication has not yet been elucidated. 
 
 
 
Figure 1.4: Cytokines critically impact differentiation and effector functions of Th1, Th2, and Th17 
cells. 
Upon antigen-presenting cell (APC)–mediated activation of the T cell receptor, naïve CD4+ T cells 
differentiate into discrete T helper (Th) cell lineages depending on the presence of specific cytokines. This 
process involves upregulation of master transcriptional regulators and signal transducer and activator of 
transcription (STAT) proteins. Each lineage expresses unique cytokine receptors responsive to cytokines 
secreted by accessory cells. IFN, interferon; IL, interleukin; p, phosphorylated; R, receptor; TGF; 
transforming growth factor; TSLP, thymic stromal lymphopoietin (Zhu et al. Annu. Rev. Immunol., 2010). 
 
 
1.2.3.2 B lymphocytes 
As pivotal components of humoral immunity, B cells and their antibodies protect the organism 
against a vast array of pathogens. Misguided B cell development, selection, and function result 
in autoimmunity, malignancy, immunodeficiencies, and allergy (Pieper, Grimbacher, and Eibel 
2013). Plasmablasts and plasma cells represent terminally differentiated B cell populations and 
are responsible for auto-ab production. Unlike long-lived plasma cells mediating lasting immunity, 
plasmablasts are short-lived effector cells of the early antibody response (Nutt et al. 2015). 
Mature B cells comprise three major subsets, to which follicular B cells, marginal zone B cells, 
and B1 cells belong (Allman and Pillai 2008; Carsetti, Rosado, and Wardmann 2004). As the 
dominant subset, follicular B cells are found in lymphoid follicles of the spleen and LN, and are 
specialized in responding to protein antigens that also trigger CD4+ T cell activation. Marginal 
zone B cells locate to the marginal sinus of the spleen, where they trap blood-borne and 
particulate antigens. B1 cells however mainly populate mucosal sites, including the peritoneal and 
pleural cavities and are thus most susceptible to environmental pathogens (Nutt et al. 2015). 
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The formation of antibody-secreting cells in response to T cell-dependent antigens involves B 
cells receiving an antigen receptor-dependent signal and finally differentiating into short-lived 
plasmablasts (MacLennan et al. 2003). The affinity of the resulting antibodies for antigen are 
modest and unvarying. Some of the activated B cells re-enter the B cell follicle and with the help 
of specialized Tfh cells form GC, eventually yielding high-affinity, long-lived plasma cells with 
robust secretion of antibody (Shlomchik and Weisel 2012; Radbruch et al. 2006). The GC reaction 
also induces memory B cells that upon re-encounter of antigen rapidly differentiate into antibody-
secreting cells (Kometani et al. 2013). 
In all mammals, B lymphocytes are derived from hematopoietic precursor cells in the BM, whereby 
their developmental stages are structured along the functional rearrangement of the Ig gene 
segments. Immature B cells displaying cell surface expression of IgM exit the BM and migrate to 
the spleen, where they complete early development upon differentiating into marginal zone or 
follicular B cells, depending on the specificity of their B cell receptor (BCR) (Pieper, Grimbacher, 
and Eibel 2013). 
B cells are identified by the general expression of CD19 and CD20, components of the BCR 
complex (Jackson et al. 2008). CD20 represents a target antagonized in the therapy of B cell 
lymphomas and autoimmune disorders, with its expression extinguished on plasma cells (Riley 
and Sliwkowski 2000). Plasmablasts, plasma cells, and memory B cells together upregulate 
surface expression of CD27, whilst expression of CD38 is confined to plasmablasts and plasma 
cells that exhibit high levels of CD38 (Pieper, Grimbacher, and Eibel 2013). 
B cells are critically involved in the initiation and perpetuation of autoimmune disorders by the 
formation of self-damaging antibodies, release of inflammatory cytokines, participation in antigen 
presentation, enhancement of T cell activation, and induction of ectopic lymphogenesis. 
Autoreactive antibodies inflict autoimmune pathology by Fc-mediated activation of the 
complement system, generation of immune complexes, and Fc receptor-mediated activation of 
both myeloid and lymphoid cells (Martin and Chan 2006). 
 
1.3 Humoral immunity 
1.3.1 Immunoglobulins 
Antibodies or Ig molecules represent the secreted form of the BCR and are composed of paired 
heavy and light polypeptide chains (Murphy et al. 2012). Functionally, they can be divided into 
variable domains that interact with antigens and constant domains that harness effector functions, 
including activation of complement or binding to Fc receptors (Schroeder and Cavacini 2010). 
Five different classes of antibodies can be distinguished according to their C regions and 
comprise IgM, IgD, IgG, IgA, and IgE. The class and related effector function are determined by 
the structure of the heavy chain (Murphy et al. 2012). B lymphocytes that maintain surface 
expression of IgM and IgD are called unswitched, whereas cells that have undergone Ig class-
switching lack IgM and IgD expression and are considered switched memory B cells (Bonilla and 
Oettgen 2010). In humans, IgG subclasses can be further separated into four subclasses, IgG1, 
IgG2, IgG3, and IgG4 with IgG1 being most abundant in serum (Murphy et al. 2012). 
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1.3.2 Cytokines and chemokines 
Cytokines and chemokines are central mediators in primarily innate, but also adaptive immunity 
and are produced by various immune and nonimmune cells of the organism. Commonly, they are 
secreted in reaction to an activating stimulus and they induce responses by binding to specific 
receptors (Murphy et al. 2012). 
DC release multiple structurally diverse cytokines including IL-1β, IL-6, IL-12, IL-23, TNF-α, and 
TGF-β to instruct differentiation of T cells into effector cells (Iwasaki and Medzhitov 2015). 
Because autoreactive CD4+ T cells play a crucial role in the induction and perpetuation of auto-
ab production in pemphigus, the particular relevance of cytokines in disease pathogenesis is 
subject to numerous investigations (Giordano and Sinha 2012). 
 
Here presented are the cytokines IL-6, TNF-α, IL-27, IL-21, and IL-33, as well as the chemokine 
receptor CCR2 selected for detection in the plasma of pemphigus patients and controls. 
The inflammatory cytokine IL-6 is synthesized by many different cell types with stimulated 
monocytes, fibroblasts, and endothelial cells representing its main sources. The phagocytosis of 
bacteria-infected apoptotic cells results in the release of both TGF-β and IL-6 by DC, which leads 
to Th17 cell differentiation. IL-6 activates the janus kinase (JAK) and transcription factors of the 
STAT family in order to induce the release of distinct cytokines from lymphocytes (Iwasaki and 
Medzhitov 2015). 
The similarly proinflammatory cytokine TNF-α is mainly produced by macrophages, monocytes, 
neutrophils, T cells, and NK cells upon stimulation with LPS. TNF-α contains local infection by 
acting on endothelial cells to upregulate adhesion molecules for the extravasation of monocytes 
and neutrophils, as well as proteins involved in blood coagulation. IL-6, TNF-α, and IL-1β induce 
production of acute-phase proteins that exhibit broad specificity for PAMP and exclusively require 
the presence of cytokines for their release (Murphy et al. 2012). Both IL-6 and TNF-α are 
implicated in the pathogenesis of autoimmune diseases with blockade of IL-6 showing therapeutic 
benefits in RA (Semerano et al. 2014), while treatment with anti-TNF-α monoclonal antibodies 
(mAb) ameliorates clinical symptoms in RA, inflammatory bowel disease (IBD), and psoriasis 
(Brzustewicz and Bryl 2015; Slevin and Egan 2015; Campa, Ryan, and Menter 2015). 
 
Identified in 2002 by Pflanz et al., IL-27 is evolutionary related to IL-12 and its expression is 
confined to activated APC (Pflanz et al. 2002). IL-27 exerts key modulatory effects on T and B 
cells with proinflammatory activities comprising the stimulation of CD8+ T cell function and the 
propagation of Tfh cells (Batten et al. 2010; Gringhuis et al. 2014). In addition, IL-27 is able to 
directly support B cell production of antibodies (Hunter and Kastelein 2012). IL-27 is involved in 
multiple disorders of autoimmune origin, including IBD (Schmidt et al. 2005; Cox et al. 2011), RA 
(Goldberg, Wildbaum, et al. 2004; Cao et al. 2008 ; Shen et al. 2011), experimental autoimmune 
encephalitis (EAE) (Goldberg, Zohar, et al. 2004; Li et al. 2005), psoriasis (Shibata et al. 2010; 
Shibata et al. 2013), type I diabetes (TID) (Wang et al. 2008), and Sjogren’s syndrome (SS) (Xia 
et al. 2012). The role of IL-27 in pemphigus pathogenesis has not yet been characterized. 
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IL-21 is the signature cytokine and produced in high amounts by Tfh cells (Crotty 2014), providing 
essential stimulation for B cells for the differentiation into class-switched plasma cells (Linterman 
et al. 2010). Increasing circulating IL-21 levels have been observed in auto-ab–mediated 
autoimmune diseases including RA and SLE (Liu et al. 2012; Dolff et al. 2011), suggesting that 
IL-21 is released by potentially autoreactive Tfh cells in the course of an ongoing autoimmune 
response (Tangye et al. 2013). 
 
IL-33 is a member of the IL-1 family and was identified in 2005 by Schmitz et al. (Schmitz et al. 
2005). IL-33 predominantly supports Th2-dependent immune responses and is constitutively 
expressed by tissue barrier cells, such as epithelial and endothelial cells, as well as macrophages 
and DC. Upon cellular stress or damage, it functions as an alarmin by signaling the presence of 
danger to adjacent cells and tissues. Importantly, IL-33 relates to autoimmune disorders, including 
RA, multiple sclerosis (MS), IBD,TID, and SLE (Pei et al. 2014). 
 
The migration of human blood monocytes underlies distinct trafficking mechanisms with the CD16-
CX3CR1lowCCR2high subset being preferentially recruited to distressed tissues in a CCR2–
chemokine (C-C motif) ligand 2 (CCL2)-dependent manner (Auffray, Sieweke, and Geissmann 
2009; Alvarez, Vollmann, and von Andrian 2008). Under inflammatory conditions, this route 
permits monocytes to exit the blood stream and access peripheral nonlymphoid tissues, which 
may also explain why blocking CCR2 was effective in attenuating disease in models of 
atherosclerosis, MS, and RA (Viola and Luster 2008; Boring et al. 1998; Izikson et al. 2000; Gong 
et al. 1997). CCR2 also localizes immature DC or their precursors to inflamed peripheral tissues 
(Sozzani 2005). 
 
1.4 Autoimmunity 
Paroxysomal nocturnal hemoglobinuria caused by anti-erythrocyte antibodies, as well as 
thyroiditis involving anti-thyroid antibodies represent the first immune disorders identified as 
autoimmune diseases. To date, more than 80 chronic inflammatory and destructive diseases 
have been attributed to an autoimmune origin, including RA, Graves’ disease, Hashimoto’s 
thyroiditis, and SS with high prevalence in the world’s population. These disorders are 
discriminated from each other by the primary organ targeted, time course of disease manifestation 
with reference to tissue damage, and major genetic associations. The cause of autoimmunity is 
idiopathic and multi-factorial with germline genetic variation accounting for less than 20% of 
disease trait variability. Typically, autoimmunity arises in late childhood to early adulthood, 
indicating that developmental factors, such as auto-ab formation and epigenetic programming, as 
well as environmental variables including intestinal microbiome and tobacco use are implicated 
in disease pathogenesis (Cho and Feldman 2015). 
The expression of auto-ab is a feature many autoimmune diseases share, although auto-ab are 
not essential. It is not yet understood what renders a self-protein autoantigenic, whereby some of 
them for instance interact with TLR or chemokine receptors (Hradetzky et al. 2013; Harlow et al. 
2012). Based on their Ig class, auto-ab display different levels of pathogenicity with for instance 
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IgM anti-double stranded DNA antibodies being less pathogenic than their IgG counterparts in 
SLE (Ross, Barland, and Grayzel 1978). 
Despite considerably low disease concordance rates in identical twins supporting the role of 
nongenetic factors in the development of autoimmunity (Bogdanos et al. 2012), the first 
experimental evidence of the HLA region conferring genetic predisposition to autoimmune 
diseases was provided in 1970 (Dick 1978). In addition, proinflammatory cytokines, especially 
TNF have been identified to exert a central function in autoimmunity with TNF blockade showing 
beneficial therapeutic effect in RA, Crohn’s disease (CD) and psoriasis (Cho and Feldman 2015). 
Strikingly, the TNF pathway as analyzed in disease tissue microarrays or in genome-wide 
association studies did not show genetic association in diseases, in which anti-TNF treatment has 
proven very effective. Apart from that, human genetic studies revealed a contribution of the IL-23 
pathway to the pathogenesis of autoimmune diseases (Cho 2008) with antagonizing IL-12/23 
demonstrating positive results in psoriasis (Griffiths et al. 2010). IL-23 propagates IL-23 receptor-
expressing pathogenic cells, including Th17 cells (Zhou, Chong, and Littman 2009). Aside from 
the MHC, the R620W polymorphism in PTPN22 was also found to be related to a number of 
autoimmune disorders, such as RA, TID, SLE, and autoimmune thyroid diseases (Criswell et al. 
2005). The tryptophan (W) allele impairs binding of PTPN22 to the c-Src tyrosine kinase altering 
thresholds for T and BCR signaling (Stanford and Bottini 2014). 
 
1.4.1 Associations of HLA polymorphisms with autoimmune diseases 
The prevalence of pemphigus is strongly associated with distinct HLA class II alleles, so here 
provided is some information about the HLA region representing the most genetically diverse 
region in the genome. 
The HLA region comprises genes with diverse immune functions beside those encoding for the 
classical antigen-presenting molecules. For the majority of autoimmune disorders, genetic 
associations with these genes are the strongest with multiple independent HLA alleles conferring 
predisposition to autoimmune diseases (Cho and Feldman 2015). HLA class II molecules are 
surface heterodimers expressed by thymic epithelial cells and APC that present antigenic 
peptides to TCR on cognate CD4+ T cells (Tsai and Santamaria 2013). They consist of three 
isotypes, including HLA-DR (encoded by HLA-DRA and –DRB1, and –DRB3, 4, and 5 in distinct 
haplotypes), HLA-DQ (encoded by HLA-DQA1 and –DQB1), and HLA-DP (encoded by HLA-
DPA1 and –DPB1) (Miyadera and Tokunaga 2015). 
Antigenic peptides are embedded in the peptide-binding groove of the HLA class II molecule, 
which is composed of two flanking α-helices on top of a β-pleated sheet. In general, these 
peptides position in the HLA class II binding cleft via their amino acid residues at four positions, 
designated pockets 1, 4, 6, and 9 (Tsai and Santamaria 2013). The observation that disease-
promoting HLA class II alleles often differ from those that do not propagate disease by only single 
amino acids of the peptide-binding cleft, neighboring key anchoring pockets (Latek et al. 2000; 
Jones et al. 2006), implies that the repertory of self-peptides presented to T cells substantially 
determines the HLA-related disease risk (Tsai and Santamaria 2013). 
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In support of this theory, the HLA-DRβ1*04:01 protein predisposing to RA was shown to provide 
the physicochemical requirements for high affinity binding of citrullinated peptides, but not 
noncitrullinated peptides (Hill et al. 2003). Structural analysis revealed that the presentation of 
citrullinated vimentin and aggrecan peptides by DRβ1*04:01 and –*04:04 proteins involved 
interaction of citrulline with lysine (K) or arginine (R) at 71β of the P4-binding pocket (Scally et al. 
2013). Similarly, the presence of aspartic acid (D70) and glutamic acid (E71) at P4 of the PV-
associated HLA-DRβ1*04:02 molecule enabled CD4+ T cell recognition of distinct HLA-
DRβ1*04:02–binding Dsg3 peptides as identified in PV patients (Veldman, Gebhard, et al. 2004) 
and described in detail in 4.2.1. 
 
1.4.2 Role of DC in autoimmunity 
As specialized sentinel cells bridging innate and adaptive immunity, the role of DC in the initiation 
and perpetuation of autoimmune diseases is currently highly discussed. Based on their 
bidirectional nature, DC might mediate immune tolerance by the generation and maintenance of 
Treg cells, as well as the induction of T cell anergy. However, inadequate activation signals or a 
cell-intrinsic disruption of negative regulation might also allow for the priming and/or effector 
differentiation of self-reactive T cells owing to the eminently efficient antigen presentation capacity 
of DC (Ganguly et al. 2013). Accordingly, DC transferred from mice with autoimmune neural 
inflammation were able to induce disease in naïve recipients (Knight et al. 1983). Observations 
in both experimental models and humans have provided considerable evidence for the 
pathogenic role of DC in autoimmune disease (Ganguly et al. 2013), whereby aberrant production 
of type I IFN of pDC is considered as a common mechanism underlying disease in psoriasis, SLE, 
and TID (Nestle et al. 2005; Bennett et al. 2003; Allen et al. 2009). 
By contrast, DC were shown to rather promote tolerance in the EAE model of MS (Yogev et al. 
2012). In various studies, the question was raised whether size of the encompassing DC 
population impacted the development of autoimmunity. Apparently, DC are not essential for 
peripheral tolerance (Birnberg et al. 2008), but rather participate in this process as DC ablation 
did not lead to overt autoimmunity (Ohnmacht et al. 2009). In addition, cytokine-induced 
augmented DC numbers have been related to the induction of Treg cells and tolerogenic 
conditions (Darrasse-Jeze et al. 2009; Swee et al. 2009; Collins et al. 2012). Albeit varying DC 
frequencies alone do not cause autoimmunity, functional alterations were shown to entail 
inflammation and/or autoimmune phenotypes (Ganguly et al. 2013). Multiple genes have been 
identified that upon their DC-specific deletion, cause autoimmune and/or inflammatory 
manifestations (Travis et al. 2007; Melillo et al. 2010; Kim et al. 2011; Hammer et al. 2011; Kool 
et al. 2011; Kaneko et al. 2012; Abram et al. 2013). However, these genes represent negative 
regulators of immune activation, for which reason their silencing in cell types other than DC also 
induced inflammation and/or autoimmunity (Yogev et al. 2012). 
 
1.5 The skin 
The skin represents one of the largest organs of the human organism with its surface being 
continuously exposed to potentially harmful environmental influences. In order to maintain 
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homeostasis, the skin not only exerts immunological, but also nonimmune functions, which 
comprise the formation of a physical and biochemical barrier, as well as providing a sensory-
receptive area. A versatile collective of both epithelial and immune cells mediate appropriate 
immune responses against a variety of trauma, toxins, and infectious agents whilst regulatory 
mechanisms ensure the perpetuation of immune tolerance (Di Meglio, Perera, and Nestle). 
Considering its diverse and wide-ranging tasks, the skin displays a layered composition with an 
outer epidermis covering an inner dermis, segregated by a basement membrane. The epidermis 
is structured from the lowermost to the uppermost layer in the stratum basale, the stratum 
spinosum, the stratum granulosum, and the stratum corneum consisting of dead keratinocytes 
(Di Meglio, Perera, and Nestle). The physical barrier primarily localizes in the stratum corneum, 
whereas the nucleated epidermis also contributes to barrier function by means of tight, gap, and 
adherens junctions, as well as desmosomes and elements of the cytoskeleton (Proksch, 
Brandner, and Jensen 2008). 
 
1.5.1 The desmosome 
Resistance of the skin towards mechanical stress is mediated by the epidermal cell contact 
structures adherens junctions and desmosomes that tightly attach adjacent cells to each other. 
Thus, desmosomes are abundantly expressed in tissues providing high mechanical stability, such 
as the stratified squamous epithelia of the skin and mucous membranes, as well as the 
myocardium (Waschke 2008). Besides ensuring cellular adhesion, desmosomes have been 
recognized as signaling scaffolds that regulate pathways of proliferation and differentiation 
(Broussard, Getsios, and Green 2015). 
Characteristically, desmosomes form disc-shaped junctions with each of the two neighboring cells 
displaying an electron-dense plaque. This plaque consists of Armadillo and Plakin family proteins 
and is organized in an outer dense plaque and a less dense inner plaque that interacts with 
intermediate filaments bundles. The desmosomal cadherins Dsg and Desmocollins (Dsc) 
constitute the intercellular adhesive interface and mediate adhesion in a strictly Ca2+-dependent 
manner. Their cytoplasmic domains are assumed to bind to Plakoglobin, which in turn attaches 
to Desmoplakin. Desmoplakin is eventually anchored to the intermediate filament cytoskeleton 
with Plakophilin providing lateral stabilization (Waschke 2008). 
In the autoimmune disorder pemphigus, Dsg-specific auto-ab disturb desmosomal integrity 
causing loss of epidermal keratinocyte adhesion, which presents clinically with flaccid blisters and 
erosions of the skin and mucous membranes (Hertl and Veldman 2001; Amagai 2002). 
 
1.5.2 Desmosomal cadherins 
The cadherin superfamily, of which four Dsg members (Dsg1–4) and three Dsc members (Dsc1–
3) are expressed in desmosomes are single-spanned transmembrane glycoproteins and 
specifically depend on Ca2+ to mediate cell-cell adhesion (Waschke 2008). Dsg2 and Dsc2 are 
primarily present in simple epithelia and are expressed at low levels in the basal layer of stratified 
epithelia, including the epidermis. Dsg1/3 and Dsc1/3 are distributed in stratified epithelia, whilst 
Dsg4 is localized in stratified epithelia and hair (Broussard, Getsios, and Green 2015). 
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Desmosomal cadherins exert important tasks in epithelial morphogenesis and differentiation, and 
their malfunction entails various diseases of the skin, hair, heart, and digestive tract, as well as 
cancer (Thomason et al. 2010). 
Structurally, desmosomal cadherins are type I integral membrane proteins with the amino-
terminal EC portion being structured in five cadherin repeats (EC1–5). Ca2+ concentrations 
increase from the basal layers to the superficial layers of the epidermis providing the Ca2+ ions 
required for conformational stability and binding activity of both desmosomal and classical 
cadherins (Waschke 2008). 
The N-terminal EC1 domain is of critical importance for the binding of Dsg3, the isoform that is 
predominantly targeted in PV. This is based on the finding that both the mAb AK23 from a PV 
mouse model, as well as Dsg3-specific antibodies from PV patients are mainly reactive against 
the N-terminal part of EC1 and exhibit high pathogenicity in vivo. Desmosomal cadherins use 
their EC1 domains for both cis and trans interactions, which involve molecules on the same cell 
and opposing cells, respectively. Concerning transinteractions, desmosomal cadherins bind in 
both homophilic and heterophilic manners. Dsg3 was shown to engage in homophilic 
transinteraction, whereas no binding was observed between Dsg1 and Dsg3 (Waschke 2008). 
Dsg1/Dsc1 and Dsg3/Dsc3 distribute inversely in skin epithelium with Dsg1/Dsc1 being enriched 
in the suprabasal layers, in which Dsg1 contributes to epidermal differentiation, but also skin 
disorders, such as PF, bullous impetigo, staphylococcal scalded skin syndrome (SSSS), and 
striate palmoplantar keratoderma (Amagai and Stanley 2012). In contrast, Dsg3/Dsc3 
accumulates in the basal epidermal layer with Dsg1/Dsc1 being expressed to only a limited extent 
(Broussard, Getsios, and Green 2015). Consequently, anti-Dsg1 auto-ab of PF patients cause 
blister formation in the most superficial layers of the skin, whilst anti-Dsg3 auto-ab of PV patients 
induce blisters in the basal layer of the skin (Kitajima 2013; Waschke 2008). 
 
 
 
 
 
20 
 
 
Figure 1.5: Composition of the human epidermis and molecular model of the desmosome. 
The human epidermis is a stratified squamous epithelia being composed of several cell layers. The basal 
layer (BL) is located above the basement membrane and consists of proliferating, transit-amplifying cells. 
The BL stratifies to give rise to differentiated layers of the spinous layer (SL), granular layer (GL), and the 
stratum corneum (SC) (a). Within the desmosome, the cadherins Desmoglein and Desmocollin interact with 
partner molecules by homophilic and heterophilic binding to the same (cis), as well as adjacent cell (trans). 
Their cytoplasmic domains form the outer dense plaque (ODP), whereas the inner dense plaque (IDP) links 
adapter molecules to the intermediate filament cytoskeleton (b) (modified from Fuchs et al. Nat Rev Genet, 
2002 [a] and Waschke et al. Histochem Cell Biol, 2008 [b]). 
 
 
1.6 Pemphigus 
Autoimmune bullous disorders (AIBD) are a group of rare and organ-specific blistering diseases 
of the skin and mucous membranes, in which primarily IgG auto-ab target distinct adhesion 
structures of the epidermis, dermoepidermal basement membrane, and dermis (Hertl, Eming, and 
Veldman 2006). PV and bullous pemphigoid (BP) are the most frequently reported AIBD with the 
incidence of pemphigus varying according to geographical area and ethnic affiliation (Alpsoy, 
Akman-Karakas, and Uzun 2015). High incidence of pemphigus (16.1/106) particularly among 
Ashkenazi Jewish in Israel (Pisanti et al. 1974) or in certain regions, such as the endemic form of 
PF in Brazil (Culton et al. 2008), points to both genetic and environmental factors being implicated 
in disease pathogenesis. In Europe, the incidence of pemphigus accounts for 0.5–8/106 (Alpsoy, 
Akman-Karakas, and Uzun 2015). 
Pemphigus comprises two major variants, PV with auto-ab specificity against Dsg3 and 
occasionally Dsg1, and PF only involving Dsg1-reactive auto-ab. More seldom forms include 
pemphigus herpetiformis, IgA pemphigus, paraneoplastic pemphigus and IgG/IgA pemphigus. 
Generally, PV is the most frequently reported clinical subtype of pemphigus and represents at 
least two thirds of patients (Baum et al. 2014). 
As a disorder predominantly afflicting the elderly, pemphigus is most often diagnosed between 
the fifth and sixth decade of life in European countries, with an enhanced prevalence in the female 
gender (Alpsoy, Akman-Karakas, and Uzun 2015). Compared to the general population, mortality 
risk of PV patients was found to be approximately threefold increased and if left untreated, 
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resulted in nearly 100% mortality at the end of five years following diagnosis (Mimouni et al. 2008). 
In pemphigus, a variety of environmental triggering factors has been proposed with drugs 
appearing to be the most common cause (Mutasim, Pelc, and Anhalt 1993). Additionally, viral 
infections, ultraviolet radiation, contact allergens, and diet have been related to the outbreak of 
pemphigus, although a distinct triggering factor could not yet been identified (Ruocco et al. 2013). 
 
However, associations between specific HLA class II alleles and pemphigus have been reported 
more than 25 years ago and repeatedly confirmed (Tron et al. 2006). HLA-DRB1*04:02, –
DRB1*14:01, and –DQB1*05:03 were the alleles found to be strongly related to the prevalence 
of pemphigus with HLA-DRB1*04:02 occurring in 92% of Ashkenazi Jewish (Ahmed et al. 1990) 
and 85% of non-Jewish Iranian (Mobini et al. 1997) patients. In contrast, HLA-DRB1*14:01 was 
predominantly identified in Japanese (Miyagawa et al. 1997), Italian (Lombardi et al. 1999; 
Lombardi et al. 1996), and Pakistani (Delgado et al. 1997) PV patients. While the association of 
PV with HLA-DRB1*04:02 and –DQB1*05:03 is primary, increased frequencies of –DRB1*14:01 
and –DQB1*03:02 were shown to be based on a linkage disequilibrium with the respective primary 
allele (Lee et al. 2006). 
 
Described in the following are clinical presentation, diagnosis, therapeutic treatment options, and 
current understanding of the pathogenesis of pemphigus. In addition, an established mouse 
model of pemphigus is presented. 
 
1.6.1 Clinical manifestation 
Disease progression of PV is chronic and primarily begins with painful and long-persisting 
erosions of the mucous membranes, especially that of the oral cavity (Kneisel and Hertl 2011a; 
Sticherling and Erfurt-Berge 2012). In addition, the throat, esophagus, conjunctivae, nasal, and 
genital mucosa can also be affected (Bystryn and Rudolph). This termed mucosal dominant type 
of PV commonly results in the mucocutaneous type upon the emergence of widespread flaccid 
blisters on normal skin (Sticherling and Erfurt-Berge 2012; Martin et al. 2009). 
Skin blisters are easily ruptured and form superficial erosions that first become encrusted and 
eventually epithelialize again. Blisters preferentially appear on the head’s scalp and sites 
subjected to increased mechanical stress, including the upper trunk and intertriginous areas 
(Bystryn and Rudolph). The active phase of PV features both direct Nikolsky sign and indirect 
Nikolsky/Asboe-Hansen/bulla spread sign, of which the former involves slight rubbing of the 
perilesional skin inducing exfoliation of the outermost layer. In contrast, indirect Nikolsky sign 
reflects in the lateral shift and enlargement of intact blisters upon application of digital pressure 
(Baum et al. 2014). 
PF is considered as a superficial subtype of pemphigus with lesions usually developing from 
numerous pruritic, crusted, and demarcated patches in seborrheic areas, including the scalp, as 
well as the face and trunk. Unlike in PV, blisters are more superficial and result in hyperkeratotic 
scales if left untreated. In addition, PF does not entail lesions of the oral mucosa and exhibits a 
more auspicious prognosis than PV (Goon and Tan 2001). 
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Figure 1.6: Clinical manifestation of the skin and mucosa in pemphigus vulgaris. 
Flaccid blisters on the upper back skin are initially exudative, become encrusted, and eventually epithelialize 
again (a). Erosions of the palatinate mucosa (b) (Department of Dermatology and Allergology, Philipps 
University, Marburg). 
 
 
1.6.2 Diagnostics 
Since pemphigus presents clinically with a rather heterogeneous picture, several parameters are 
taken to secure proper diagnosis, including clinical findings, histology, direct and indirect 
immunofluorescence (DIF and IIF, respectively) microscopy, and detection of autoantigen-
specific serum IgG antibodies (Kneisel and Hertl 2011b). 
As described in 1.6.1, PV patients typically display painful erosions of the mucous membrane, 
fragile blisters and crusts, as well as positive direct and indirect Nikolsky signs. In contrast, beside 
fragile blister formation, PF patients exhibit puff pastry-like scales in seborrheic areas. Histological 
skin biopsies serve as a means of determining the localization of loss of cell adhesion with 
pemphigus patients generally showing intraepidermal split formation. Specifically, specimens 
from PV patients display suprabasal acantholysis, while those from PF patients feature superficial 
subcorneal acantholysis concurrent with a slight inflammatory infiltration of the upper dermis 
(Kneisel and Hertl 2011b). 
Apart from the histological findings, DIF microscopy represents the gold standard of AIBD 
diagnostics, allowing for the visualization of tissue-bound IgG auto-ab. Using DIF, all pemphigus 
subtypes characteristically exhibit intercellular net-like deposits in the epidermis with emphasis 
on the suprabasal and subcorneal epidermis in PV and PF, respectively. By contrast, the 
technique of IIF microscopy permits detection of circulating auto-ab upon application of patient 
serum onto mostly monkey esophagus substrate. Compared to DIF microscopy, IIF microscopy 
yields lower sensitivity. Finally, serological confirmatory tests, such as ELISA, immunoblot, and 
immunoprecipitation complete the diagnostic procedure of AIBD (Kneisel and Hertl 2011b). In 
pemphigus, auto-ab primarily target desmosomal structure proteins with mucosal dominant PV 
showing exclusive reactivity against Dsg3. Following transition into the mucocutaneous type, PV 
patients additionally display Dsg1-specific auto-ab. Unlike in PV, PF solely features Dsg1-
responsive auto-ab (Amagai, Komai, et al. 1999). When monitored in individual pemphigus 
patients, the titers of serum anti-Dsg3 and anti-Dsg1 IgG auto-ab generally correlate with disease 
activity (Ishii et al. 1997; Sams and Jordon 1971). 
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Figure 1.7: Histological picture of acantholysis in pemphigus vulgaris. 
Typical loss of keratinocyte adhesion (acantholysis) in the suprabasilar layer of the epidermis of pemphigus 
vulgaris patients (a). Desmoglein-specific IgG antibodies binding to the surface of keratinocytes as detected 
by direct immunofluorescence microscopy (b) (Department of Dermatology and Allergology, Philipps 
University, Marburg). 
 
 
1.6.3 Therapy 
In the initial phase of pemphigus therapeutic treatment, application of high-dose systemic 
corticosteroids combined with adjuvant immune suppressants, including azathioprine (AZA), 
mycophenolate mofetil (MMF), and mycophenolic acid (MMA) is recommended for fast 
subsidence of clinical symptoms. During the progression of therapy, dosage of systemic 
corticosteroids is slowly reduced and adjusted to clinical manifestations (Eming 2015). Additional 
therapy options in particularly severe pemphigus comprise removal of circulating IgG antibodies 
by extracorporal immunoadsorption, which has proven effective in achieving both rapid and long-
term remission, highlighting the pathogenic capacity of pemphigus auto-ab (Eming and Hertl 
2006). Administration of high-dose intravenous Ig (IVIG) on the contrary ameliorates disease 
through various mechanisms, such as the prevention of auto-ab–induced apoptosis of 
keratinocytes (Michael and Grando 2008). 
Depletion of circulating autoreactive B cells, the precursors of auto-ab–secreting plasma cells, 
represents a targeted treatment strategy with considerable potential of inducing long-lasting 
clinical remission in pemphigus patients (Eming 2015). Off-label use of the chimeric anti-CD20 
mAb Rituximab was shown to cause prompt and complete clearance of B cells in peripheral blood 
and is indicated for severe and refractory pemphigus (Joly et al. 2007). Apart from systemic 
immunosuppressive therapy, anti-inflammatory topical medications, such as corticosteroid 
adhesive creams also contribute to a relief of clinical symptoms (Kneisel and Hertl 2011b). 
 
1.6.4 Pathogenesis 
1.6.4.1 Autoantigens 
In PV, IgG auto-ab mainly target the cadherin-type desmosomal adhesion proteins Dsg3 and 
Dsg1. In mucosal dominant PV, IgG reactivity primarily confines to Dsg3, whereas in the 
mucocutaneous type, auto-ab are directed against both Dsg3 and Dsg1. In contrast, PF only 
features production of anti-Dsg1 IgG (Baum et al. 2014). Analogous to other typical cadherins, 
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both Dsg3 and Dsg1 display five tandemly repeated EC domains, termed EC1–EC5 (Amagai, 
Klaus-Kovtun, and Stanley 1991). Using domain-swapped molecules between Dsg3 and Dsg1, 
the N-terminal residues 1–161 within EC1 and partly EC2 were identified to contain the major 
determinant of conformational epitopes of Dsg3 in PV (Futei et al. 2000), and are considered 
functionally critical for mediating cell-cell adhesion (Amagai et al. 1992). In addition, pathogenic 
Dsg3-reactive mAb were demonstrated to preferably bind to epitopes in mature Dsg3, whilst 
nonpathogenic anti-Dsg3 mAb recognized both mature and precursor forms (Sharma et al. 2009). 
Beside Dsg-responsive IgG, sera from PV patients were found to also exhibit reactivity to further 
autoantigens, including E-cadherin (Evangelista et al. 2008) and Dsc (Rafei et al. 2011), as well 
as acetylcholine receptors (AChR) (Grando 2000) and mitochondrial proteins (Marchenko et al. 
2010) with not yet clarified function in PV pathology. 
 
 
 
Figure 1.8: Binding sites of potent and weak pathogenic monoclonal antibodies within the 
Desmoglein 3 molecule. 
The desmosomal cadherin Desmoglein 3 (Dsg3) contains a cytoplasmic, transmembrane, and extracellular 
(EC) domain, the latter of which is structured in five subdomains (EC1–EC5). Pathogenic monoclonal 
antibodies (mAb) preferably recognize amino-terminal epitopes within the EC1 and EC2 region (Amagai et 
al. Curr Dir Autoimmun, 2008). 
 
 
1.6.4.2 B lymphocytes and autoantibodies 
In the pathogenesis of pemphigus, substantial data provide evidence of Dsg-specific IgG auto-ab 
directly inducing loss of epidermal keratinocyte adhesion, a typical hallmark of the disease (Payne 
et al. 2004). Accordingly, passive transfer of IgG derived from PV patients into neonatal mice was 
sufficient to trigger pemphigus pathology (Anhalt, Labib, and Voorhes 1982). Similarly, neonates 
of mothers suffering from active pemphigus transiently displayed blisters due to the transplacental 
transfer of maternal auto-ab (Avalos-Diaz et al. 2000). By contrast, removal of circulating IgG 
resulted in rapid subsidence of clinical manifestations in pemphigus patients (Eming and Hertl 
2006). Finally, in most pemphigus patients, serum anti-Dsg IgG titers were shown to correlate 
with disease activity (Amagai, Komai, et al. 1999; Ishii et al. 1997). 
The auto-ab response in pemphigus is polyclonal with most auto-ab belonging to the IgG4 
subclass in acute onset or active stage of disease, while remittent patients rather exhibit auto-ab 
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of the IgG1 subtype (Hertl 2000). Recently, a shared gene usage of the IgG heavy chain has been 
found for pathogenic auto-ab cloned from PV patients (Cho et al. 2014), indicating common 
humoral immune responses in disease pathogenesis. Interestingly, autoreactive B cells were 
shown to exert various functions beside the secretion of IgG auto-ab. Based on the observation 
of PV patients treated with the anti-CD20 mAb Rituximab not only exhibiting depletion of 
circulating B cells, but also decreased frequencies of autoreactive Th cells, B cells may 
additionally act as critical APC (Eming et al. 2008). 
 
1.6.4.3 Desmoglein compensation theory 
In pemphigus, the mechanism of blister formation is proposed to be based on differing 
intraepithelial distribution patterns of Dsg1 and Dsg3 between the skin and mucous membranes, 
and is termed Dsg compensation theory. In mucosal dominant PV, serum IgG auto-ab against 
Dsg3 cause mucosal lesions, while in mucocutaneous PV, auto-ab targeting Dsg1 and Dsg3 
induce blisters and erosions of both the skin and mucous membranes. Contrariwise, sera from 
PF patients merely contain Dsg1-reactive auto-ab resulting in extensive blistering confined to the 
skin (Amagai 2002). In mucous membranes, Dsg1 and Dsg3 are similarly distributed throughout 
the squamous mucosal epithelia with the expression intensity of Dsg1 falling much below that of 
Dsg3 (Shirakata et al. 1998). By contrast, in the skin, Dsg1 is mainly expressed in the superficial 
layers, whereas Dsg3 accumulates in the basal and parabasal layers of the epidermis (Amagai 
et al. 1996). 
Anti-Dsg1 IgG exclusively induce blisters in the superficial epidermis of the skin, in which 
coexpression of Dsg3 is absent. Deeper layers remain unharmed because the presence of Dsg3 
compensates for the impaired function of Dsg1. Similarly, anti-Dsg1 auto-ab interfere with Dsg1 
of the mucous membranes, yet coexpression of Dsg3 is sufficient to maintain epidermal integrity. 
Thus, in PF, anti-Dsg1 IgG solely entail superficial blistering of the skin (Amagai 2002). 
Inversely, in the skin, in which coexpression of Dsg1 compensates for hampered Dsg3 function, 
serum displaying merely anti-Dsg3 reactivity does not induce blister formation. However, low 
expression levels of Dsg1 in mucous membranes are not able to compensate for loss of Dsg3 
function. Therefore, anti-Dsg3–reactive sera from PV patients afflicted with the mucosal dominant 
type rather present with oral lesions, but lack skin manifestations. This compensation principle 
fails in patients with the mucocutaneous type of PV whose sera exhibit IgG directed against both 
Dsg3 and Dsg1, leading to extensive blister and erosion formation of the skin and mucous 
membranes (Amagai 2002). 
Certainly, the Dsg compensation theory refers to a simplified model of serum IgG reactivity 
against Dsg in pemphigus pathology. In favor of this hypothesis is the observation of discrete 
pemphigus subtypes displaying their own individual Dsg-specific auto-ab profile (Amagai, 
Tsunoda, et al. 1999). However, multiple additional autoantigens identified in pemphigus gave 
rise to the proposal of acantholysis relying on the synergistic targeting of several different 
structures expressed by keratinocytes (Cirillo et al. 2012). The relevance of these auto-ab has 
not yet been confirmed in the pathogenesis of pemphigus. 
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Figure 1.9: The Desmoglein compensation theory. 
In pemphigus, blister formation is assumed to be based on the Desmoglein (Dsg) compensation theory. 
Differing intraepithelial distribution of Dsg isoforms between the skin and mucous membranes determines 
the localization of auto-ab–induced loss of keratinocyte adhesion. In the skin, Dsg1 accumulates in the 
superficial layers, while Dsg3 is primarily found in the basal layers of the epidermis. Loss of Dsg1 function 
cannot, whereas loss of Dsg3 function can be compensated by coexpression of basal Dsg1. Conversely, 
Dsg1 and Dsg3 are evenly expressed throughout the mucous membranes with reduced expression levels 
of Dsg1. Hampered Dsg1 function can be compensated by coexpression of Dsg3, whilst disrupted Dsg3 
function cannot due to the minimal basal expression intensity of Dsg1 (Sharma et al. J Dermatol Sci, 2007). 
 
 
1.6.4.4 Effector T lymphocytes 
In pemphigus, the generation of circulating IgG auto-ab is critically regulated by autoreactive CD4+ 
T cells targeting Dsg3 and/or Dsg1 as shown by numerous studies (Amagai 2008; Hertl, Eming, 
and Veldman 2006). Accordingly, a high association of pemphigus prevalence with the expression 
of specific HLA class II alleles testifies of APC-mediated activation of autoreactive CD4+ T cells 
playing a key role in pemphigus pathogenesis (Tong et al. 2006; Wucherpfennig et al. 1995). 
Dsg3-reactive T cells have been identified in peripheral blood of PV patients, as well as healthy 
carriers of PV-related HLA alleles recognizing epitopes of the Dsg3 EC domain that bind to the 
respective HLA class II molecules (Veldman, Gebhard, et al. 2004). Furthermore, depleting 
peripheral blood mononuclear cells (PBMC) from PV patients of CD4+ cells in vitro resulted in 
abolished anti-Dsg3 IgG production, which could also be achieved upon addition of an anti–HLA-
DR or anti–HLA-DQ mAb to the cultures (Nishifuji et al. 2000). In addition, data obtained from 
experimental PV demonstrated that induction of a disease-like phenotype relied on loss of Dsg3-
specific tolerance of both T and B cells (Tsunoda et al. 2002). In concordance with this 
observation, application of an anti-CD40 ligand (CD40L or CD154) mAb impeding CD40/CD40L 
interaction between APC, including B cells and activated T cells, respectively, was able to prevent 
the generation of anti-Dsg3 IgG (Aoki-Ota et al. 2006). 
Concerning a specific pemphigus-associated Th cell polarization, increased Dsg3-specific Th2 
cell activity was found in PV patients with active disease compared to autoreactive Th1 cell 
responses (Rizzo et al. 2005). Correspondingly, the IgG4 subclass of auto-ab being linked with 
Th2 cell activation predominates in active pemphigus, while IgG1 relies on a Th1 cell-dependent 
response (Ayatollahi et al. 2004; Romagnani 1992). An active mouse model of PV provided further 
evidence for autoreactive Th2 cells mediating activation of B cells, resulting in pathogenic anti-
Dsg3 IgG production by release of the Th2 cell-related cytokine IL-4 (Takahashi et al. 2008). 
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Furthermore, frequencies of both circulating and tissue-infiltrating inflammatory Th17 cells were 
determined in pemphigus patients. Although Th17 cells were detected in skin lesions of PV 
patients, their occurrence neither correlated with serum autoreactive IgG titers nor with the clinical 
severity of disease (Arakawa et al. 2009). More recent studies identified significantly enhanced 
numbers of Th17 cells in the blood of PV patients with yet unclarified relevance in disease 
pathology (Xu et al. 2013; Asothai et al. 2015). 
 
1.6.4.5 Cytokines 
B cell activation and antibody production generally rely on the cognate interaction of B cells with 
CD4+ T cells and numerous studies have provided evidence for CD4+ T cell recognition of Dsg 
being central to the initiation and maintenance of pathogenic B cell responses in pemphigus (Hertl 
2000; Yokoyama and Amagai 2010). Induction of both cellular and humoral immune responses 
thereby relies on a large array of different cytokines and chemokines acting as inflammatory 
mediators. 
In concordance with enhanced frequencies of Th2 cells in active pemphigus patients (Rizzo et al. 
2005), augmented amounts of circulating Th2 cell-related cytokines could also be detected in PV 
patients (Satyam et al. 2009; Bhol et al. 2000). However, concerning an expected decline of 
serum Th1 cell cytokines because of the Th1 cell-inhibitory effects of Th2 cell cytokines, 
conflicting data exist. Although PV patients were reported to display a Th1 cell profile (Hertl, 
Amagai, et al. 1998a), another group observed reduced concentrations of circulating Th1 cell 
signature cytokines (Satyam et al. 2009). 
Inflammatory cytokines, including TNF-α and IL-6 have been additionally characterized in 
pemphigus with IL-6 being also secreted by Th2 cells. Several studies found significantly elevated 
serum levels of TNF-α in PV patients compared to HC (D/'Auria, Bonifati, and Mussi 1997; Alecu 
et al. 1999), as well as increasing circulating amounts of IL-6 (Narbutt et al. 2008; Alecu et al. 
1999). 
 
1.6.4.6 Immune regulation 
The finding of healthy carriers of PV-associated HLA class II alleles exhibiting circulating Dsg3-
specific Th1 cells (Veldman et al. 2003b; Hertl, Amagai, et al. 1998a), as well as a considerable 
proportion of healthy, immediate relatives of PV patients showing Dsg3-reactive auto-ab (Kricheli 
et al. 2000), hints at the existence of additional regulatory mechanisms taking effect and 
preventing disease development in those individuals. Accordingly, anti-inflammatory Dsg3-
specific IL-10–secreting Treg (Tr1) cells with constitutive expression of FOXP3 were numerically 
increased in healthy carriers of PV-linked HLA class II alleles compared to PV patients (Veldman, 
Hohne, et al. 2004). A further study confirmed markedly reduced frequencies of blood Treg cells 
concurrent with both diminished gene and protein expression of FOXP3 in CD4+CD25+ T cells in 
PV patients (Sugiyama et al. 2007). Moreover, frequencies of Treg cells in acute onset PV 
patients also appeared to fall below those of patients with remittent stage of disease (Xu et al. 
2013). In experimental PV, Treg cells induced in a Dsg3-deficient mouse were able to inhibit the 
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production of anti-Dsg3 IgG upon transfer into mice with active generation of auto-ab, highlighting 
the therapeutic potential of Treg cells in pemphigus (Yokoyama et al. 2011). 
 
Beside the well-established IL-10–producing Treg cells being subject to numerous studies that 
explore the pathogenesis of autoimmune disease, B cells with regulatory functions have recently 
been identified in humans, particularly within the subset of CD19+CD24highCD38high B cells (Blair 
et al.). Pemphigus patients with active disease displayed enhanced frequencies of blood 
CD19+CD24highCD38high IL-10–secreting B regulatory (Breg) cells (Zhu et al. 2015), yet concurrent 
with reduced functional capacities, including the ability to release IL-10 (Cho, Ellebrecht, and 
Payne). Similarly, patients with other autoimmune disorders also exhibited expanded populations 
of Breg cells (Iwata et al. 2011) showing deficiencies in IL-10 production, as well as in T cell 
suppressive function (Blair et al.). 
 
1.6.5 Mouse models of pemphigus vulgaris 
Mouse models of PV were created to investigate pathological immunomechanisms of this disease 
under in vivo conditions in a living organism. The currently most established model was developed 
by Amagai et al. in 2000 reproducing active autoimmune disease by making use of a Dsg3-
deficient mouse without acquired tolerance against the absent molecule (Amagai et al. 2000). 
Immunization with murine Dsg3 protein induces an antigen-specific IgG response, which does 
not result in PV pathology as the target structure is missing (Amagai et al. 2000). However, 
adoptive transfer of Dsg3-reactive lymphocytes from these mice into immunodeficient 
recombination activating gene 2 knockout (Rag2-/-) mice competent of Dsg3 expression leads to 
the generation of IgG auto-ab and manifestation of the pemphigus phenotype (Amagai et al. 
2000). A subsequent study identified Dsg3-specific loss of tolerance in both T and B cells as a 
prerequisite for efficient production of pathogenic IgG auto-ab and induction of PV-like clinical 
symptoms (Tsunoda et al. 2002). Although this model reliably reproduces ongoing autoimmune 
responses in PV, it does not take into consideration the triggering events of the disease, such as 
the strong association of distinct HLA class II alleles in pemphigus patients. 
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2 Materials 
 
2.1 Ethical approval of experiments 
Each patient gave written consent before being included in the study, which was approved by the 
Ethics Committee of the Medical Faculty of Philipps-University, Marburg (Az.: Studie 20/14). The 
study was conducted according to the Declaration of Helsinki principles. 
 
All animal experiments were reviewed approved by the local Laboratory Animal Ethics 
Committees at the Philipps University, Marburg (V 54 – 19 c 20 15 h 01 MR 20/4 – Nr. 15/2008 
and V 54 – 19 c 20 15 h 01 MR Nr. 80/2014) and the Karolinska Institutet, Stockholm, respectively. 
The experiments were done in compliance with local policies and guidelines on the use of 
laboratory animals. 
 
2.2 Patient material 
Fresh peripheral venous blood 
Patients of the Department of Dermatology and 
Allergology, Philipps University, Marburg 
Cryopreserved peripheral blood 
mononuclear cells (PBMC) 
 
2.3 Mouse material 
Fresh peripheral venous blood 
HLA-DRB1*04:02–tg mice bred at Experimental 
Animal Facilities, Philipps University, Marburg 
(Biomedizinisches Forschungszentrum) 
Organs and tissues: 
spleen, lymph nodes, bone marrow, buccal 
and palatinal mucosa 
 
2.4 Immortalized cell lines 
Murine hybridoma cell line X6310 
transfected with granulocyte-macrophage 
colony-stimulating factor (GM-CSF) 
expression construct 
Kindly provided by Prof. M. Schnare, Institute of 
Immunology, Philipps University, Marburg 
 
2.5 Antigens 
2.5.1 Recombinant proteins 
All recombinant proteins were produced as soluble proteins in a baculovirus expression system 
and were purified from insect cell culture supernatant by affinity chromatography. Linkage of 
proteins to an E tag and 6  histidine tag was introduced for technical reasons. 
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Recombinant 
Protein 
Description of Recombinant Amino Acid 
Sequence 
References 
Dsg3 EC of human Dsg3 (EC1–5) 1–566 (Hertl, Amagai, et al. 
1998b; Veldman, 
Gebhard, et al. 2004; 
Veldman et al. 2003a; 
Eming et al. 2008) 
Dsg3 EC of mouse Dsg3 (EC1–5) 1–566 (Anzai et al. 2004) 
Col VII Noncollagenous domain 1 
(NC1) of human Collagen VII 
17–610 (Muller et al. 2010; 
Jedlickova et al. 2012) 
 
2.5.2 Peptides 
Fifteen- and 17-mer Dsg3 peptides were synthesized by fluorenylmethyloxycarbonyl chloride 
(FMOC-Cl) chemistry resulting in 95% purity (peptides & elephants, Potsdam) and were 
solubilized in dimethyl sulfoxide (DMSO) acetic acid buffer (stock concentration, 2 mg/mL). 
 
2.5.2.1 HLA-DRβ1*04:02–binding human Dsg3 peptides: 
Dsg3 Peptides       P1   P4  P6      
Dsg3(97–111)   F G I F V V D K N T G D I N I 
Dsg3(190–204)   L N S K I A F K I V S Q E P A 
Dsg3(206–220)   T P M F L L S R N T G E V R T 
Dsg3(251–265)   C E C N I K V K D V N D N F P 
Dsg3(375–391) I N V R E G I A F R P A S K T F T 
 
2.5.2.2 HLA-DRβ1*04:02–non-binding human Dsg3 peptides: 
Dsg3 Peptides       P1   P4  P6      
Dsg3(85–101) Y R I S G V G I D Q P P F G I F V 
Dsg3(145–161) V K I L D I N D N P P V F S Q Q I 
Dsg3(240–256) A D K D G E G L S T Q C E C N I K 
Dsg3(295–311) E E Y T D N W L A V Y F F T S G N 
Dsg3(400–416) K L V D Y I L G T Y Q A I D E D T 
Marked in bold are the amino acid anchor motifs critical for peptide binding to HLA-DRβ1*04:02 
(Wucherpfennig et al. 1995; Tong et al. 2006). 
 
2.5.3 Mitogens 
Product Company 
Ionomycin Merck KGaA, Darmstadt 
Phorbol 12-myristate 13-acetate (PMA) Promega Corporation, Mannheim 
Phytohemagglutinin (PHA) Sigma-Aldrich Chemie GmbH, Schnelldorf 
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2.6 Growth factors 
GM-CSF secreted by X6310 cell line into 
the supernatant  
Department of Dermatology and Allergology, 
Philipps University, Marburg 
 
2.7 Chemicals and reagents 
Product Company 
Acetic acid (C2H4O2) Merck KGaA, Darmstadt 
Acrylamide (C3H5NO) Carl Roth GmbH & Co. KG, Karlsruhe 
Aluminum hydroxide (alum, Al(OH)3) Sigma-Aldrich Chemie GmbH, Schnelldorf 
3-Amino-9-ethylcarbazole (AEC, C
14
H
14
N2) Sigma-Aldrich Chemie GmbH, Schnelldorf 
Ammonium chloride (NH4Cl) Mallinckrodt Baker, Griesheim 
Ammonium persulfate (APS, (NH4)2S2O8) Sigma-Aldrich Chemie GmbH, Schnelldorf 
2,2′-Azino-bis(3-ethylbenzothiazoline-6-
sulfonic acid) (ABTSTM, C18H24N6O6S4) 
Merck KGaA, Darmstadt 
Bovine serum albumin – Fraction V (BSA) Carl Roth GmbH & Co. KG, Karlsruhe 
Bromophenol blue solution 2% Sigma-Aldrich Chemie GmbH, Schnelldorf 
5(6)-Carboxyfluorescein diacetate N-
succinimidyl ester (CFSE) 
Thermo Fisher Scientific, Langenselbold 
Citric acid (C6H8O7) Grüssing GmbH Analytika, Filsum 
Disodium hydrogen phosphate (Na2HPO4) Merck KGaA, Darmstadt 
DMSO (C2H6OS) Sigma-Aldrich Chemie GmbH, Schnelldorf 
Dulbecco's Phosphate-Buffered Saline (PBS) 
1x (without Ca2+, Mg2+) 
PAN-Biotech GmbH, Aidenbach 
ECL Western Blotting Substrate Thermo Fisher Scientific, Langenselbold 
Ethanol 70% (C2H6O) Otto Fischar GmbH, Saarbrücken 
(Ethylenedinitrilo)tetraacetic acid (EDTA, 
C
10
H
16
N
2
O8) 
Sigma-Aldrich Chemie GmbH, Schnelldorf 
FACSTM Clean Solution Becton Dickinson GmbH, Heidelberg 
FACSFlowTM Sheath Fluid Becton Dickinson GmbH, Heidelberg 
FACSRinse Solution Becton Dickinson GmbH, Heidelberg 
Fetal calf serum (FCS) Biochrom AG, Berlin 
G 418 disulfate salt solution Sigma-Aldrich Chemie GmbH, Schnelldorf 
Glycerol (C3H8O3) Amersham Pharmacia Biotech, Freiburg 
Glycine (C2H5NO2) Carl Roth GmbH & Co. KG, Karlsruhe 
GolgiStopTM Protein Transport Inhibitor 
(contains monensin) 
Becton Dickinson GmbH, Heidelberg 
Heparin Sigma-Aldrich Chemie GmbH, Schnelldorf 
Horseradish peroxidase (HRP) Streptavidin 
for ELISPOT 
Becton Dickinson GmbH, Heidelberg 
32 
 
Hydrogen peroxide 30% (H2O2) Merck KGaA, Darmstadt 
L-Glutamine (200 mM) with 
Penicillin (10,000 U/mL), 
Streptomycin (10,000 mg/mL) 
PAA Laboratories GmbH, Cölbe 
Lipopolysaccharides (LPS) from Escherichia 
coli 055:B5 
Sigma-Aldrich Chemie GmbH, Schnelldorf 
2-Mercaptoethanol (2-ME, C2H6OS) 
(Gibco® 2-Mercaptoethanol) 
Life Technologies GmbH, Darmstadt 
Methanol (CH3OH) Sigma-Aldrich Chemie GmbH, Schnelldorf 
Mounting medium (IF) 
(VECTASHIELD Antifade Mounting Medium 
for fluorescence) 
LINARIS Biologische Produkte GmbH, 
Dossenheim 
Nonfat dried milk powder AppliChem GmbH, Darmstadt 
Normal Mouse Serum Thermo Fisher Scientific, Langenselbold 
Pancoll human; density 1,077 g/L PAN-Biotech GmbH, Aidenbach 
Paraformaldehyde (PFA, OH(CH
2
O)
n
H) Merck KGaA, Darmstadt 
Potassium hydrogen carbonate (KHCO3) Merck KGaA, Darmstadt 
2-Propanol (C3H8O) Sigma-Aldrich Chemie GmbH, Schnelldorf 
Protein ladder (10–250 kDa) Thermo Fisher Scientific, Langenselbold 
Rabbit serum Thermo Fisher Scientific, Langenselbold 
RPMI Media 1640 PAA Laboratories GmbH, Cölbe 
Saponin from quillaja bark (20–35%) Sigma-Aldrich Chemie GmbH, Schnelldorf 
Sodium acetate (C2H3NaO2) Merck KGaA, Darmstadt 
Sodium azide (NaN3) Merck KGaA, Darmstadt 
Sodium dodecyl sulfate (SDS, NaC12H25SO4) Carl Roth GmbH & Co. KG, Karlsruhe 
Tetramethylethylenediamine (TEMED, 
C6H16N2) 
Carl Roth GmbH & Co. KG, Karlsruhe 
Tissue-Tek® O.C.T.™ Compound Sakura Finetek GmbH, Staufen 
TiterMax® Gold Adjuvant Sigma-Aldrich Chemie GmbH, Schnelldorf 
Tris(hydroxymethyl)aminomethane (TRIS, 
C4H11NO3) 
Carl Roth GmbH & Co. KG, Karlsruhe 
Trypan Blue solution 0.4% Sigma-Aldrich Chemie GmbH, Schnelldorf 
Tween®-20 (Polysorbate) Merck KGaA, Darmstadt 
X-VivoTM Medium Lonza Group Ltd., Köln 
 
2.8 Buffers and culture media 
Description Production 
ABTS solution 515 mL 0.2 M Na2HPO4 
+ 485 mL 0.1 M citric acid 
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Adjust pH to 5.0. 
+ 1 g ABTS 
Store at -20 °C. 
Ammonium chloride–potassium hydrogen 
carbonate (ACK) lysis buffer 
0.15 M NH4Cl 
+ 1 mM KHCO3 
+ 0.1 mM EDTA 
Adjust volume to 1 L ddH2O, 
Adjust pH to 7.2–7.4. 
Store at room temperature (RT). 
DC differentiation medium  X-VIVOTM medium 
+ 10% GM-CSF 
Store at 4 °C. 
ddH2O Deionization and sterile filtration of tap water by 
ultrapure water purification system. 
If necessary sterilization at 121 °C, 20 min. 
Store at RT. 
DIF blocking buffer PBS 1x 
+ 10% rabbit serum 
DIF dilution buffer PBS 1x 
+ 2% rabbit serum 
EDTA–heparin buffer  PBS 1x 
+ 5 U/mL heparin 
+ 1 mM EDTA 
Store at 4 °C. 
ELISPOT assay blocking buffer PBS 1x 
+ 1% BSA 
ELISPOT assay dilution buffer PBS 1x 
+ 0.5% BSA 
+ 0.02% NaN3 
ELISPOT assay substrate solution 20 mL 0.1 M acetate solution 
148 mL 0.2 M acetic acid 
+ 352 mL 0.2 M sodium acetate 
Adjust volume to 1 L ddH2O, 
Adjust pH to 5.0. 
+ 666.7 µL AEC stock solution 
+ 10 µL H2O2 for activation 
Sterile filtrate (0.45 µm). 
ELISPOT assay washing buffer PBS 1x 
+ 0.05% Tween®-20 
Fixation buffer PBS 1x 
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+ 1% PFA 
Store at -20 °C. 
FACS buffer PBS 1x 
+ 1% BSA 
+ 0.1% NaN3 
Store at 4 °C. 
Freezing medium FCS, sterile filtered (0.22 µm) 
+ 10% DMSO 
Store at -20 °C. 
Immunoblotting blocking buffer PBS 1x 
+ 0.05% Tween®-20 
+ 5% nonfat dried milk powder 
Immunoblotting washing buffer PBS 1x 
+ 0.05% Tween®-20 
MACS buffer PBS 1x 
+ 0.5% BSA 
+ 2 mM EDTA 
Sterile filtrate (0.22 µm) 
Store at 4 °C. 
Permeabilization buffer PBS 1x 
+ 1% BSA 
+ 0.1% NaN3 
+ 0.1 % saponin 
Store at 4 °C. 
RPMI++ RPMI 1640 
+ 2 mM l-glutamine 
+ 100 U/mL penicillin 
+ 100 µg/mL streptomycin 
Store at 4 °C. 
Running buffer 10x 286 g 190 mM glycine 
+ 60.6 g 25 mM TRIS 
+ 20 g SDS 0.1% 
Add 2 L ddH2O. 
Store at RT. 
Sample buffer 5x 1 g SDS 
+ 5 mL glycerol 99% 
+ 4 mL 1 M TRIS, pH= 6.8 
+ 1 mL 2-mercaptoethanol 
+ 0.5 mL bromophenol blue 2% 
Store at 4 °C. 
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SDS-polyacrylamide gel electrophoresis 
(PAGE) separating gel (n= 4) 12.5% 
 
8.7 mL acrylamide 30% 
+ 3.75 mL 2 M TRIS, pH= 8.8 
+ 7.9 mL ddH2O 
+ 206.3 µL SDS 10% 
+ 77.5 µL APS 10% 
+ 15.5 µL TEMED 
SDS-PAGE stacking gel (n= 4) 12.5% 
  
833 µL acrylamide 30% 
+ 620 µL 1 M TRIS, pH= 6.8 
+ 3.54 mL ddH2O 
+ 50 µL SDS 10% 
+ 25 µL APS 10% 
+ 10 µL TEMED 
Transfer buffer  6 g TRIS 
+ 28.8 g glycine 
+ 400 mL methanol 
Adjust volume to 2 L ddH2O and store at RT. 
 
2.9 Antibodies 
2.9.1 Antibodies for cell culture and cell preparation 
Specificity Clone Isotype Company 
CD3 UCHT1 Mouse IgG1, κ 
 
Becton Dickinson 
GmbH, Heidelberg 
CD13/CD16 2.4G2  Rat IgG2b, κ Becton Dickinson 
GmbH, Heidelberg 
 
2.9.2 Antibodies for ELISA 
Specificity Clone Isotype Conjugate Company 
Mouse IgG Polyclonal Rabbit IgG HRP Dako GmbH, 
Hamburg 
 
2.9.3 Antibodies for ELISPOT 
Product Company 
Mouse IFN- ELISPOT Pair Becton Dickinson GmbH, Heidelberg 
Mouse IL-4 ELISPOT Pair Becton Dickinson GmbH, Heidelberg 
 
2.9.4 Antibodies for flow cytometry 
Specificity Clone Isotype Conjugate Company 
CCR2 48607 Mouse IgG2b, κ Allophycocyanin 
(APC) 
R&D Systems 
GmbH, Wiesbaden 
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CD3 UCHT1 Mouse IgG1, κ 
 
Phycoerythrin 
(PE) 
Becton Dickinson 
GmbH, Heidelberg 
CD4 RPA-T4 Mouse IgG1, κ 
 
Fluorescein 
isothiocyanate 
(FITC) 
Becton Dickinson 
GmbH, Heidelberg 
CD4 RPA-T4 Mouse IgG1, κ 
 
PE Becton Dickinson 
GmbH, Heidelberg 
CD4 RM4-5 Rat IgG2a, κ APC Becton Dickinson 
GmbH, Heidelberg 
CD8 RPA-T8 Mouse IgG1, κ 
 
FITC Becton Dickinson 
GmbH, Heidelberg 
CD11c B-ly6 Mouse IgG1, κ 
 
APC Becton Dickinson 
GmbH, Heidelberg 
CD14 M5E2 Mouse IgG2a, κ 
 
FITC Becton Dickinson 
GmbH, Heidelberg 
CD14 MEM-18 Mouse IgG1, κ 
 
PE ImmunoTools, 
Friesoythe 
CD16 3G8 Mouse IgG1, κ 
 
PE Becton Dickinson 
GmbH, Heidelberg 
CD16 B73.1 Mouse IgG1, κ 
 
APC Becton Dickinson 
GmbH, Heidelberg 
CD86 2331 (FUN-1) Mouse IgG1, κ 
 
PE Becton Dickinson 
GmbH, Heidelberg 
CD303 AC144 Mouse IgG1, κ 
 
APC Miltenyi Biotec, 
Bergisch-Gladbach 
HLA-DR G46-6 Mouse IgG2a, κ 
 
PE Becton Dickinson 
GmbH, Heidelberg 
HLA-DQ Tu169 Mouse IgG2a, κ 
 
FITC Becton Dickinson 
GmbH, Heidelberg 
I-A[b] 25-9-17 Mouse (C3H) 
IgG2a, κ 
FITC Becton Dickinson 
GmbH, Heidelberg 
IFN- 25723.11 Mouse IgG2b, κ APC Becton Dickinson 
GmbH, Heidelberg 
IL-4 MP4-25D2 Rat IgG1, κ APC Becton Dickinson 
GmbH, Heidelberg 
IL-6 MQ2-13A5 Rat IgG1, κ PE eBioscience, 
Frankfurt 
IL-10 JES3-19F1 Rat IgG2a, κ APC Becton Dickinson 
GmbH, Heidelberg 
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IL-17A N49-653 Mouse IgG1, κ 
 
Alexa Fluor® 647 Becton Dickinson 
GmbH, Heidelberg 
TNF-α MAb11 Mouse IgG1, κ 
 
PE Becton Dickinson 
GmbH, Heidelberg 
Isotype control MOPC-21 Mouse IgG1, κ 
 
Alexa Fluor® 647 Becton Dickinson 
GmbH, Heidelberg 
Isotype control MOPC-21 Mouse IgG1, κ 
 
APC Becton Dickinson 
GmbH, Heidelberg 
Isotype control MOPC-21 Mouse IgG1, κ 
 
FITC Becton Dickinson 
GmbH, Heidelberg 
Isotype control MOPC-21 Mouse IgG1, κ 
 
PE Becton Dickinson 
GmbH, Heidelberg 
Isotype control G155-178 Mouse IgG2a, κ 
 
FITC Becton Dickinson 
GmbH, Heidelberg 
Isotype control G155-178 Mouse IgG2a, κ 
 
PE Becton Dickinson 
GmbH, Heidelberg 
Isotype control MPC-11 Mouse IgG2b, κ APC Becton Dickinson 
GmbH, Heidelberg 
Isotype control R3-34   Rat IgG1, κ APC Becton Dickinson 
GmbH, Heidelberg 
Isotype control R35-95   Rat IgG2a, κ APC Becton Dickinson 
GmbH, Heidelberg 
Isotype control PPV-06 Mouse IgG1, κ 
 
PE ImmunoTools, 
Friesoythe 
Isotype control IS5-21F5 Mouse IgG1, κ 
 
APC Miltenyi Biotec, 
Bergisch-Gladbach 
Isotype control 133303 Mouse IgG2b, κ APC R&D Systems 
GmbH, Wiesbaden 
Isotype control eBRG1 Rat IgG1, κ PE eBioscience, 
Frankfurt 
 
2.9.5 Antibodies for immunoblotting 
Specificity Clone Isotype Conjugate Company 
E tag Polyclonal Rabbit IgG - Abcam plc, 
Cambridge, U.K. 
Mouse IgG Polyclonal Rabbit IgG HRP Dako GmbH, 
Hamburg 
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2.9.6 Antibodies for immunofluorescence 
Specificity Clone Isotype Conjugate Company 
Mouse IgG Polyclonal Rabbit IgG FITC Thermo Fisher Scientific, 
Langenselbold 
 
2.10 Commercial test kits for serological and cellular diagnostics 
Kit Company 
ACHRAB® - Assay DLD Diagnostika, Hamburg 
Alexa Fluor® 488 Protein Labeling Kit  Thermo Fisher Scientific, Langenselbold 
Anti-Desmoglein 1/3-ELISA Euroimmun, Lübeck 
CD4 (L3T4) MicroBeads mouse Miltenyi Biotec, Bergisch-Gladbach 
IL-6 ELISA Ready-SET-Go!® eBioscience, Frankfurt 
IL-27 ELISA Ready-SET-Go!® eBioscience, Frankfurt 
LEGEND MAXTM Human IL-33 ELISA Kit eBioscience, Frankfurt 
Neurology Mosaic 1 (titin) Euroimmun, Lübeck 
NOVA Lite® (IFA) Monkey Esophagus Werfen GmbH, Kirchheim 
TNF-α ELISA Ready-SET-Go!® eBioscience, Frankfurt 
 
2.11 Consumables 
Product Company 
6/24/48-well plates Nunc GmbH & Co. KG, Wiesbaden 
96-well plates, flat-bottom Nunc GmbH & Co. KG, Wiesbaden 
96-well plates, round-bottom Nunc GmbH & Co. KG, Wiesbaden 
96-well polyvinylidene fluoride (PVDF) 
membrane plates (MAIPSWU10) 
Millipore GmbH, Schwalbach 
Cannulas, 26/30 G (BD MicrolanceTM) Becton Dickinson GmbH, Heidelberg 
Cell culture flasks, 25/75/125 cm2 Greiner, Frickenhausen 
Cell strainers, 40 µm Becton Dickinson GmbH, Heidelberg 
Centrifugation tubes, 15/50 mL Greiner, Frickenhausen 
Combitips®, 5 mL Eppendorf, Hamburg 
Coverslips for Neubauer counting chamber, 
20  26 mm 
Thermo Fisher Scientific, Langenselbold 
Cryogenic tubes, 2 mL Greiner, Frickenhausen 
Dissecting instruments (scissors, forceps) AESCULAP Surgical instruments, Tuttlingen; 
Dumont, Montignez, Switzerland 
Filter papers (Whatman®)  Sigma-Aldrich Chemie GmbH, Schnelldorf 
Flow cytometry tubes, polystyrene, 5 mL Sarstedt, Nümbrecht 
Hose connector, metal (P334.1) Carl Roth GmbH & Co. KG, Karlsruhe 
Luer lock syringes, 3 mL (Z248002) Sigma-Aldrich Chemie GmbH, Schnelldorf 
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MACS®, MS columns Miltenyi Biotec, Bergisch-Gladbach 
Micro hematocrit blood tubes, heparinized Brand GmbH + Co KG, Wertheim 
Microscope coverslips Thermo Fisher Scientific, Langenselbold 
Microscope slides, 1 mmm, 26  76 mm Thermo Fisher Scientific, Langenselbold 
Monovette® (citrate-phosphate-dextrose-
adenine, CPDA) 
Sarstedt, Nümbrecht 
Mouse ear punch Carl Roth GmbH & Co. KG, Karlsruhe 
Pasteur pipettes, glass Hirschmann Laborgeräte GmbH & Co. KG, 
Eberstadt 
Petri dishes, bacteriological, 100 mm Becton Dickinson GmbH, Heidelberg 
Pipette tips Kalensee, Gießen 
Reaction tubes, 1.5 mL Eppendorf, Hamburg 
Rotilabo® tetrafluorethylene-
perfluorpropylene (FEP) hose (Y505.1) 
Carl Roth GmbH & Co. KG, Karlsruhe 
Serological pipettes, 5/10/25 mL Greiner, Frickenhausen 
Stericup® filter units, 250/500 mL, 0.22 µm Millipore GmbH, Schwalbach 
Steriflip® filter units, 0.22 µm Millipore GmbH, Schwalbach 
SteritopTM filter units, 0.45 µm Millipore GmbH, Schwalbach 
Syringes, 1 mL (Omnifix®-F Duo) B. Braun Melsungen AG, Melsungen 
Transfer membrane, nitrocellulose, 0.45 µm Millipore GmbH, Schwalbach 
 
2.12 Laboratory equipment 
Equipment Company 
Absorbance reader SunriseTM-Basic Tecan GmbH, Gröding, Austria 
Analytical balance 770 Gottlieb Kern & Sohn GmbH, Balingen-
Frommern 
Autoclave FVA3 Fedegari Autoclavi Spa, Albuzzano, Italy 
CO2 incubator BBD 6220 Thermo Fisher Scientific, Langenselbold 
CO2 incubator HERAcell® Heraeus Kendro Laboratory Products GmbH, 
Langenselbold 
Cryogenic container Qualifreeze Nunc GmbH & Co. KG, Wiesbaden 
Documentation device  VWR International GmbH, Erlangen 
Electroblotting apparatus Bio-Rad Laboratories, Hercules, USA 
ELISPOT Scanner Eli.Scan A.EL.VIS, Hannover 
Flow cytometer FACSCaliburTM Becton Dickinson GmbH, Heidelberg 
Fluorescence microscope Olympus BH-2 Olympus, Tokyo, Japan  
Gel electrophoresis apparatus Bio-Rad Laboratories, Hercules, USA 
Heating block Eppendorf, Hamburg 
Light microscope Axiostar Carl Zeiss MicroImaging GmbH, Göttingen 
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Magnetic stirrer IKAMAG® RET IKA Labortechnik, Staufen 
MiniMACS® separator Miltenyi Biotec, Bergisch-Gladbach 
Multichannel pipette Discovery 20-200 µL ABIMED, Langenfeld 
Multipette® plus Eppendorf, Hamburg 
Neubauer counting chamber Paul Marienfeld GmbH & Co. KG, Lauda-
Königshofen 
Nitrogen tank Chronos 200 Cryotherm GmbH & Co. KG, Kirchen 
pH meter CyberScan pH 510 Eutech Instruments Europe bv, Nijkerk, 
Netherlands 
Pipettes Research® 10 µL, 100 µL, 200 µL, 
1,000 µL 
Eppendorf, Hamburg 
Refrigerated centrifuge Megafuge® 1.0R Heraeus Kendro Laboratory Products GmbH, 
Langenselbold 
Sterile bench HERASafe® Heraeus Kendro Laboratory Products GmbH, 
Langenselbold 
Ultrapure water purification system Astacus MembraPure GmbH, Henningsdorf 
Vortex mixer IKA® Genius 3 IKA Labortechnik, Staufen 
Water bath GFL 1083 Gesellschaft für Labortechnik mbH, Burgwedel 
 
2.13 Software 
Program Company 
CellQuest ProTM 5.2 Becton Dickinson GmbH, Heidelberg 
Eli.Analyse ELISPOT Analysis Office 
Software 4.2 
A.EL.VIS, Hannover 
Endnote X7 Thomson ResearchSoft, USA 
FlowJo© 7.6.3 TreeStar Inc., Ashland, USA 
GraphPad Prism© 6.02 GraphPad Software Inc., La Jolla, USA 
Microsoft© Office Excel© Microsoft Corporation, Redmond, USA 
Microsoft© Office PowerPoint© Microsoft Corporation, Redmond, USA 
Microsoft© Office Word© Microsoft Corporation, Redmond, USA 
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3 Methods 
 
3.1 Human study 
3.1.1 Patients 
In this study, 34 pemphigus patients, 31 MG patients serving as a control for a further unrelated 
auto-ab–mediated organ-specific disorder, and 32 HC were included. Data is primarily shown 
from nine PV and three PF patients. The clinical diagnosis of pemphigus and MG was confirmed 
by standard criteria. The MG patients suffered from very mild to moderate disease, whereas the 
pemphigus patients could be categorized according to active (act. P) or remittent (rem. P) stage 
of disease. Remission was defined as the absence of any mucosal blisters and/or skin erosions 
for at least two months (Murrell et al. 2008). Since systemic immunosuppressive therapy with 
prednisolone (Pred) significantly impacted DC numbers in a dose-dependent manner (Figure 
4.13), patients with a daily intake of ≥10 mg of Pred were excluded from this analysis. Patients 
with pathological leukocyte counts were also excluded from this study. HC were matched 
according to gender and age, and did not display any signs of skin autoimmune inflammation. 
Pemphigus and MG patients averaged 54 and 57 years, respectively, whilst the average age of 
HC was 50 years. Here provided is an overview of the pemphigus and MG patients’ clinical and 
serological characteristics indicated in relative units (RE)/mL: 
 
 
Table 3.1: Clinical phenotype and auto-ab profile of pemphigus vulgaris and pemphigus foliaceus 
patients. 
  
Clinical phenotype1 
 
Auto-ab profile (IgG)3 
  
Skin Mucosa Medication per day2 Dsg3 Dsg1 
Patient Status 
     
PV1 Active Isolated erythematous 
plaques with crusty erosions 
on legs and feet 
Erosions on lower lip None 18 9 
PF2 Active Crusty erosions on the face, 
neck, and trunk 
None None 0 34 
PV3 Active None Erosions in oral cavity None 529 2 
PV4 PR4 None Erosions in oral cavity None 0 9 
PF5 Active Extensive dry erosions on 
the scalp, trunk, and legs 
None MMF 2 g 3 632 
PV6 CR5 None None None 2 4 
PV7 Active Isolated crusty erosion on 
the hand 
None None 491 0 
PV8 Active None Erosions on palate, 
tongue, and gingiva 
None 40 0 
PV9 Active None Erosion in oral cavity None 176 0 
PV10 Active None Dry erythematous 
plaques on genitals 
None 1148 0 
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PF11 Active Extensive open erosions on 
the face and neck 
None None 0 534 
PV12 CR None None None 0 0 
1At time of study. 
2MMF, mycophenolate mofetil. 
3Determined by ELISA with recombinant Dsg1 or Dsg3 in RE/mL (cut-off value: 20 RE/mL). 
4PR, partial remission off therapy as defined by Murrell et al. J Am Acad Dermatol, 2008. 
5CR, complete remission off therapy as defined by Murrell et al. J Am Acad Dermatol, 2008. 
 
 
Table 3.2: Clinical status and auto-ab profile of myasthenia gravis patients. 
   
Auto-ab profile (IgG)2 
  
Medication per day1 AChR Titin 
Patient Status 
   
MG1 Very mild IVIG 1.6 0 
MG2 Very mild IVIG, MMF 1g, Pred 5 mg 65 640 
MG3 No symptoms MTX 7.5 mg weekly 3.5 80 
MG4 Moderate AZA 150 mg, Pred 5 mg 4.6 0 
MG5 Mild IVIG 0.1 0 
MG6 Mild IVIG 0.1 320 
MG7 Moderate IVIG, TRL 0.39 0 
MG8 Very mild AZA 100 mg 190 0 
MG9 No symptoms AZA 150 mg 0 0 
MG10 Moderate AZA 150 mg 560 0 
MG11 No symptoms None 58 80 
MG12 Very mild MTX 7.5 mg weekly 110 1280 
1
AZA, azathioprine; IVIG, intravenous Ig; MTX, methotrexate; Pred, prednisolone; TRL, tacrolimus. 
2Determined by 125I-radio receptor assay for anti-acetylcholine receptor (AChR) IgG in nmol/L (cut-off 
value: 0.25–0.4 nmol/L) and IIF microscopy for anti-titin IgG (cut-off value: titer of 80). 
 
 
3.1.2 Serological diagnostics 
3.1.2.1 Blood collection and autoimmune serology 
Peripheral blood samples (~50 mL) were collected from pemphigus, MG patients, and HC by 
clinical staff of the Department of Dermatology and Allergology of Philipps-University, Marburg. 
The presence of IgG auto-ab against Dsg1 and/or Dsg3 in the sera of the pemphigus patients 
was detected by a commercially available ELISA kit (2.10) by staff of the diagnostic laboratory of 
the Department of Dermatology and Allergology of Philipps-University, Marburg according to the 
manufacturer’s protocol. Circulating IgG anti-AChR antibodies in the sera of the MG patients were 
detected by staff of the Bioscientia Institute of Medical Diagnostics, Ingelheim using a 
commercially available 125I-radio receptor assay (2.10) according to the manufacturer’s manual. 
Auto-ab against striated muscle (titin) were detected by IIF microscopy using a commercially 
available testing system (2.10) by staff of the Department of Laboratory Medicine and 
Pathobiochemistry, Molecular Diagnostics, Philipps-University, Marburg according to the 
manufacturer’s protocol. For isolation of both mononuclear cells and blood plasma, peripheral 
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blood was treated with the anticoagulant citrate-phosphate-dextrose-adenine (CPDA) and was 
prepared on the following day of withdrawal (3.1.3.1). 
 
3.1.2.2 Detection of plasma cytokines by ELISA 
The cytokines IL-6, TNF-α, IL-21, IL-27, and IL-33 present in the plasma of pemphigus patients 
were quantified by ELISA with the help of commercially available ELISA kits (2.10) according to 
the manufacturers’ protocols. Cytokine concentrations were derived from a four parameter logistic 
calibration curve using GraphPad Prism© software (2.13). 
 
3.1.3 Cellular diagnostics 
3.1.3.1 Isolation of PBMC by density gradient centrifugation 
PBMC were isolated from peripheral blood treated with the anticoagulant CPDA using density 
gradient centrifugation. This purification method is based on a watery solution of the high-
molecular-weight sucrose polymer Ficoll with a specific gravity of 1.077 g/mL, as well as density 
differences between mononuclear cells and other components of the blood sample (Fuss et al. 
2009). Upon centrifugation of a preparation of Ficoll and whole blood diluted with phosphate-
buffered saline (PBS), the single cell populations distribute in distinct layers, with the density of 
Ficoll exceeding those of lymphocytes, monocytes, and platelets, but falling below those of 
granulocytes and red blood cells (RBC). Therefore, mononuclear cells and platelets collect 
between the upper PBS and the lower Ficoll layer, whereas RBC and granulocytes form sediment 
at the bottom of the Ficoll layer. Platelets are removed within the mononuclear cell fraction by 
subsequent centrifugation. 
 
Procedure: 
The cellular fraction of the patient’s CPDA–blood sample is pelleted by centrifugation at 350 g (1 
g= 9.81 ms-2) at room temperature (RT) for 10 min, and the blood plasma is subsequently 
separated, centrifuged at 1,860 g at 4 °C for 10 min and frozen at -20 °C. The leukocyte/RBC 
fraction is diluted in the ratio of 1:2 with PBS, carefully layered in the ratio of 1:3 onto the Ficoll 
solution, and centrifuged at 450 g at RT for 30 min with deactivation of the brakes. Following 
centrifugation, the PBMC fraction located between the PBS and Ficoll layer of the obtained 
density gradient is aspirated using a Pasteur pipette and is transferred into a fresh centrifugation 
tube filled with 50 mL PBS at 4 °C and centrifuged at 550 g at 4 °C for 10 min. Thereafter, the 
cells are again washed with PBS, centrifuged at 350 g at 4 °C for 10 min and resuspended in 
RPMI++ (2.8) to determine the cell number utilizing a Neubauer counting chamber (3.1.3.2). 
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Figure 3.1: Separation of blood components on a Ficoll gradient. 
Peripheral blood mononuclear cells (PBMC) collect between the upper phosphate-buffered saline and lower 
Ficoll layer (modified from Fuss et al. Curr Protoc Immunol, 2009). 
 
 
3.1.3.2 Cell count determination 
The number of viable cells present in a cell suspension was determined under a light microscope 
with the help of a Neubauer counting chamber and dye exclusion test (Phelan and Lawler 2001; 
Strober 2001). A sample of the cell suspension was thoroughly diluted in a suitable ratio with 
0.4% Trypan Blue solution to obtain a uniform suspension, which was then transferred underneath 
the coverslip of the counting chamber. Since vital cells possess intact cell membranes that 
exclude the permeability of distinct dyes, (such as Trypan Blue), only the cytosolic proteins of 
dead cells are selectively stained. Hence upon optical analysis, live cells appeared clear, whilst 
dead cells exhibited a blue cytoplasm. Cell counts in each of the four corners of the Neubauer 
counting chamber were recorded and the cell density was determined by the following calculation: 
Cells/mL= average count per square dilution factor  104. 
 
3.1.3.3 Cryopreservation and thawing of cells 
Cryopreservation is required for the long-term storage and maintenance of principle cellular 
functions of mononuclear cells (Yokoyama, Thompson, and Ehrhardt 2012). In order to 
functionally characterize leukocyte populations of pemphigus patients, PBMC were frozen and 
thawed according to the following procedure: Upon isolation of the PBMC, cells were 
resuspended in RPMI++ (2.8) and centrifuged at 350 g at 4 °C for 10 min. The cell pellet was 
resuspended at a density of 5–10  106 cells/mL in freezing medium (2.8), which consisted of fetal 
calf serum (FCS) supplemented with 10% dimethyl sulfoxide (DMSO). The cells were then 
transferred into cryogenic storage tubes. The addition of the cryoprotective agent DMSO, as well 
as the selection of appropriate freezing rates prevent cellular damage caused by the formation of 
intracellular ice crystals and osmotic effects. The optimum freezing rate (1 °C/min temperature 
reduction until -80 °C) was achieved by storing the cryogenic tubes in specific freezing containers 
filled with 2-propanol. For long-term preservation, PBMC were stored in liquid nitrogen at -170 °C. 
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To slowly thaw the cryopreserved PBMC, frozen cells were exposed to a water bath of 37 °C, 
added dropwise to RPMI++, and subsequently centrifuged at 350 g at 4 °C for 10 min. Thereafter, 
cells were cultured in their respective growth mediums for further functional analysis. 
 
3.1.3.4 Flow cytometry 
The investigational technique of flow cytometry/fluorescence-activated cell sorting (FACS) can 
perform multiple simultaneous measurements at the single cell level at very rapid rates. It is based 
on detecting both scattered light and fluorescence from suitably stained constituents in individual 
cells. Therefore, the stained cells are streamed single file in fluid suspension through the focus of 
a high-intensity light source (laser beam). Each cell passing through the focus emits a flash of 
scattered and/or fluorescent light. This light is collected by a system of lenses and filtered before 
reaching a photodetector that quantitatively converts it into an electronic signal. The diffraction of 
light (forward scatter, FSC) thereby indicates the size, whereas the refraction of light (side scatter, 
SSC) indicates the granularity of the cell. A feature of all biological molecules is their capacity to 
absorb light, which increases the energy state of the molecule above its ground state. The 
molecule will revert to its ground state by a number of mechanisms, amongst which is the 
emission of light with a longer wavelength compared to that of the exciting light. A fluorescent dye 
attached to an antibody absorbs light most efficiently at a distinct wavelength within its specific 
absorption spectrum. In this study, we applied the fluorochromes fluorescein isothiocyanate 
(FITC), phycoerythrin (PE), and allophycocyanin (APC) (2.9.4) for flow cytometry measurement. 
The FACSCaliburTM (2.12) displays two laser beams operating at specific wavelengths (488 nm, 
635 nm) to excite four dyes at the same time. 
Analysis of FSC and SSC of peripheral blood leukocytes yields clearly defined populations of 
lymphocytes, monocytes, granulocytes, and debris clusters. The debris cluster consists of cell 
fragments, RBC, and platelet aggregates. Because detection of RBC interferes with the detection 
of lymphocytes, RBC need to be removed from CPDA–blood by adding hypotonic ammonium 
chloride–potassium hydrogen carbonate (ACK) lysis buffer (2.8) causing burst of erythrocytes. 
In this thesis, flow cytometry was used to phenotypically and functionally characterize subsets of 
human circulating DC, monocytes, and lymphocytes. Prior to analyzing antibody binding to 
distinct surface molecules or intracellular proteins, the respective leukocyte populations were 
preselected by gating based on FSC and SSC analysis (Watson 1991; Dean and Hoffman 2001). 
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Figure 3.2: Longitudinal cross-sectional view of the flow chamber of a flow cytometer. 
The cell sample is contained in the sheath fluid, which guides the cells to the center of the flow chamber. 
The laser beam is directed onto the cell stream (modified from Dean et al. Current Protocols in Cytometry, 
2001). 
 
 
3.1.3.5 Detection of cell surface markers in whole blood by FACS 
In order to phenotypically characterize monocyte and DC populations of pemphigus patients, 
whole blood was analyzed for cell type-specific and activation/migration cell surface markers. 
Therefore, peripheral blood–CPDA samples were incubated for 30 min at 4 °C in a dark 
environment with the respective fluorescently labeled antibodies, as well as matching isotype 
controls according to the manufacturers’ protocols. RBC were lysed upon twofold incubation in 
ACK lysis buffer (2.8) for 5 min at RT. Following double washing with FACS buffer (2.8) at 535 g 
at 4 °C for 5 min, cells were resuspended in 250 µL with the same buffer for measurement. Flow 
cytometry analysis was performed using FACSCaliburTM (2.12) and FlowJo© single cell analysis 
software (2.13). 
 
3.1.3.6 Stimulation of PBMC for detection of intracellular cytokines by FACS 
To assess the capacity of monocytes and CD4+ T cells from pemphigus patients to produce 
distinct cytokines, PBMC were stimulated according to the following procedure: Blood samples 
were rested overnight at RT before PBMC were isolated using density gradient centrifugation 
(3.1.3.1) and cells were stored at -80 °C until further use. Depending on the assay, after overnight 
culture in RPMI++ (2.8) supplemented with 10% FCS, thawed cells were either stimulated with 0.1 
µg/mL LPS overnight or 5 ng/mL phorbol myristate acetate (PMA) and 500 ng/mL ionomycin for 
5 hours at 37 °C and 5% CO2. LPS is the major component of the outer membrane of Gram-
negative bacteria and it is the best-described ligand of the TLR4 expressed by several immune 
cells, including DC, monocytes, and macrophages. TLR4 signals from the plasma membrane as 
part of the LPS-multireceptor complex, which induces the expression of various proinflammatory 
cytokines, such as TNF-α, IL-1, and IL-6 (Brubaker et al. 2015a). The pharmacological agents 
PMA and ionomycin together are the most robust and nonspecific stimuli for most T cell cytokines. 
Their application largely reconstitutes the effects of T cell activation: Whereas ionomycin allows 
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EC Ca2+ to flow into the cell, PMA is an activator of the protein kinase C (Foster et al. 2007). In 
order to avoid release of the stimulation-induced cytokines into the supernatant, secretory activity 
of the Golgi apparatus was blocked by adding GolgiStopTM according to the manufacturer’s 
protocol, 5 hours prior to antibody staining. 
 
3.1.3.7 Detection of intracellular proteins of stimulated PBMC by FACS 
Activated PBMC were washed with FACS buffer (2.8) (535 g, 4 °C, 5 min) and incubated with the 
respective fluorescently labeled antibodies for staining of cell surface structures, as well as 
appropriate isotype controls according to the manufacturers’ protocols for 20 min at 4 °C in a dark 
environment. After washing (535 g, 4 °C, 5 min), cells were first fixed with 0.5 mL fixation buffer 
(2.8) for 10 min at RT, washed twice with 2 mL FACS buffer (535 g, 4 °C, 5 min), and then 
permeabilized with permeabilization buffer (2.8) for 10 min at 4 °C in a dark environment. After 
centrifugation (535 g, 4 °C, 5 min), intracellular cytokines were detected by incubation with the 
respective fluorescently labeled antibodies, as well as appropriate isotype controls according to 
the manufacturers’ protocols for 30 min at 4 °C in a dark environment. Prior to flow cytometry 
analysis, cells were washed twice with permeabilization buffer (535 g, 4 °C, 5 min) and then 
resuspended in 500 µL of the same buffer for flow cytometry analysis. 
 
3.1.3.8 Antigen uptake assay 
Antigen uptake belongs to the most important functions of monocytes and DC (Nuñez 2001). In 
order to check whether this property is altered in monocytes of pemphigus patients their capacity 
of protein internalization was analyzed by flow cytometry. Therefore 1  105 freshly thawed PBMC 
were resuspended in RPMI++ (2.8) supplemented with 10% FCS and stored on ice for 10 min. 
Upon addition of fluorescently labeled recombinant Dsg3 (2.10), cells were incubated for various 
lengths of time (5 min, 10 min, and 30 min) at 37 °C in the incubator or stored on ice in a dark 
environment as a control. The process of antigen uptake was abolished by adding 2 mL ice-cold 
FACS buffer (2.8). After double washing with FACS buffer (350 g, 4 °C, 10 min) cell surface 
markers were stained with fluorescently labeled antibodies according to the manufacturers’ 
protocols. Following repeated washing, PBMC were fixed in fixation buffer (2.8) and directly 
analyzed using flow cytometry. The difference in mean fluorescence intensity (MFI) between the 
sample incubated at 37 °C and its control determines the monocyte uptake capability. 
 
3.1.3.9 Statistics 
Statistical evaluation of the data obtained from flow cytometry analysis was performed using 
GraphPad Prism© software (2.13). For comparison of a variable between two groups of a small 
sample size that are not related to each other, a nonparametric two-tailed test for comparison of 
unpaired sample sizes (Mann-Whitney-U) was selected. Differences were considered significant 
for p 0.05 (indicated as *), very significant for p 0.01 (indicated as **), and highly significant for 
p 0.001 (indicated as ***). Spearman correlation coefficients were displayed for at least medium 
correlation of r> 0.6. 
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3.2 Mouse study 
3.2.1 HLA-DR4–tg mice 
HLA-DRA1*01:01-DRB1*04:02/-DQA1*03:01, -DQB1*03:02 (DQ8)–tg DBA/1J mice were 
generated as described previously (Congia et al. 1998; Cope et al. 1999). The mice express the 
human CD4 coreceptor and are deficient in I-Aβ (I-Aβ-/-) (Killeen, Sawada, and Littman 1993). 
Transgenic C57/BL/10 mice coexpressing DRB1*04:01 and human CD4, but devoid of 
endogenous murine MHC class II and a functional Ncf1 gene were used as control animals by 
the research group of Johan Bäcklund, Department of Medical Biochemistry and Biophysics, 
Karolinska Institutet, Stockholm, Sweden (Backlund et al. 2002; Hultqvist et al. 2004; Batsalova 
et al. 2010). 
 
3.2.1.1 Blood collection and phenotyping of HLA-DR4–tg mice 
In order to phenotype immune cells of HLA-DRB1*04:02–tg mice, blood samples were extracted 
from the orbital sinus with a heparinized capillary. Alternatively, blood was drawn from immunized 
mice to assess Dsg3-specific IgG reactivity in the sera separated by centrifugation at 4,500 g at 
4 °C for 10 min. The collected blood was diluted with 100 µL (ethylenedinitrilo)tetraacetic acid 
(EDTA)–heparin buffer (2.8) to prevent blood coagulation. Surface expression of human CD4, 
HLA-DR, and HLA-DQ, as well as lack of I-Aβ of leukocytes were determined by flow cytometry 
analysis. For this purpose, unlabeled anti-CD16/CD32 antibody (1:200) was added to 60 µL blood 
sample to impede unspecific antibody binding by saturation of Fc receptors, and incubated on ice 
for 10–15 min. Thereafter, fluorescently labeled antibodies were added to the sample in the ratio 
of either 1:25 (human CD4, HLA-DR, and HLA-DQ) or 1:5,000 (I-Aβ), and incubated on ice for 30 
min in a dark environment. Blood cells were washed and RBC removed by twofold addition of 
ACK lysis buffer (2.8) for 5 min at RT in a dark environment (350 g, 4 °C, 5 min). Finally, cells 
were resuspended with 200 µL FACS buffer (2.8) for flow cytometry analysis. 
 
3.2.1.2 Immunization of HLA-DR4–tg mice 
To induce Dsg3-reactive T cell responses, 8–12 week old HLA-DRB1*04:02–tg mice were 
immunized by intraperitoneal (i.p.) injection of 20–40 µg recombinant human Dsg3 protein (2.5.1) 
or the Dsg3 peptides (2.5.2) in aluminum hydroxide (alum) on days 0, 14, and 28 (Figure 3.3a). 
Blood samples were taken (3.2.1.1) to assess the induction of anti-Dsg3 IgG by ELISA (3.2.2.1), 
immunoblotting (3.2.2.2), or immunofluorescence microscopy (3.2.2.3). 
To induce locally restricted Dsg3-specific T cell responses, mice were injected subcutaneously 
(s.c.) into the hind foot paws with 20–40 µg Dsg3 peptides in the adjuvant TiterMaxTM on day 0. 
Draining LN were harvested on day seven for ELISPOT analysis (3.2.3.3) of Th cell-related 
cytokine secretion upon in vitro restimulation with antigen (Figure 3.3b). 
 
49 
 
 
 
Figure 3.3: Immunization scheme of HLA-DR4–transgenic mice. 
For induction of Dsg3-specific CD4+ T cell responses, HLA-DRB1*04:02–tg mice were immunized by 
intraperitoneal (i.p.) injection of recombinant human Dsg3 protein or the Dsg3 peptides emulsified in 
aluminum hydroxide (alum) and serum samples were drawn according to the above illustrated scheme (a). 
To induce locally restricted Dsg3-specific T cell responses, mice were injected subcutaneously (s.c.) into the 
hind foot paws with the Dsg3 peptides in the adjuvant TiterMaxTM and draining lymph nodes (LN) were 
harvested for in vitro restimulation according to the above illustrated scheme (b). 
 
 
3.2.2 Serological diagnostics 
3.2.2.1 Dsg3 ELISA 
With the help of an ELISA the amount of Dsg3-specific IgG antibodies can be assessed in a semi-
quantitative manner. The assay relies on binding of antibodies contained in patients’ sera or 
culture supernatant to recombinant Dsg3 coated on a microtiter plate. Following washing off of 
unbound antibodies, the amount of Dsg3-reactive IgG can be determined by e.g. an horseradish 
peroxidase (HRP)-coupled detection antibody that catalyzes the reaction of the colorimetric 
substrate 2,2′-Azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) (Hornbeck 2001). 
 
Procedure: 
The presence of circulating IgG antibodies against recombinant Dsg3 (2.5.1) in the sera of HLA-
DRB1*04:02–tg mice i.p. immunized (3.2.1.2) with human Dsg3 or a set of five Dsg3 peptides 
(2.5.2.1) was detected by a commercially available ELISA kit (2.10) according to the 
manufacturer’s manual with modification: Mouse sera were diluted in the ratio of 1:20 and an anti-
mouse IgG HRP-coupled antibody (1:2,000) was used as secondary antibody. 
 
3.2.2.2 Immunoblotting 
IgG cross-reactivity against mouse Dsg3 of sera from HLA-DRB1*04:02–tg mice i.p. immunized 
(3.2.1.2) with human Dsg3 (both 2.5.1) was analyzed by immunoblotting. This technique is applied 
to identify specific protein sequences separated by electrophoresis and transferred to a suitable 
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membrane by polyclonal or mAb. The primary antibody is specific for the protein of interest, 
whereas the secondary antibody is IgG-reactive and coupled to HRP or alkaline phosphatase 
enzyme, and upon addition of chromogenic or luminescent substrates, the antigen–antibody 
complex is visualized (Gallagher et al. 2001). 
 
Procedure: 
Protein samples are solubilized with sample buffer (2.8) for 5 min at 95 °C and separated by 
sodium dodecyl sulfate (SDS)–polyacrylamide gel electrophoresis (PAGE) for 30 min at 100 V. 
Thereafter, the antigens are electrophoretically transferred in a semidry transfer apparatus to a 
nitrocellulose membrane for 60 min at 150 mA. The gel is thereby positioned on the membrane, 
which is enclosed by two stacks of four sheets of filter paper soaked with transfer buffer (2.8). 
This way, the proteins bound to the surface of the membrane provide access for the mouse serum 
IgG antibodies. Remaining binding sites are blocked by immersion of the membrane in blocking 
buffer (2.8) for 2 hours at RT. Mouse sera are diluted in the ratio of 1:200 in the same buffer and 
incubated for 1 hour at RT. Because proteins are synthesized attached to an E tag, application of 
an anti-E tag antibody (1:2,000) serves as a positive control. Following threefold washing with 
washing buffer (2.8) for 10 min, the membrane is incubated with the secondary anti-IgG antibody 
coupled to HRP diluted in the ratio of 1:2,000 in blocking buffer for 1 hour at RT. After repeated 
threefold washing with washing buffer for 10 min, antigen–antibody complexes are visualized by 
applying 2 mL of the two ECL chemiluminescent substrates (1:1) on the membrane for 5 min at 
RT. For record, the membrane is instantly photographed. 
 
3.2.2.3 Immunofluorescence 
Proteins can be localized within a histological sample by the technique of immunofluorescence. 
IIF microscopy relies on proper fixation of cells to retain cellular distribution of antigen and to 
preserve cellular morphology. Application of permeabilizing reagents, such as saponin, provides 
access for the primary antibody to the epitope of the protein of interest. The bound primary 
antibody is labeled by incubation with a fluorescently tagged secondary antibody targeting the 
primary antibody host species. Finally, the specimen can be viewed under a fluorescence 
microscope (Donaldson 2001). 
DIF is utilized to detect antibodies instantaneously bound to tissues in vivo and thus requires 
exclusive addition of a fluorescently labeled secondary antibody. In order to assess whether IgG 
induced in HLA-DRB1*04:02–tg mice by i.p. immunization (3.2.1.2a) with human Dsg3 cross-
reacts with murine Dsg3 (both 2.5.1) under in vivo conditions, DIF was performed on mouse tissue 
specimens. For this purpose, buccal and palatinal mucosa of immunized mice were embedded in 
Tissue-Tek® O.C.T.TM Compound, frozen at -80 °C, and cut into sections of 3–4 µm. After blocking 
with blocking buffer (2.8), samples were stained with a rabbit anti-mouse IgG FITC-labeled 
antibody diluted in the ratio of 1:250 in dilution buffer (2.8) for 30 min at RT in a dark environment. 
To study whether i.p. immunization of HLA-DRB1*04:02–tg mice with human Dsg3 protein (2.5.1) 
or a set of five Dsg3 peptides (2.5.2.1) induces IgG against native human Dsg3, IIF microscopy 
with mouse serum samples (1:25) was performed on monkey esophagus (2.10) according to the 
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manufacturer’s protocol with modification: As secondary antibody, a rabbit anti-mouse IgG FITC-
labeled antibody (1:500) was used instead. 
 
3.2.3 Cellular diagnostics 
3.2.3.1 Generation of bone marrow-derived DC 
In order to study APC-induced activation of antigen-specific Th cells, mDC were generated from 
hematopoietic precursors in mouse BM using granulocyte-macrophage colony-stimulating factor 
(GM-CSF) (Lutz et al. 1999). For this purpose, femurs and tibiae of 4–12 week old HLA-
DRB1*04:02–tg mice were separated and purified from the surrounding muscle tissue by rubbing 
them with tissues. Thereafter, joints were removed at both ends of the bone with scissors so that 
the BM could be thoroughly flushed out using a 10 mL syringe and needle (26 G) filled with RPMI++ 
(2.8). Following centrifugation at 300 g at 4 °C for 5 min, RBC were destroyed by adding 4 mL 
ACK lysis buffer (2.8) for 5 min at RT and upon neutralization with 8 mL RPMI++, bone particles 
were removed using a cell strainer (40 µm). After repeated centrifugation (300 g, 4 °C, 5 min), 
cells were resuspended in RPMI++ to determine the cell number with the help of a Neubauer 
counting chamber (3.1.3.2). Cells were then centrifuged and seeded at a density of 3–6  106 cells 
per petri dish in 10 mL DC differentiation medium (2.8) for seven days. On day three and six of 
culture, 10 mL fresh DC differentiation medium was added to the BM cells developing into DC. 
Upon complete differentiation on day seven, bone marrow-derived DC (BMDC) were matured 
with 0.1 µg/mL LPS, pulsed with 10 µg/mL antigen (2.5), and incubated for 18 hours at 37 °C and 
5% CO2. 
Murine GM-CSF (2.6) was obtained from the GM-CSF–producing cell line X6310 (2.4) that was 
grown in RPMI++ supplemented with 10% FCS and 1 mg/mL G418 solution for two weeks. 
Following additional two weeks of incubation in RPMI++ supplemented with 10% FCS without 
addition of fresh medium, the supernatant was collected, sterile filtered, and stored at 4 °C. 
 
3.2.3.2 Coculture of antigen-pulsed BMDC with antigen-specific CD4+ T cells 
Preparation of splenocytes 
APC-mediated activation of Th cells was studied in the HLA-DRB1*04:02–tg mouse model by the 
following approach: BMDC generated in vitro using GM-CSF were matured with LPS and pulsed 
with antigen (3.2.3.1) to be cultured together with antigen-specific CD4+ T cells induced by 
repetitive i.p. immunization (3.2.1.2a) of mice with recombinant human Dsg3 protein (2.5.1). For 
this purpose, the spleen of immunized mice was removed and splenocytes were liberated from 
the capsule by placing it between two microscope slides that were moved carefully against each 
other. Splenocytes were rinsed off the slides, resuspended in PBS and capsule constituents were 
removed using a cell strainer (40 µm). After centrifugation (350 g, 4 °C, 10 min), RBC were 
destroyed upon incubation in ACK lysis buffer (2.8) for 5 min at RT, and cells were again 
centrifuged (350 g, 4 °C, 10 min). Thereafter, cells were resuspended in RPMI++ (2.8) and 
prepared for further purification of CD4+ T cells by magnetic-activated cell sorting (MACS). 
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Isolation of murine CD4+ T cells using magnetic cell separation 
The MACS technique is based on covalent binding of paramagnetic nano particles (micro beads) 
to antibodies that are for instance cell type-specific so that the targeted cells are held back upon 
application of a magnetic field. It is an efficient method to purify distinct cell populations under 
sterile conditions. 
In order to isolate CD4+ T cells from the splenocyte suspension, the MACS mouse CD4+ T cell 
positive selection kit (2.10) was utilized according to the manufacturer’s protocol. Application of 
magnetically labeled CD4-specific antibodies resulted in the immobilization of CD4+ cells in the 
magnetic field of the MACS separator. This way cells devoid of CD4 were collected in the flow 
through of the column and discarded, whereas the CD4+ cells attached to the column were used 
for the coculture experiment. Purity of the isolated CD4+ T cells was 95% as confirmed by FACS 
analysis. 
 
CFSE proliferation assay 
Usage of carboxyfluorescein diacetate succinimidyl ester (CFSE) is a widely applied method to 
measure lymphocyte proliferation in vitro by flow cytometry. The amino-reactive succinimidyl side 
chain of the dye allows CFSE to covalently couple to intracellular proteins. Upon cell division, the 
fluorescence intensity is halved in the two daughter cells, visualized as individual generation 
peaks by histogram analysis. 
CD4+ T cells isolated by MACS were stained with CFSE according to the protocol described by 
Quah et al. (Quah and Parish 2012). Thereafter, 2  105 CFSE-labeled CD4+ T cells were cultured 
together with titrated numbers of BMDC (1–5  104) in serum-free X-VIVOTM medium in 96-well 
plate round-bottom microtiter plates and incubated for six days at 37 °C and 5% CO2. Cell division 
capacity was assessed using an anti-CD3 antibody as positive control. At the end of the culture, 
BMDC-induced proliferation of CD4+ T cells was analyzed by flow cytometry. 
 
3.2.3.3 ELISPOT assay for detection of cytokine-secreting T cells 
Compared to conventional ELISA, the ELISPOT assay provides information about a single 
cytokine-secreting cell, but does not require the output of many cells to achieve a measurable 
protein concentration in culture supernatant. Therefore, cytokine-specific high-affinity antibodies 
are at first attached to a solid matrix. To prevent nonspecific interactions, the plates are blocked, 
and the respective cells are incubated in the antibody-coated wells upon addition of the antigen 
to stimulate the release of cytokines. Throughout a distinct period of time (2–24 hours), the 
secreted proteins bind to the antibodies located below the producer cells. After removing the cells 
by extensive washing, the immobilized proteins are recognized by a secondary biotinylated 
antibody targeting a further epitope of the cytokine. Addition of first streptavidin-conjugated 
enzyme and second colorimetric substrate yields dark precipitates (“spots”) that reflect the 
location of the cytokine-releasing cell. Hence, the number of spots correlates with the frequency 
of cytokine-producing cells and can be quantified visually or electronically (Klinman 2008). 
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Procedure:  
ELISPOT assays were performed with cells isolated from popliteal and inguinal LN of mice s.c. 
injected (3.2.1.2b) with the Dsg3 peptides (2.5.2) emulsified in adjuvant into the hind food pads 
for seven days. In order to detect the frequency of antigen-specific Th1 and Th2 cells, LN cells 
were assayed for release of their signature cytokines IFN- and IL-4, respectively. Firstly, the 
capture antibody (100 µL/well) is diluted in the ratio of 1:200 with sterile PBS and incubated 
overnight at 4 °C. After discarding the capture antibody, the membranes are washed and then 
blocked with blocking buffer (2.8) for 2 hours at RT. Prior to adding the freshly isolated LN cells 
(500,000 cells in 100 µL/well), the blocking solution is discarded and the stimulation medium (100 
µL/well) consisting of double concentrated (20 µg/mL) antigen solution added. Usage of 1.5% 
mouse serum supplemented in RPMI++ (2.8) thereby prevents xenogenic immune reactions of LN 
cells to FCS proteins. The medium alone serves as a negative control, whereas cell viability is 
controlled by application of 1% of the mitogen PHA. Cells are added in triplicates and incubated 
for 24 hours at 37 °C and 5% CO2. On the next day, cells are aspirated carefully and plates are 
washed twice with double-distilled water (ddH2O) (2.8) (200 µL/well, 3–5 min) and three times 
with washing buffer (2.8) (200 µL/well). The biotinylated detection antibody is then diluted in the 
ratio of 1:250 with dilution buffer (2.8) (100 µL/well) and incubated for 2 hours at RT. After 
discarding the detection antibody solution, plates are washed with washing buffer (200 µL/well, 
1–2 min) and the enzyme conjugate streptavidin–HRP is diluted in the ratio of 1:100 in dilution 
buffer (100 µL/well) and incubated for 1 hour at RT. To remove unbound conjugate, plates are 
washed four times with washing buffer (200 µL/well, 1–2 min) and twice with PBS (200 µL/well). 
For development of the spots the substrate solution (2.8) is added (100 µL/well) and incubated 
for 60 min. The enzymatic reaction is abolished by washing with ddH2O (200 µL) twice and plates 
are subsequently dried overnight at RT in a dark environment. The number of spots is quantified 
using automatic analyzing software and the frequency of antigen-specific cells is determined by 
the median of the respective triplicate samples. Finally, the number of spots of the unstimulated 
controls is deducted from the spot numbers of the samples stimulated with antigen. 
 
3.2.3.4 Statistics 
Statistical evaluation of the data obtained from ELISPOT analysis was performed using GraphPad 
Prism© software (2.13). For comparison of a variable between two groups of a small sample size 
that are not related to each other, a nonparametric two-tailed test for comparison of unpaired 
sample sizes (Mann-Whitney-U) was selected. Differences were considered significant for p 
0.05. 
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4 Results 
 
4.1 Human study 
4.1.1 Patient characteristics 
In the first part of this thesis, cellular and humoral immune responses, including APC, CD4+ T 
cells, plasma cytokines, and the auto-ab response were characterized in pemphigus patients and 
controls. The cohort of pemphigus patients participating in this cross-sectional study was 
comprised of 34 test subjects as described in 3.1.1, whereas data was mainly derived from a 
group of twelve selected patients as listed in Table 3.1. This clinically well characterized group 
was composed of nine PV patients, the most common subtype of pemphigus with auto-ab reactive 
against Dsg3 and occasionally Dsg1, as well as three PF patients with exclusively Dsg1-
responsive auto-ab. Since the pathoimmunological mechanisms of these two subtypes are 
believed to not critically differ from each other, results and conclusions presented in this study 
relate to the pathogenesis of pemphigus in general. The selected pemphigus patients fulfilled the 
inclusion criteria of a physiological blood analysis concerning quantities of leukocytes, monocytes, 
and lymphocytes as established by the Department of Laboratory Medicine and 
Pathobiochemistry, Molecular Diagnostics, Philipps-University, Marburg. In addition, the daily 
intake of glucocorticoids for medical treatment of pemphigus patients was determined to not 
exceed 10 mg since systemic immunosuppressive therapy with Pred significantly influenced the 
composition of blood leukocyte populations in a dose-dependent manner as clearly illustrated in 
Figure 4.13. Consequently, the number of test subjects chosen for profound investigations 
needed to be limited. In pemphigus patients, immune responses, such as the polarization of CD4+ 
T cell subpopulations (Rizzo et al. 2005) or IgG subclasses of auto-ab (Zhu et al. 2012) have 
been shown to be specific for the individual state of disease. Therefore, pemphigus patients were 
categorized according to either active or remittent stage of disease as defined by Murrell et al. 
2008. Active test subjects consisted of patients with acute exacerbation of disease, as well as 
chronic appearance of lesions that did not heal spontaneously within one week. Remittent test 
subjects were classified according to partial remission (PR) off therapy, in which transient new 
lesions healed spontaneously within one week in the absence of systemic therapy for at least two 
months, and complete remission (CR) off therapy, in which new or established lesions where 
absent without systemic therapy for at least two months. The study cohort embraced nine active 
pemphigus patients, as well as two completely remittent and one partially remittent patient off 
therapy. The IgG antibody titers against Dsg1 and Dsg3 detected in the sera of pemphigus 
patients were elevated to a varying extent in patients with active disease, whilst remittent patients 
did not display auto-ab production beyond background level. As an autoimmune disorder primarily 
affecting the elderly, pemphigus patients averaged 54 years. Furthermore, the male–female ratio 
amounted four to eight. 
In order to specify the findings obtained in this study for pemphigus, 31 patients with MG that 
clinically presents with fluctuating muscle weakness were selected as control test subjects for a 
further unrelated auto-ab–mediated disorder that specifically targets tissues or organs. Analogous 
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to pemphigus patients, twelve MG patients following the inclusion criteria of physiological 
circulating leukocyte, monocyte, and lymphocyte counts, as well as daily systemic therapy with 
glucocorticoids below 10 mg were chosen for comprehensive analysis as presented in Table 3.2. 
In contrast to pemphigus patients who were grouped according to active and remittent stage of 
disease, MG patients were afflicted with very mild to moderate disease or did not exhibit clinical 
symptoms at all. The MG control cohort comprised three asymptomatic patients, four patients 
suffering from mild disease, whereas two and three patients presented with mild to moderate 
disease, respectively. Serum samples from MG patients displayed IgG reactivity against nicotinic 
AChR located in the neuromuscular junctions of somatic muscles, as well as titin that is found in 
striated muscle tissue. Unlike pemphigus patients, IgG auto-ab titers of the cohort of MG patients 
did not relate to disease activity. MG patients averaged 57 years, which was comparable to 
pemphigus patients and the number of males and females was evenly balanced. 
 
The third study group was composed of 32 HC that were matched according to gender and age 
of pemphigus patients and did not display any signs of autoimmune inflammation. Compared to 
pemphigus patients, average age of the twelve selected HC was slightly reduced and amounted 
50 years. 
 
4.1.2 Phenotypic characterization of APC in whole blood of pemphigus patients 
In the pathogenesis of pemphigus, the role of APC, including populations of monocytes and DC 
has not yet been elucidated. As potent inducers of CD4+ T cell activation, DC have been shown 
to be critically involved in the pathogenesis of several autoimmune disorders, such as SLE, TID, 
and psoriasis (Ganguly et al. 2013). Similarly, alterations in the distribution of distinct monocyte 
subsets have been mostly implicated in RA and IBD (Wong et al. 2012). Since the major 
autoantigens of pemphigus, the desmosomal cadherins Dsg3 and Dsg1 are expressed by 
keratinocytes in the suprabasilar layer of the epidermis, aberrant APC function is suspected to 
mainly reflect in the intricate network of the skin DC subsets. For reasons of practical feasibility 
however, both qualitative and quantitative analysis of APC populations was confined to those 
found in peripheral blood being yet interconnected with their skin counterparts. Assessment of 
cell type-specific surface markers, as well as markers for activation and migration of APC was 
performed using flow cytometry analysis according to the procedure described in 3.1.3.5. 
Human DC comprise two major phenotypically and functionally different classes, the mDC and 
pDC that may represent the precursors of the DC localized to tissues and secondary lymphoid 
organs (Collin, McGovern, and Haniffa 2013). To date, four different populations of human DC 
are generally acknowledged to be present in the blood circulation, to which the CD1c+ (BDCA-1+) 
DC (mDC type 1), CD141+ (BDCA-3+) DC (mDC type 2), pDC, and CD16+ DC belong (Kim and 
Diamond 2015). Opposed to CD1c+ DC and CD141+ DC, CD16+ DC are lacking in tissues and 
resemble monocytes (Randolph et al. 2002). In this study, CD1c+ DC being the more frequent 
mDC subtype and CD141+ DC were identified together as mDC based on the simplified pattern 
of high expression of the integrin CD11c and absence of CD14 (CD14-CD11c++) (Kim and 
Diamond 2015) as illustrated in Figure 4.2a. With regard to morphological characteristics, 
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analysis of FSC and SSC determining cell size and granularity, respectively, confirmed mDC 
being localized between the populations of lymphocytes and monocytes as demonstrated in 
Figure 4.2b. 
 
 
 
Figure 4.1: Preselected cell populations for phenotypic analysis of antigen-presenting cells. 
In order to phenotypically characterize circulating antigen-presenting cell (APC) populations by flow 
cytometry, whole blood of patients was prepared and stained with fluorescently labeled antibodies. Upon 
analysis, viable leukocytes were at first segregated from cell debris, platelets, and remaining erythrocytes 
based on cellular morphology as determined by forward scatter (FSC) and side scatter (SSC) (a). For 
quantitative assessment of APC subsets, granulocytes were excluded from the selected populations of 
primarily smaller lymphocytes and large monocytes, and 200,000 single events were detected (b). 
Leukocyte, lymphocyte, and monocyte counts were confirmed to be within the specified physiological range 
as determined by blood analysis. 
 
 
 
Figure 4.2: Gating strategy of myeloid dendritic cells (CD14-CD11c++). 
Upon incubation with both an anti-human CD14 antibody and anti-human CD11c antibody labeled with PE 
and FITC, respectively, the population of myeloid dendritic cells (mDC) clearly segregated as cells negative 
for CD14 and high in expression of CD11c. Monocytes were separated by expression of both CD14 and 
CD11c, and cells lacking CD14, but displaying low levels of CD11c represented T and B lymphocytes, as 
well as NK cells (a). As shown by forward scatter (FSC) and side scatter (SSC) analysis of cellular size and 
granularity, respectively, mDC (blue) typically scattered between lymphocyte and monocyte populations 
(both red) (b). Separation of cell populations was performed using the appropriate isotype controls. 
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In addition, the subset of pDC was identified by expression of the cell type-specific marker CD303 
(BDCA-2), whereas it represents the only circulating DC subset that is typically absent of CD11c 
(CD11c-CD303+) as presented in Figure 4.3a. The recently identified subset of slanDC within the 
heterogeneous population of blood CD16+CD14- inflammatory monocytes was shown to be 
present in the inflammatory infiltrate in psoriasis, RA, and IBD (Schakel et al. 2002; Schakel 
2009). As visualized in Figure 4.4, the population of slanDC was determined by characteristic 
expression of CD16 (FcR-III), HLA-DR, and the costimulatory molecule CD86 (CD14-CD16+HLA-
DR+/CD86+). Analogous to all circulating DC subsets, they are negative for Lin markers, including 
CD14 (Kim and Diamond 2015). In contrast to blood DC populations, monocyte-derived DC 
positive for CD14 are observed only under inflammatory conditions and mainly locate to 
cutaneous tissues (Kim and Diamond 2015). 
 
 
 
Figure 4.3: Gating strategy of plasmacytoid dendritic cells (CD11c-CD303+). 
Addition of both an anti-human CD11c antibody and anti-human CD303 antibody conjugated to FITC and 
APC, respectively, yielded a clearly distinguished population of plasmacytoid dendritic cells (pDC) devoid of 
CD11c, but high in expression of CD303. Neutrophils also exhibiting surface expression of CD303 were 
excluded from analysis as shown in Figure 4.1, as well as CD303+ macrophages separating by additional 
expression of CD11c (a). Forward scatter (FSC) and side scatter (SSC) analysis of pDC (blue) confirmed 
their morphological localization adjacent to subsets of lymphocytes and monocytes (both red) (b). Separation 
of cell populations was performed using the appropriate isotype controls. 
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Figure 4.4: Gating strategy of 6-sulfo LacNAc dendritic cells (CD14-CD16+HLA-DR+/CD86+). 
Characterization of 6-sulfo LacNAc dendritic cells (slanDC) by independent staining of cells lacking surface 
expression of CD14 and expressing Fc receptor-III (FcR-III, CD16) with either HLA-DR (a and b) or CD86. 
NK cells being also positive for CD16 and devoid of CD14 were segregated by lack of CD86 expression (d 
and e). Forward scatter (FSC) and side scatter (SSC) analysis assigned slanDC (blue) morphology between 
subsets of lymphocytes and monocytes (both red) (c and f). Separation of cell populations was performed 
using the appropriate isotype controls. 
 
 
Besides circulating DC populations, peripheral blood of pemphigus, MG patients, and HC was 
further analyzed for alterations in the monocyte compartment. Monocytes represent a leukocyte 
population with augmented cell size and granularity. Besides expression of CD14 being part of 
the LPS multireceptor complex (Brubaker et al. 2015b), monocytes are positive for the myeloid 
phenotype marker CD11c, a feature shared with mDC (Auffray, Sieweke, and Geissmann 2009) 
as presented in Figure 4.5. Human blood monocytes are heterogeneous and conventionally 
comprise two major subsets segregated by differential expression of CD16, the designated 
classical CD16- and CD16+ monocytes (Wong et al. 2012) as visualized in Figure 4.6c. Classical 
monocytes account for the majority, i.e. 80% to 90% of circulating monocytes (Auffray, Sieweke, 
and Geissmann 2009). CD16+ monocytes have been shown to produce TNF-α upon stimulation 
with LPS and they are found in larger numbers in the blood of patients with acute inflammation 
and infectious diseases (Auffray, Sieweke, and Geissmann 2009). According to a recent 
nomenclature, CD16+ monocytes can be further subdivided into two functionally and 
phenotypically different subsets on the basis of relative expression of CD14 (Wong et al. 2012) 
as demonstrated in Figure 4.6c. 
In order to study the migratory behavior of APC, expression of CCR2 was additionally determined 
on both mDC and CD14+ monocytes based on geometrical mean values of the anti-CCR2 
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antibody signal intensity as presented in Figure 4.7. Classical monocytes and mDC are subject 
to the axis of CCL2-CCR2 that enables these cells to exit the blood stream and access peripheral 
nonlymphoid tissues, such as the skin in the state of inflammation (Auffray, Sieweke, and 
Geissmann 2009). 
 
 
 
Figure 4.5: Gating strategy of monocytes (CD14+CD11c+). 
Binding of both an anti-human CD14 PE-coupled antibody and anti-human CD11c FITC-coupled antibody 
segregated circulating monocytes from DC subsets positive for CD11c, but devoid of CD14. Separation of 
cell subsets was done using the appropriate isotype controls. 
 
 
 
Figure 4.6: Gating strategy of classical (CD14+CD16-) and CD14+CD16+ monocytes. 
Monocytes were selected based on forward scatter (FSC) and side scatter (SSC) analysis since they 
represent a morphologically distinct population with increased cell size and granularity compared to 
lymphocytes (a). Upon addition of an anti-human CD14 FITC-labeled antibody and an anti-human CD16 
APC-labeled antibody, a subset positive for CD14 was segregated with differential expression of CD16. Cells 
negative for both CD14 and CD16 may represent myeloid dendritic cells (b). Analysis of cells with CD14 
expression yielded two populations that comprise monocytes devoid of CD16 and CD16+ monocytes partly 
displaying high expression of CD16. CD16+ monocytes were further categorized according to diminished 
and high expression of CD14, referred to as nonclassical (CD14dimCD16+) and intermediate CD14+CD16+ 
monocytes (c). Separation of cell populations was performed using the appropriate isotype controls. 
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Figure 4.7: CCR2 expression of monocytes. 
In order to quantify the expression level of C-C chemokine receptor 2 (CCR2) on circulating monocytes in 
patients’ whole blood using flow cytometry, leukocytes were at first preselected as illustrated in Figure 4.1. 
Incubation with both an anti-human CD14 PE-coupled antibody and anti-human CD11c FITC-coupled 
antibody identified CD14+CD11c+ blood monocytes (a). Monocytes were additionally stained with an anti-
human CCR2 antibody coupled to APC. Cell surface expression of CCR2 was determined by geometrical 
mean values of the antibody signal intensity (b). Gates were set according to the appropriate isotype 
controls. 
 
 
Taken together, in order to assess whether an ongoing autoimmune response in active 
pemphigus shows in alterations within the APC compartment, we both phenotypically and 
functionally characterized populations of DC and monocytes in peripheral blood of both 
pemphigus patients and control groups. At first, we determined the frequencies of the main 
subsets of circulating DC, including mDC and pDC, as well as slanDC. In addition, we assessed 
the number of peripheral classical and CD16+ monocytes, of which the latter was further 
subdivided into two subsets. Moreover, we analyzed expression of the activation markers HLA-
DR and CD86 of slanDC, as well as the migration marker CCR2 of mDC and CD14+ monocytes. 
 
Compared to HC, the population of circulating mDC was slightly decreased (p= 0.0875) in blood 
of active pemphigus patients, whereas in MG patients, increasing (p= 0.2113) frequencies of mDC 
could be observed (Figure 4.8a). Similarly, active pemphigus patients displayed slightly reduced 
(p= 0.1140) and MG patients slightly elevated (p= 0.2987) populations of pDC (Figure 4.8b). The 
subsets of blood slanDC however did not vary (p= 0.9445, CD14-CD16+HLA-DR+ and p= 0.8831, 
CD14-CD16+CD86+) between active pemphigus patients and HC, but were again significantly 
augmented (p= 0.0083) for CD14-CD16+CD86+ cells and slightly augmented (p= 0.2751) for 
CD14-CD16+HLA-DR+ cells in MG patients (Figure 4.9). As mDC frequencies significantly differed 
(p= 0.0180) between active pemphigus and MG patients, a disease-related alteration in the mDC 
population of pemphigus patients can be suggested (Figure 4.8a). A similar effect of reduced 
frequencies of both pDC (p= 0.0075) (Figure 4.8b) and slanDC (p= 0.3541, CD14-CD16+HLA-
DR+ and p= 0.0239, CD14-CD16+CD86+) (Figure 4.9) was also observed in active pemphigus 
patients compared to MG controls. 
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Figure 4.8: Reduced population of mDC and pDC in active pemphigus patients compared to 
myasthenia gravis controls. 
Active pemphigus patients (act. P, n= 9) displayed a slightly reduced (p= 0.0875) subset of blood myeloid 
dendritic cells (mDC), whilst myasthenia gravis patients (MG, n= 12) exhibited increased frequencies (p= 
0.2113) of mDC compared to healthy controls (HC, n= 32). In addition, mDC significantly differed (p= 0.0180) 
between act. P and MG patients, pointing to a disease-related alteration in the mDC population of pemphigus 
patients (a). Similarly, plasmacytoid DC (pDC) were decreased (p= 0.1140) in act. P patients compared to 
HC, but slightly elevated (p= 0.2987) in MG patients. Compared to MG controls, act. P patients displayed a 
significantly reduced (p= 0.0075) population of pDC (b). Rem. P, remittent pemphigus patients. Statistical 
analysis was carried out using Mann-Whitney U test with p values indicated as *p< 0.05 and **p 0.01. 
 
 
 
Figure 4.9: Reduced population of CD14-CD16+CD86+ slanDC in active pemphigus patients compared 
to myasthenia gravis controls. 
The subset of circulating 6-sulfo LacNAc dendritic cells (slanDC) was detected by flow cytometry analysis 
by a combination of two blood samples. Between active pemphigus patients (act. P, n= 9) and healthy 
controls (HC, n= 32), the population sizes of CD14-CD16+HLA-DR+ cells (p= 0.9445, a) and CD14-
CD16+CD86+ cells (p= 0.8831, b) did not differ, yet were significantly elevated (p= 0.0083, b) for CD14-
CD16+CD86+ cells and slightly elevated (p= 0.2751, a) for CD14-CD16+HLA-DR+ cells in myasthenia gravis 
patients (MG, n= 12). Moreover, act. P patients exhibited reduced frequencies of CD14-CD16+HLA-DR+ cells 
(p= 0.3541, a) and CD14-CD16+CD86+ cells (p= 0.0239, b) compared to MG controls. Rem. P, remittent 
pemphigus patients. Statistical analysis was carried out using Mann-Whitney U test with p values indicated 
as *p< 0.05 and **p 0.01. 
 
 
In active pemphigus patients, decreased population sizes of circulating mDC could be a sign for 
enhanced migration from the blood stream possibly into the inflamed skin, for which reason we 
additionally assessed expression of the migratory receptor CCR2 of mDC. Indeed, compared to 
HC, we could detect a significantly upregulated (p= 0.0239) expression of CCR2 on mDC in acute 
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pemphigus patients (Figure 4.11a). Because of the misguided excessive immune responses in 
pemphigus, we also expected an upregulation of the activation markers HLA-DR and CD86 of 
slanDC. However, increased expression of neither HLA-DR nor CD86 as a sign for enhanced DC 
activation could be detected in active pemphigus patients compared to HC (Figure 4.12). 
Apart from that, concerning the monocyte compartment, we could observe increased frequencies 
of CD16+ monocytes in active pemphigus (p= 0.0399), as well as MG patients (p= 0.0087) 
compared to HC (Figure 4.10a). Therefore, these findings could rather reflect an effect unrelated 
to pemphigus, but characteristic for a general state of inflammation. Furthermore, the recently 
identified subset of nonclassical monocytes within the population of CD16+ monocytes was 
elevated in active pemphigus patients with significance close to the threshold (p= 0.0596) (Figure 
4.10b). Moreover and analogous to mDC, we additionally tested for altered CCR2 expression of 
CD14+ monocytes to examine their migratory behavior. Similarly, CD14+ monocytes of both active 
pemphigus (p= 0.0166) and MG patients (p= 0.0083) displayed a significantly upregulated 
expression of CCR2 compared to HC (Figure 4.11b). 
 
 
 
Figure 4.10: Elevated subset of CD14+CD16+ monocytes in active pemphigus patients compared to 
healthy controls. 
Both active pemphigus (act. P, n= 9; p= 0.0399) and myasthenia gravis patients (MG, n= 12; p= 0.0087) 
showed significantly increased frequencies of CD16+ monocytes compared to healthy controls (HC, n= 32) 
(a). Concerning the nonclassical subtype within CD16+ monocytes, act. P patients displayed elevated 
frequencies (p= 0.0596) compared to HC (b). Rem. P, remittent pemphigus patients. Statistical analysis was 
carried out using Mann-Whitney U test with p values indicated as *p< 0.05 and **p 0.01. 
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Figure 4.11: Augmented expression of CCR2 on myeloid dendritic cells and CD14+ monocytes in 
active pemphigus patients compared to healthy controls. 
Compared to healthy controls (HC, n= 32), C-C chemokine receptor 2 (CCR2) expression of myeloid 
dendritic cells (mDC) was significantly (p= 0.0239) elevated in active pemphigus (act. P, n= 9) and slightly 
elevated (p= 0.0526) in myasthenia gravis patients (MG, n= 12) (a). Moreover, CCR2 expression on CD14+ 
monocytes was enhanced in both act. P (p= 0.0166) and MG patients (p= 0.0083) compared to HC (b). 
Rem. P, remittent pemphigus patients. Statistical analysis was carried out using Mann-Whitney U test with 
p values indicated as *p< 0.05 and **p 0.01. 
 
 
 
 
 
Figure 4.12: No differential expression of both HLA-DR and CD86 of slanDC in active pemphigus 
patients. 
Compared to healthy controls (HC, n= 32), active pemphigus patients (act. P, n= 9) displayed neither an 
enhanced expression of HLA-DR (a) nor CD86 on circulating 6-sulfo LacNAc dendritic cells (slanDC) (b). 
MG, myasthenia gravis patients; rem. P, remittent pemphigus patients. Statistical analysis was carried out 
using Mann-Whitney U test. 
 
 
Furthermore, we assessed the impact of immunosuppressive treatment with Pred on circulating 
leukocyte populations of both pemphigus and MG patients. As clearly demonstrate in Figure 4.13, 
application of Pred resulted in a drastic reduction of mDC subsets in both pemphigus and MG 
patients depending on the respective dosage given. Consequently, as described in 4.1.1 test 
subjects exceeding a daily intake of 10 mg of Pred were excluded from analysis. 
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Figure 4.13: Relationship of systemic treatment with prednisolone and myeloid dendritic cell 
population sizes from both pemphigus and myasthenia gravis patients. 
Both pemphigus (n= 34, a) and myasthenia gravis patients (n= 31, b) displayed shrinking myeloid dendritic 
cell (CD14-CD11c++) subsets with increasing dosages of prednisolone administered. As a consequence, 
patients with a daily intake of more than 10 mg of Pred were excluded from analysis. Statistical analysis was 
carried out using Mann-Whitney U test with p values indicated as **p 0.01. 
 
 
Taken together, active pemphigus patients displayed a reduced subset of mDC and pDC 
concurrent with an elevated CCR2 expression of mDC, hinting at an enhanced migration of mDC 
into the inflamed skin. In addition, blood CD16+ monocytes and nonclassical CD14dimCD16+ 
monocytes were increased in active pemphigus patients who also displayed augmented CCR2 
expression of CD14+ monocytes. 
 
4.1.3 Functional characterization of APC from pemphigus patients 
4.1.3.1 Cytokine production of monocytes upon stimulation with LPS 
Besides their phenotypic analysis, circulating APC were also assayed for functional alterations, 
including the capability to produce (3.1.3.6) and secrete (3.1.2.2) distinct cytokines, as well as the 
capability to take up antigen as described in 3.1.3.8. For this purpose, PBMC were isolated from 
peripheral blood of pemphigus patients and control groups by density gradient centrifugation as 
presented in 3.1.3.1. 
In order to assess the capacity of CD14+ monocytes to produce the proinflammatory cytokines IL-
6 and TNF-α, monocytes were stimulated overnight with bacterial LPS (3.1.3.6), the best-
described ligand of TLR4 (Brubaker et al. 2015a). Produced cytokines were detected by flow 
cytometry analysis of intracellularly stained proteins with fluorescently labeled antibodies as 
described in 3.1.3.7 and illustrated in Figure 4.14. As shown in Figure 4.15a and b, neither IL-6 
nor TNF-α production of CD14+ monocytes differed between the groups, but varied over a wide 
range, particularly concerning TNF-α production in active pemphigus patients. Thus, circulating 
monocytes of pemphigus patients do not seem to be in a condition of enhanced immunogenicity 
as assessed by this assay. Yet, interestingly, monocytes of active pemphigus patients produced 
IL-6 and TNF-α to the same extent (p= 0.0002) as visualized in Figure 4.15c. Moreover, only 
monocytes from four active pemphigus patients displayed the highest values of proinflammatory 
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cytokine production, which could be a sign for enhanced monocyte immunogenicity at least in 
individual pemphigus patients. 
 
 
 
Figure 4.14: Production of IL-6 and TNF-α upon stimulation of monocytes with LPS. 
The population of monocytes was selected by opposing binding of an anti-human CD14 FITC-coupled 
antibody to the autofluorescence signal of monocytes detected in a channel being not in use (a). Binding of 
an anti-human interleukin (IL)-6 PE-coupled antibody and anti-human tumor necrosis factor (TNF)-α PE-
coupled antibody, respectively, visualized cytokine synthesis of CD14+ monocytes (b and c). For 
quantification of IL-6 (b) and TNF-α (c) production of monocytes, the geometrical mean values of the 
respective antibody signal intensities were determined. Separation of cell populations was performed using 
the appropriate isotype controls. LPS, lipopolysaccharides. 
 
 
 
Figure 4.15: No differential production of both IL-6 and TNF-α of monocytes in active pemphigus 
patients. 
Production of interleukin (IL)-6 and tumor necrosis factor (TNF)-α of CD14+ monocytes stimulated with 
lipopolysaccharides (LPS) was determined by flow cytometry analysis. Neither synthesis of IL-6 (a) nor TNF-
α (b) varied between active pemphigus (act. P, n= 9) and myasthenia gravis (MG) patients (n= 12). Yet, 
compared to healthy controls (HC, n= 12) only monocytes of act. P patients synthesized IL-6 and TNF-α to 
the same extent (p= 0.0002). Moreover, four act. P patients displayed the highest values of cytokine 
production, hinting at an enhanced immunogenicity of CD14+ monocytes in at least individual pemphigus 
patients (c). Rem. P, remittent pemphigus patients. Statistical analysis was carried out using Mann-Whitney 
U test. Spearman correlation coefficients (r) are shown as p values, indicated as ***p 0.001. 
 
 
4.1.3.2 Antigen uptake capability of monocyte subsets 
The capability to take up and process antigen belongs to the most important functions of APC. In 
order to test whether this property is altered in pemphigus, PBMC from pemphigus patients and 
control groups were exposed to fluorescently labeled human Dsg3 protein (2.5.1) as described in 
3.1.3.8, and analyzed by flow cytometry as illustrated in Figure 4.16. Incubation of monocytes at 
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37 °C for various lengths of time (5 min, 10 min, and 30 min) enabled efficient antigen take up, 
whereas control samples stored at 4 °C were used for determining background activity. The 
difference in MFI between the sample stored at 37 °C and its 4 °C control reflected the uptake 
capability. 
The antigen uptake capacity of neither CD16+ (p= 0.3730, a) nor classical (p= 0.2754, b) 
monocytes significantly varied between active pemphigus patients and HC as presented in Figure 
4.18. In accordance with reports in the literature (Auffray, Sieweke, and Geissmann 2009), 
internalization capability of classical monocytes exceeded that of CD16+ monocytes and 
maximum antigen take up was achieved after ca. 30 min of protein incubation as demonstrated 
in Figure 4.17. The time point of 50% antigen take up of classical monocytes was determined to 
assess the kinetics of antigen internalization as shown in Figure 4.18c. Concerning the velocity 
of antigen take up of classical monocytes, no significant (p= 0.1687) differences were observed 
between active pemphigus patients and HC (Figure 4.18c). Taken together, neither the capability 
of maximum antigen internalization nor the speed of antigen take up were proven altered in 
pemphigus. 
 
 
 
Figure 4.16: Uptake of fluorescently labeled Dsg3 protein of CD16+ and classical monocytes. 
Antigen uptake capability of CD14+CD16+ (a) and classical (CD14+CD16-, b) monocytes within the peripheral 
mononuclear cells (PBMC) from patients’ blood was assessed by flow cytometry analysis. Internalization of 
fluorescently labeled human Desmoglein 3 (huDsg3) was measured at various lengths of time (5 min, 10 
min, and 30 min) for PBMC stored at 37 °C and on ice as a control. As illustrated by histogram presentation, 
the difference in mean fluorescence intensity between the sample stored at 37 °C (bright line) and its control 
(dark line) determined the monocytes uptake capability. Shown is the antigen uptake of CD16+ monocytes 
and classical monocytes upon incubation of huDsg3 for 10 min. 
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Figure 4.17: Kinetics of antigen uptake of CD16+ and classical monocytes. 
Internalization of fluorescently labeled human Desmoglein 3 (huDsg3) protein of CD16+ and classical 
monocytes was analyzed by flow cytometry. The capability of antigen uptake of CD16+ monocytes (bright 
line) and classical monocytes (dark line) was assessed after 5 min, 10 min, 30 min, and 60 min of protein 
incubation. Maximum uptake of antigen was reached following ca. 30 min of protein exposure. Capacity of 
classical monocytes to internalize protein clearly exceeded that of CD16+ monocytes. ΔMFI huDsg3 
describes the difference in mean fluorescence intensity (MFI) between the sample stored at 37 °C and its 4 
°C control upon incubation with huDsg3 protein, and determines the monocyte uptake capability. 
 
 
 
Figure 4.18: Uptake of fluorescently labeled Dsg3 protein of monocytes from active pemphigus 
patients. 
Maximum uptake of fluorescently labeled human Desmoglein 3 (huDsg3) protein of CD16+ and classical 
monocytes from patients’ blood was analyzed by flow cytometry. Following 30 min of protein incubation, 
neither the antigen uptake capability of CD16+ (a) nor classical (b) monocytes differed between active 
pemphigus patients (act. P, n= 12) and healthy controls (HC, n= 12). Similarly, no differences in the velocity 
of protein internalization were observed between act. P patients and HC (c). Rem. P, remittent pemphigus 
patients. ΔMFI huDsg3 describes the difference in mean fluorescence intensity (MFI) between the sample 
stored at 37 °C and its 4 °C control upon incubation with huDsg3 protein, and determines the monocyte 
uptake capability. Time0.5 max uptake reflects the time span until half of the maximum protein internalization 
capacity was reached. Statistical analysis was carried out using Mann-Whitney U test. 
 
 
4.1.3.3 Detection of cytokines derived from APC in plasma 
Owing to their capacity to mediate T cell function, cytokines are critically involved in the 
pathogenesis of pemphigus (Giordano and Sinha 2012). Yet, to date, the role of disease-
propagating cytokines in pemphigus has not been fully elucidated. Therefore, cytokines related 
to both APC and T cells, including IL-6, TNF-α, IL-33, and IL-27 were analyzed in the plasma of 
pemphigus patients and control groups as described in 3.1.2.2. 
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As presented in Figure 4.19a, the plasma levels of IL-6 tended to be increased in both active 
pemphigus (p= 0.1211) and MG patients (p= 0.0543). Similarly, the plasma levels of TNF-α were 
significantly and visibly elevated in active pemphigus (p= 0.0259) and MG patients (p= 0.0907), 
respectively, as shown in Figure 4.19b. 
 
 
 
Figure 4.19: Plasma concentrations of IL-6 and TNF-α in pemphigus patients and controls. 
Both active pemphigus (act. P, n= 9; p= 0.1211) and myasthenia gravis (MG) patients (n= 12; p= 0.0543) 
displayed elevated plasma concentrations of interleukin (IL)-6 compared to healthy controls (HC, n= 12). 
The plasma of remittent pemphigus (rem. P) patients did not exhibit detectable amounts of IL-6 (a). 
Compared to HC (n= 12), both act. P (n= 9; p= 0.0259) and MG patients (n= 12; p= 0.0907) exhibited 
elevated plasma concentrations of tumor necrosis factor (TNF)-α with act. P patients reaching statistical 
significance. Similar to IL-6, the plasma levels of TNF-α of the three rem. P patients were below the detection 
limit (b). Statistical analysis was carried out using Mann-Whitney U test with p values indicated as *p< 0.05. 
 
 
As demonstrated in Figure 4.20a, the plasma concentrations of IL-33 were also slightly 
augmented in both active pemphigus (p= 0.1687) and MG patients (p= 0.1171). Strikingly, the 
immunomodulatory IL-27 was significantly increased in active pemphigus (p= 0.0136) and MG 
patients (p= 0.0326) compared to HC as presented in Figure 4.20b. Of note, the three remittent 
pemphigus patients displayed very low values for each cytokine measured (Figures 4.19 and 
4.20). 
 
To summarize, active pemphigus patients exhibited elevated plasma levels of the 
proinflammatory cytokines IL-6 and TNF-α, as well as IL-27. 
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Figure 4.20: Plasma concentrations of IL-33 and IL-27 in pemphigus patients and controls. 
The plasma levels of interleukin (IL)-33 tended to be enhanced in both active pemphigus (act. P, n= 9; p= 
0.1687) and myasthenia gravis (MG) patients (n= 12; p= 0.1171) compared to healthy controls (HC, n= 12). 
The plasma samples of the three remittent pemphigus (rem. P) patients did not exhibit detectable amounts 
of IL-33 (a). Intriguingly, concentrations of IL-27 were significantly elevated in the plasma of both act. P. (n= 
9; p= 0.0136) and MG patients (n= 12; p= 0.0326) despite the primarily immunomodulatory function of IL-
27. In addition, the plasma levels of IL-27 of the three rem P. patients were below the detection limit (b). 
Statistical analysis was carried out using Mann-Whitney U test with p values indicated as *p< 0.05. 
 
 
4.1.4 Functional characterization of CD4+ T cell subpopulations in pemphigus 
patients 
In the pathogenesis of pemphigus, the generation of auto-ab is critically regulated by autoreactive 
CD4+ T cells specific for Dsg3 and/or Dsg1 as demonstrated by numerous studies (Amagai 2008; 
Hertl, Eming, and Veldman 2006). Based on the found enhanced production of APC-derived 
proinflammatory cytokines, including IL-6, TNF-α, and IL-27, we next assessed whether the 
polarization of CD4+ T cells is altered. For this purpose, PBMC were isolated from peripheral 
blood of pemphigus patients and control groups by density gradient centrifugation as described 
in 3.1.3.1. In order to induce synthesis of the Th1, Th2, Th17, and Treg cell signature cytokines 
IFN-, IL-4, IL-17, and IL-10, respectively, PBMC were stimulated with the mitogens PMA and 
ionomycin in the presence of a secretion inhibitor as presented in 3.1.3.6. As described in 3.1.3.7 
and illustrated in Figure 4.22, production of cytokines was detected by flow cytometry analysis of 
the respective fluorescently labeled antibodies targeting intracellular proteins. 
Since surface expression of CD4 is downregulated upon activation (Pelchen-Matthews, Parsons, 
and Marsh 1993 ), CD4+ T cells were identified by expression of CD3 and lack of CD8 as 
visualized in Figure 4.21. 
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Figure 4.21: Identification of CD4+ T cells by flow cytometry. 
Staining of CD4+ cells with either an anti-CD4 PE-coupled antibody (45.1% CD4+ T cells, a) or the 
combination of an anti-CD3 PE-coupled and anti-CD8 FITC-coupled antibody (47.0% CD3+CD8- cells, b) 
yielded similar population sizes. Separation of cell populations was performed using the appropriate isotype 
controls. FSC, forward scatter. 
 
 
 
Figure 4.22: Detection of intracellular cytokines of CD4+ T cells by flow cytometry. 
CD4+ T cells within patients’ peripheral blood mononuclear cells were stimulated with phorbol myristate-
acetate and ionomycin for 5 hours to induce synthesis of the T helper (Th) 1, Th2, Th17, and T regulatory 
cell signature cytokines interferon (IFN)- (a), interleukin (IL)-4 (b), IL-17 (c), and IL-10 (d), respectively. 
Cytokine production of CD3+CD8- cells was detected by flow cytometry analysis of fluorescently labeled 
antibodies targeting intracellular proteins. Separation of cell populations was performed using the 
appropriate isotype controls. SSC, side scatter. 
71 
 
In active pemphigus patients, a general shift towards a more pronounced Th1 (p= 0.9047) or Th2 
(p= 0.7974) cell response, defined by the frequencies of IFN-– and IL-4–producing T cells, 
respectively, could not be observed compared to HC as presented in Figure 4.23a and b. Thus, 
the Th2-biased T cell response in pemphigus seems to be rather confined to single autoreactive 
Dsg3-specific CD4+ T cells as shown by several studies (Veldman et al. 2003b). Interestingly, IL-
17–producing CD4+ T cells were elevated in both active pemphigus (p= 0.0003) and MG patients 
(p= 0.0200) as demonstrated in Figure 4.23c. Moreover, IL-10–producing T cells were 
significantly increased (p= 0.0278) in active pemphigus patients, whilst in MG patients, their 
frequency was reduced (p= 0.0283) compared to HC (Figure 4.23d). Taken together, active 
pemphigus patients did not display differing Th1 and Th2 cell responses, but elevated populations 
of both Th17 cells and IL-10–producing T cells. 
 
 
 
Figure 4.23: CD4+ T cell subpopulations in active pemphigus patients. 
Active pemphigus patients (act. P, n= 9) did not display a general imbalance of T helper (Th) 1 (p= 0.9047, 
a) and Th2 cells (p= 0.7974, b) compared to healthy controls (HC, n= 12). However, act. P patients showed 
significantly increased (p= 0.0003) populations of Th17 cells, which was also observed in myasthenia gravis 
(MG) controls (n= 12; p= 0.0200) (c). Unexpectedly, act. P patients similarly exhibited elevated (p= 0.0278) 
frequencies of interleukin (IL)-10–producing T cells, whereas in MG patients, their frequency was 
significantly reduced (p= 0.0283) (d). Since IL-10 is also secreted by Th2 cells, IL-10–producing cells do not 
only represent T regulatory cells. IFN-, interferon-; rem. P, remittent pemphigus patients. Statistical 
analysis was carried out using Mann-Whitney U test with p values indicated as *p< 0.05 and ***p 0.001. 
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4.1.5 Characterization of auto-ab responses in pemphigus patients 
Purpose of this study was to characterize immune responses in pemphigus in a phenotypical and 
functional manner. So far, we have found particularities in the cellular immune response of active 
pemphigus patients, including qualitative and quantitative alterations in the APC compartment, 
differing cytokine expression patterns, as well as imbalances between CD4+ T cell 
subpopulations. Concerning APC behavior, frequencies of both mDC and pDC were slightly 
reduced in active pemphigus patients (Figure 4.8) concurrent with significantly enhanced CCR2 
expression of mDC (Figure 4.11a). Similarly, active pemphigus patients exhibited significantly 
elevated CCR2 expression levels of CD14+ monocytes (Figure 4.11b), suggesting an increased 
migration of APC potentially into the inflamed skin. In addition, frequencies of CD16+ monocytes 
(Figure 4.10a) and nonclassical CD14dimCD16+ monocytes (Figure 4.10b) were augmented in 
both active pemphigus patients and MG controls. Moreover, active pemphigus patients displayed 
slightly and significantly elevated plasma levels of the proinflammatory cytokines IL-6 (Figure 
4.19a) and TNF-α (Figure 4.19b), respectively. Interestingly, significantly increased levels of the 
immunomodulatory IL-27 reflect its disease-promoting function in pemphigus (Figure 4.20b), 
whereas the plasma levels of the Th2 cell-related IL-33 were only slightly enhanced in active 
pemphigus patients (Figure 4.20a). Considering CD4+ T cell subpopulations, active pemphigus 
patents displayed both significantly elevated frequencies of Th17 cells (Figure 4.23c) and IL-10–
producing T cells compared to HC (Figure 4.23d). 
In pemphigus, the titers of serum anti-Dsg1 and anti-Dsg3 IgG auto-ab generally correlate with 
disease activity when monitored in individual patients (Ishii et al. 1997). Similarly, in our cohort of 
PV patients, increased Dsg3-reactive IgG auto-ab titers varied within a wide range and were 
predominantly exhibited by active, but not remittent PV patients as presented in Figure 4.24. 
 
 
 
Figure 4.24: Dsg3-specific antibody titer of active and remittent pemphigus vulgaris patients. 
Titers of anti-Desmoglein 3 (Dsg3) immunoglobulin (Ig) G antibodies were determined in the sera of 
pemphigus vulgaris (PV) patients by enzyme-linked immunosorbent assay. In contrast to remittent (rem.) 
PV patients (n= 4), patients with active disease (act. PV, n= 23) displayed anti-Dsg3 IgG reactivity that varied 
within a wide range. The cut-off value of the assay was 20 RE/mL. 
 
 
In order to investigate the relationship between APC, APC-derived cytokines, CD4+ T cells, and 
antibody production in pemphigus, Dsg1- and Dsg3-specific IgG auto-ab titers were correlated 
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with the respective parameters assessed in this study. As a main result and as demonstrated in 
Figure 4.25, the anti-Dsg1 IgG levels from PF patients combined with the anti-Dsg3 IgG levels 
from PV patients correlated (r= 0.6683) with the plasma levels of IL-6. Accordingly, anti-Dsg3 IgG 
levels from PV patients alone as well correlated (r= 0.6967) with the IL-6 plasma concentrations. 
In contrast, anti-AChR IgG titers from MG controls did not correlate (r= -0.1507) with the plasma 
levels of IL-6. 
 
 
 
 
Figure 4.25: Correlation of auto-ab titers with IL-6 plasma levels in pemphigus and myasthenia gravis 
patients. 
Anti-Desmoglein 1 (Dsg1) immunoglobulin (Ig) G levels and anti-Dsg3 IgG levels were determined in the 
sera from pemphigus foliaceus (PF, n= 3) and pemphigus vulgaris (PV) patients (n= 9) by enzyme-linked 
immunosorbent assay. Autoantibody (auto-ab) IgG titers from PF and PV patients together correlated (r= 
0.6683) with the plasma levels of interleukin (IL)-6 (a). Similarly, anti-Dsg3 IgG levels from PV patients alone 
also correlated (r= 0.6967) with the plasma concentrations of IL-6 (b). In contrast, a correlation was not 
observed (r= -0.1507) between anti-acetylcholine receptor (AChR) IgG levels and IL-6 plasma levels from 
myasthenia gravis (MG) controls (n= 12) (c). Data of pooled active and remittent pemphigus patients is 
presented. Spearman correlation coefficients (r) are shown with p values indicated as *p 0.5. 
 
 
Similarly, auto-ab IgG titers from both PF and PV patients correlated (r= 0.6072) with the plasma 
levels of TNF-α, which was also observed in the cohort of exclusively PV patients (r= 0.7902). 
MG controls however only displayed a correlation (r= -0.6299) between anti-AChR IgG levels and 
TNF-α plasma concentrations in an inverse manner as illustrated in Figure 4.26. 
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Figure 4.26: Correlation of auto-ab titers with TNF-α plasma levels in pemphigus and myasthenia 
gravis patients. 
In the sera from pemphigus foliaceus (PF, n= 3) and pemphigus vulgaris (PV) patients (n= 9), anti-
Desmoglein 1 (Dsg1) and anti-Dsg3 IgG titers were determined by enzyme-linked immunosorbent assay. 
Similarly to interleukin-6, autoantibody (auto-ab) immunoglobulin (Ig) G titers from the combination of PF 
and PV patients correlated (r= 0.6072) with the plasma levels of tumor necrosis factor (TNF)-α (a). Anti-Dsg3 
IgG levels from PV patients alone as well correlated (r= 0.7902) with the plasma levels of TNF-α (b). 
However, only a negative correlation was observed (r= -0.6299) between anti-acetylcholine receptor (AChR) 
IgG levels and TNF-α plasma levels from myasthenia gravis (MG) controls (n= 12) (c). Data of pooled active 
and remittent pemphigus patients is presented. Spearman correlation coefficients (r) are shown with p values 
indicated as *p 0.5. 
 
 
Interestingly, IL-27 plasma levels not only strongly correlated with the combined anti-Dsg1 and 
anti-Dsg3 IgG titers from PF and PV patients, respectively (r= 0.7965), but also with the anti-Dsg3 
IgG levels from PV patients alone (r= 0.8909). Yet, in MG controls, we could not observe a 
correlation between auto-ab IgG titers and IL-27 plasma levels as shown in Figure 4.27. 
 
 
 
Figure 4.27: Correlation of auto-ab titers with IL-27 plasma levels in pemphigus and myasthenia 
gravis patients. 
Anti-Desmoglein 1 (Dsg1) and anti-Dsg3 immunoglobulin (Ig) G levels were detected in the sera from 
pemphigus foliaceus (PF, n= 3) and pemphigus vulgaris (PV) patients (n= 9) by enzyme-linked 
immunosorbent assay (ELISA). As determined by ELISA, autoantibody (auto-ab) IgG titers from PF and PV 
patients together strongly correlated (r= 0.7965) with the plasma levels of interleukin (IL)-27 (a). In 
accordance with that, anti-Dsg3 IgG levels from PV patients alone again strongly correlated (r= 0.8909) with 
the plasma concentrations of IL-27 (b). On the contrary, no correlation was found (r= -0.5330) between anti-
acetylcholine receptor (AChR) IgG levels and IL-27 plasma levels from myasthenia gravis (MG) controls (n= 
12) (c). Data of pooled active and remittent pemphigus patients is presented. Spearman correlation 
coefficients (r) are shown with p values indicated as **p 0.01. 
 
 
Taken together, in pemphigus, a correlation was found between serum auto-ab IgG titers and the 
plasma concentrations of proinflammatory cytokines, including IL-6 (Figure 4.25a and b) and 
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TNF-α (Figure 4.26a and b), concurrent with elevated plasma levels of the respective cytokines 
(Figure 4.19). 
Again, a disease-promoting function could be confirmed for IL-27 since it was not only elevated 
(Figure 4.20b), but also correlated with auto-ab titers in both pooled pemphigus and PV patients 
(Figure 4.27a and b). This observation was further supported by IL-27 plasma levels also strongly 
correlating (r= 0.9287) with TNF-α plasma levels as presented in Figure 4.28a. Moreover, IL-27 
plasma levels correlated (r= 0.7526) with plasma levels of IL-33 in pemphigus patients as shown 
in Figure 4.28b. 
 
 
 
Figure 4.28: Correlation of IL-27 plasma levels with TNF-α and IL-33 in pemphigus patients. 
As determined by enzyme-linked immunosorbent assay, interleukin (IL)-27 plasma levels of pemphigus 
patients (n= 12) strongly correlated (r= 0.9287) with the plasma levels of tumor necrosis factor (TNF)-α (a). 
Similarly, a strong correlation (r= 0.7526) was observed between plasma concentrations of IL-27 (r= 0.8909) 
and the plasma levels of IL-33 (b). Spearman correlation coefficients (r) are shown with p values indicated 
as **p 0.01 and ***p 0.001. 
 
 
On the basis of the found elevated plasma levels of IL-27 (Figure 4.20b) in active pemphigus 
patients, as well as IL-27 plasma levels correlating with both serum IgG auto-ab titers (Figure 
4.27a and b) and plasma TNF-α levels (Figure 4.28a), IL-27 is suggested to exert a disease-
propagating function in pemphigus. Although MG controls also exhibited enhanced plasma levels 
of IL-27 (Figure 4.20b), we did not observe a correlation between IL-27 levels and anti-AChR 
titers (Figure 4.27c). Therefore, we assume a disease-specific role of IL-27 in pemphigus. A 
potential mechanistic link between IL-27 and antibody production was recently provided by Batten 
et al. who demonstrated that IL-27 signaling to T cells induced the release of IL-21 (Batten et al. 
2010). Moreover, IL-27 enhanced both the survival of active CD4+ T cells and the expression of 
the Tfh cell markers CXCR5, PD-1, and inducible T cell costimulator (ICOS). IL-21–producing Tfh 
cells are specialized and essential providers of B cell help to both form and maintain GC, and to 
regulate the maturation of B cells into memory B cells, as well as plasma cells secreting high-
affinity antibodies (Tangye et al. 2013). Altered Tfh cell behavior has been reported in several 
antibody-mediated autoimmune disorders, including SLE and RA, in which the expansion of Tfh 
cells could be related to disease activity (Simpson et al. 2010; Wang et al. 2013). To investigate 
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whether the observed increased IL-27 plasma titers possibly affected Tfh cells in pemphigus, we 
additionally detected circulating IL-21 in plasma samples of the test subjects. Indeed, as 
presented in Figure 4.29, both active pemphigus patients (p= 0.0062) and MG controls (p= 
0.0003) exhibited significantly enhanced titers of IL-21 compared to HC. In addition, plasma of 
the remittent pemphigus patients did not display detectable amounts of IL-21. The cellular source 
of IL-21 was traced back by our group in a further cohort of pemphigus and MG patients 
demonstrating elevated populations of CD4+CXCR5+ Tfh cells in active pemphigus patients, again 
concurrent with increased plasma levels of IL-21 (Hennerici et al. 2016). Taken together, these 
findings indicate a novel role of IL-27 and IL-21–producing T cells in the pathogenesis of 
pemphigus. 
 
 
 
Figure 4.29: Plasma concentrations of IL-21 in pemphigus and myasthenia gravis patients. 
Levels of interleukin (IL)-21 were measured in the patients’ plasma samples by enzyme-linked 
immunosorbent assay. Interestingly, concentrations of IL-21 were significantly elevated in the plasma of both 
active pemphigus (act. P, n= 9; p= 0.0062) and myasthenia gravis (MG) patients (n= 12; p= 0.0003) 
indicating an expansion of T follicular helper (Tfh) cells in both autoimmune disorders. Moreover, levels of 
IL-21 of the three remittent pemphigus (rem. P) patients were below the limit of detection. IL-21 is vastly 
produced by Tfh cells and also by Th 17 cells. HC, healthy control. Statistical analysis was carried out using 
Mann-Whitney U test with p values indicated as **p< 0.01 and ***p< 0.001. 
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4.2 Mouse study 
 
4.2.1 HLA-DRB1*04:02–tg mice as a model for PV 
The second part of this thesis deals with the HLA-DRB1*04:02–tg mouse model of PV, in which 
Dsg3-specific pathoimmunological mechanisms, including APC-mediated CD4+ T cell activation 
and antibody production were investigated considering the strong genetic association of this 
disease. The highly increased prevalence of distinct HLA class II alleles in PV patients, especially 
HLA-DRB1*04:02 and –DQB1*05:03, was confirmed to provide the physicochemical properties 
required for efficient positioning of antigenic Dsg3 peptides in the HLA-DR pocket (Tong et al. 
2006). This finally results in the activation of autoreactive CD4+ T cells by the HLA-DR–peptide 
complex. Since the β-chain of the HLA-DRβ1*04:02 binding groove displays the negatively 
charged amino acid residues aspartic acid (D70) and glutamic acid (E71) at the critical relative 
position four (P4), peptides with a positively charged amino acid at P4 are high affinity-bound and 
preferably presented to CD4+ T cells as illustrated in Figure 4.30b. On the basis of this peptide 
binding algorithm, our group (Veldman, Gebhard, et al. 2004) identified Dsg3-specific CD4+ T cell 
clones from PV patients that recognized a limited set of epitopes within the human Dsg3 EC as 
shown in Figure 4.30a. These designated immunodominant Dsg3 peptides binding to HLA-
DRβ1*04:02 typically share a positively charged amino acid residue at P4, either arginine (R) or 
lysine (K). Besides human Dsg3 protein and the noncollagenous (NC1) domain of Collagen VII 
(Col VII) as a control (2.5.1), a set of five HLA-DRβ1*04:02–binding Dsg3 peptides (2.5.2.1) was 
applied for immunization of the HLA-DRB1*04:02–tg mice. A control set was comprised of five 
HLA-DRβ1*04:02–non-binding Dsg3 peptides (2.5.2.2). 
 
 
 
Figure 4.30: Location of Dsg3 peptides within the Dsg3 EC and algorithm for peptide binding to HLA-
DRβ1*04:02. 
The extracellular portion of Desmoglein 3 (Dsg3) is subdivided into five domains (EC1–5), of which the 
indicated peptides represent epitopes of Dsg3-specific CD4+ T cells (a). Genetic susceptibility of pemphigus 
vulgaris is strongly conferred by expression of distinct HLA class II alleles, especially HLA-DRB1*04:02 and 
–DQB1*05:03. The molecular basis for this observation is provided by an algorithm for peptide binding to 
HLA-DRβ1*04:02 proposed by Wucherpfennig et al. (Wucherpfennig et al. 1995) and confirmed by Tong et 
al. (Tong et al. 2006). The HLA-DRβ1*04:02–binding immunodominant Dsg3 peptides bear a positively 
charged amino acid residue (R or S) at P4, where it interacts with the negatively charged amino acids D70 
and E71 of the HLA-DR binding cleft (b) (modified from Veldman et al. J. Immunol., 2004). 
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In order to study human Dsg3-specific cellular and humoral immune responses of PV in vivo 
under the genetic impact of HLA-DRB1*04:02, DBA/1J mice transgenic for HLA-DRB1*04:02 and 
–DQB1*03:02 (which is linked to DRB1*04:02 in a disequilibrium) were generated. Expression of 
the human CD4 coreceptor was introduced to retain efficient APC–CD4+ T cell interaction and 
mice were devoid of functional murine MHC class II (I-Aβ-/-). 
At first, the respective phenotype was confirmed for each HLA-DRB1*04:02–tg mouse used in 
this study by flow cytometry analysis of peripheral venous blood samples as described in 3.2.1.1 
and illustrated in Figure 4.31. Leukocytes of mice transgenic for HLA-DRB1*04:02 displayed a 
high intensity of the bound anti-human CD4 PE-coupled antibody unlike those of wild type mice 
that merely exhibited background fluorescence (Figure 4.31a). Similarly, although less well 
resolved did the anti-human HLA-DR and anti-human HLA-DQ antibodies labeled with PE and 
FITC, respectively, target the respective cell surface markers expressed by HLA-DRB1*04:02–tg 
mice only (Figure 4.31b and c). However, contrary to HLA-DRB1*04:02–tg mice, binding of the 
anti–I-Aβ FITC-coupled antibody solely occurred on immune cells from wild type mice. 
Homozygosity of wild type mice for I-Aβ reflects in two single intensity peaks of the bound antibody 
(Figure 4.31d). 
 
 
 
Figure 4.31: Phenotype of HLA-DRB1*04:02–transgenic mice. 
Flow cytometry histogram presentation of the transgenes expressed by HLA-DRA1*01:01-DRB1*04:02 /-
DQA1*03:01-DQB1*03:02 (DQ8)–transgenic (tg) mice on a DBA/1J background: In contrast to wild type 
mice (blue line) that only exhibited background fluorescence, HLA-DRB1*04:02–tg mice (red line) displayed 
binding of an anti-human CD4–PE antibody (a), anti–HLA-DR–PE antibody (b), and anti–HLA-DQ–FITC 
antibody (c). Binding of an anti–I-Aβ–FITC antibody only occurred on leukocytes from wild type mice with 
two single peaks of fluorescence intensity representing the two different alleles of the gene expressed (d). 
Representative result of each experimental mouse used in this study. 
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4.2.2 Immunization of HLA-DR4-tg mice with human Dsg3 induces Dsg3-specific IgG 
In order to study Dsg3-reactive CD4+ T and B cell responses, as well as determine the level of 
the Dsg3-specific serum IgG antibody titer, mice transgenic for HLA-DRB1*04:02 were repetitively 
immunized with recombinant human Dsg3 protein (2.5.1) according to the pattern presented in 
3.2.1.2a. For detection of the IgG antibodies by ELISA (3.2.2.1), mice sera were diluted in the 
ratio of 1:20 and optical density (OD) of the colorimetric substrate was measured at 405 nm. As 
presented in Figure 4.32, following two i.p. immunizations with human Dsg3 emulsified in alum 
on days 0 and 14, the antibody titer strongly rose until a plateau exceeding 2 OD was reached 
from day 21 on. Maintenance of this titer for at least three weeks was achieved by several booster 
immunizations. Unlike HLA-DRB1*04:02–tg mice immunized with human Dsg3 protein, control 
mice injected with PBS and adjuvant alone only displayed background activity. 
 
 
 
Figure 4.32: Human Dsg3-reactive IgG antibody titer of HLA-DRB1*04:02–transgenic mice. 
Immunization of HLA-DRB1*04:02–transgenic (tg) mice with human Dsg3 resulted in a robust Desmoglein 
3 (Dsg3)-specific immunoglobulin (Ig) G antibody response as detected by enzyme-linked immunosorbent 
assay. Two immunizations with human Dsg3 on days 0 and 14 yielded the maximum level of the antigen-
specific IgG titer, which was perpetuated by several booster immunizations. HLA-DRB1*04:02–tg mice 
injected with phosphate-buffered saline (PBS) and adjuvant only served as controls. OD, optical density. 
Representative result of two individual experiments is shown. 
 
 
In addition to detecting antigen-specific IgG antibodies by ELISA (Figure 4.32), serum samples 
from HLA-DRB1*04:02–tg mice repetitively immunized with human Dsg3 (2.5.1) in alum were 
also assayed for binding reactivity to native Dsg3 protein as determined by IIF microscopy 
(3.2.2.3). For this purpose, monkey esophagus epithelium was at first incubated with mouse 
serum samples diluted in the ratio of 1:25, followed by application of the FITC-labeled anti-mouse 
detection antibody. Apart from recognizing recombinant human Dsg3 (Figure 4.32), antibodies 
abundantly bound to native Dsg3 antigen present on the cell surface of epidermal keratinocytes 
as visualized in Figure 4.33a. In order to test for antigen specificity of the humoral immune 
response, mice were also immunized with the NC1 domain of Col VII (2.5.1) as a control protein 
since it is produced in the same insect cell expression system, but does not exhibit sequence 
homology to human Dsg3. Clearly visible, immunization of mice with Col VII did not result in the 
respective “chicken wire” pattern characteristic of Dsg3-specific IgG tissue deposition, but 
antibodies bound to Col VII located in the basal membrane zone revealing a typical linear pattern 
(Figure 4.33b). 
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Figure 4.33: Indirect immunofluorescence microscopy of human Dsg3-reactive IgG induced in HLA-
DRB1*04:02–transgenic mice. 
Immunization of HLA-DRB1*04:02–transgenic mice with human Desmoglein 3 (Dsg3) resulted in the 
production of Dsg3-specific immunoglobulin (Ig) G antibodies that recognized native Dsg3 protein present 
on monkey esophagus epithelium as detected by indirect immunofluorescence microscopy (a). However, 
immunization with the noncollagenous domain of Collagen VII (Col VII) as a control protein did not induce 
IgG antibodies that interacted with Dsg3 antigen, but Col VII located in the basal membrane zone revealing 
a typical linear pattern (b). Representative result of three individual experiments is presented. 
 
 
4.2.3 T cell recognition of human Dsg3 epitopes is tightly HLA-DRB1*04:02–
restricted 
4.2.3.1 In vitro culture of BMDC with Th cells and CFSE proliferation assay 
In PV patients, it was demonstrated that Dsg3-reactive CD4+ T cells are responsive to distinct 
epitopes of the Dsg3 EC under the restriction by HLA-DRB1*04:02 (Veldman, Gebhard, et al. 
2004) based on the peptide binding algorithm presented in 4.2.1. To assess whether this finding 
can be reproduced in the HLA-DRB1*04:02–tg mouse model of PV, Dsg3-specific CD4+ T cells 
were exposed to a set of five HLA-DRβ1*04:02–binding (2.5.2.1) and –non-binding (2.5.2.2) Dsg3 
peptides under ex vivo conditions according to the experimental approach described in 3.2.3.2: 
As professional APC, mDC were differentiated from BM cells from HLA-DRB1*04:02–tg mice by 
in vitro culture with GM-CSF for seven days as presented in 3.2.3.1. Since the T cell stimulatory 
capacity of BMDC rises with cell maturity, BMDC were stimulated with bacterial LPS overnight 
upon complete differentiation. As confirmed by flow cytometry analysis, maturation of BMDC 
entailed increased surface expression of HLA-DR required for antigenic peptide presentation and 
activation of CD4+ T cells (13.8% of CD11c+HLA-DRhigh cells [Figure 4.34b] versus 8.7% of 
CD11c+HLA-DRhigh cells in the unstimulated sample [Figure 4.34a]). Upon application of LPS, 
BMDC were also loaded with a set of five Dsg3 peptides that either bind or as a control do not 
bind to HLA-DRβ1*04:02. Addition of an anti-CD3 mAb was used as a positive control. BMDC 
pulsed with antigen were subsequently cultured for six days together with Dsg3-responsive CD4+ 
T cells induced by immunization of HLA-DRB1*04:02–tg mice with human Dsg3 protein (2.5.1) 
according to the pattern described in 3.2.1.2a. In order to obtain a pure population of CD4+ T cells, 
splenocytes underwent positive selection by CD4+ MACS, which yielded a purity grade exceeding 
95% as confirmed by application of an anti-mouse CD4 APC-coupled antibody using flow 
cytometry analysis (Figure 4.35). To visualize the proliferative response of splenic CD4+ T cells 
against the Dsg3 peptides presented by activated BMDC using flow cytometry, CD4+ T cells were 
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stained with the fluorescent dye CFSE that binds to cytosolic proteins. Upon mitosis, distribution 
and dilution of the dye onto daughter cells was discernible by separated cell generation peaks 
detected in the FITC channel. For optimum stimulation, Dsg3-responsive CD4+ T cells and 
antigen-pulsed BMDC were cultured together at different ratios, of which a BMDC–T cell ratio of 
1:20 yielded the strongest proliferative response with minimal background cell division activity. A 
representative result of two respective experiments is presented in Figure 4.36. 
 
 
 
Figure 4.34: Bone marrow-derived dendritic cells from HLA-DRB1*04:02–transgenic mice before and 
after stimulation with LPS. 
Bone marrow-derived DC (BMDC) from HLA-DRB1*04:02–transgenic mice were generated by in vitro 
culture of BM cells with granulocyte macrophage colony-stimulating factor for seven days. Compared to 
untreated cells (a), incubation with lipopolysaccharides (LPS) overnight (b) resulted in augmented HLA-DR 
expression of CD11c+ BMDC as detected by application of an anti-mouse CD11c-antibody and an anti-
human HLA-DR antibody conjugated to APC and PE, respectively, using flow cytometry. Representative 
result of two individual experiments is presented. 
 
 
 
Figure 4.35: Magnetic-activated cell sorting of mouse splenic CD4+ T cells from HLA-DRB1*04:02–
transgenic mice. 
Positive selection of murine splenic CD4+ T cells from HLA-DRB1*04:02–transgenic mice immunized with 
human Desmoglein 3 using magnetic-activated cell sorting yielded a population of CD4+ T cells with purity 
95% as confirmed by application of an anti-mouse CD4 antibody coupled to APC using flow cytometry 
analysis (b). Based on forward scatter (FSC) and side scatter (SSC), lymphocytes were preselected before 
quantification of CD4+ T cells (a). Representative result of two individual experiments is shown. 
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As expected and in concordance with the peptide binding algorithm for HLA-DRβ1*04:02 (4.2.1), 
Dsg3-responsive splenic CD4+ T cells purified from mice immunized with human Dsg3 protein 
markedly proliferated (12.0%) upon presentation of a set of five HLA-DRβ1*04:02–binding Dsg3 
peptides by BMDC from HLA-DRB1*04:02–tg mice stimulated with LPS (Figure 4.36a). Ex vivo 
challenge of splenic CD4+ T cells with a set of Dsg3 peptides that do not bind to HLA-DRβ1*04:02 
however did not induce a proliferative response beyond background level (5.87%) (Figure 4.36b). 
Culture of splenic CD4+ T cells together with BMDC devoid of antigenic cargo served as a 
negative control (6.64%), whereas addition of an anti-CD3 mAb was used as a positive control 
(30.7%) (Figure 4.36c and d). These findings illustrate that in the HLA-DRB1*04:02–tg mouse 
model of PV, T cell recognition of human Dsg3 epitopes depends on HLA-DRB1*04:02. 
 
 
 
Figure 4.36: Carboxyfluorescein succinimidyl ester proliferation assay of Dsg3-specific T cells and 
antigen-loaded bone marrow-derived dendritic cells from HLA-DRB1*04:02–transgenic mice. 
Reactivity of Desmoglein 3 (Dsg3)-responsive splenic CD4+ T cells induced by repetitive immunization of 
HLA-DRB1*04:02–transgenic mice with human Dsg3 was specified by ex vivo challenge of T cells with bone 
marrow-derived DC (BMDC) from the same mice loaded with a set of either five HLA-DRβ1*04:02–binding 
or –non-binding Dsg3 peptides. Upon stimulation with BMDC pulsed with a set of five HLA-DRβ1*04:02–
binding peptides, Dsg3-specific splenic CD4+ T cells mounted a pronounced proliferative response as shown 
by sequential dilution of the carboxyfluorescein succinimidyl ester (CFSE) dye (a). Upon exposure to BMDC 
loaded with a set of peptides that do not bind to HLA-DRβ1*04:02 however, the proliferative response of T 
cells was similar to that of exposure to BMDC devoid of antigen (b). Challenge with BMDC without addition 
of antigenic peptides represented the extent of background proliferation (c). Application of an anti-CD3 
monoclonal antibody to BMDC and splenic CD4+ T cells was used as a positive proliferative control (d). 
Representative result of two individual experiments is presented. 
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4.2.3.2 ELISPOT assay of T cells challenged with Dsg3 epitopes 
In the reverse experimental approach, in order to induce a locally restricted CD4+ T cell response 
in the draining popliteal and inguinal LN following seven days, HLA-DRB1*04:02–tg mice were 
immunized into the hind foot pads with a set of five HLA-DRβ1*04:02–binding Dsg3 peptides 
(2.5.2.1) emulsified in TiterMaxTM according to the pattern described in 3.2.1.2b. As a control, 
mice were also immunized with a set of peptides that do not bind to HLA-DRβ1*04:02 (2.5.2.2). 
Upon isolation, LN T cells were challenged ex vivo with a panel of antigens consisting of a set of 
HLA-DRβ1*04:02–binding and –non-binding Dsg3 peptides, as well as human Dsg3 and the NC1 
of Col VII protein (2.5.1). Stimulation-induced cytokine secretion was quantified following 
incubation of antigens for 24 hours by ELISPOT assay as described in 3.2.3.3. As presented in 
Figure 4.37, analysis revealed a significantly increased release of the Th1- and Th2 cell-related 
signature cytokines IFN- and IL-4, respectively, of LN T cells upon both ex vivo challenge with 
human Dsg3 protein (2.5.1) or the HLA-DRβ1*04:02–binding Dsg3 peptides. However, ex vivo 
restimulation of LN T cells with the HLA-DRβ1*04:02–non-binding Dsg3 peptides (2.5.2.2) or the 
NC1 of Col VII control protein (2.5.1) did not result in a T cell response beyond background level. 
In contrast, immunization of mice with a set of five Dsg3 peptides that do not bind to HLA-
DRβ1*04:02 exclusively resulted in an IFN-+ T cell response to the same set of Dsg3 peptides, 
whereas importantly, no detectable cytokine release was induced upon ex vivo challenge of LN 
T cells with human Dsg3 protein. 
 
 
 
Figure 4.37: Quantitative determination of cytokine-secreting lymph node T cells by ELISPOT assay. 
Shown are representative enzyme-linked immunospot (ELISPOT) assay membranes seeded with lymph 
node (LN) cells isolated from HLA-DRB1*04:02–transgenic mice immunized with the HLA-DRβ1*04:02–
binding Desmoglein 3 (Dsg3) peptides. The LN T cells were ex vivo challenged with phytohemagglutinin 
(PHA) or left unstimulated as a positive and negative control, respectively. HLA-DRβ1*04:02–binding and –
non-binding peptides, as well as the proteins Dsg3 and Collagen VII (Col VII) were the antigens used for ex 
vivo restimulation of LN T cells. Interleukin (IL)-4+ cells represent T helper (Th) 2 cells, whereas Th1 cells 
are interferon (IFN)-+. For calculation of the number of cytokine-secreting LN T cells, the number of spots 
of the unstimulated control was subtracted from the samples stimulated with antigen. The number of spots 
is indicated per 1  105 LN T cells. 
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Figure 4.38: Dsg3-specific T cells from HLA-DRB1*04:02–transgenic mice recognized a limited set of 
Dsg3 peptides. 
Draining lymph node T cells from HLA-DRB1*04:02–transgenic mice immunized with a set of five HLA-
DRβ1*04:02–binding Desmoglein 3 (Dsg3) peptides displayed both interferon (IFN)-+ (b) and interleukin 
(IL)-4+ (a) T cell responses upon ex vivo challenge with human Dsg3 and the HLA-DRβ1*04:02–binding 
Dsg3 peptides, unlike with the HLA-DRβ1*04:02–non-binding Dsg3 peptides or Collagen VII (Col VII) control 
protein. Immunization of mice with the Dsg3 peptides that do not bind to HLA-DRβ1*04:02 only resulted in 
an IFN-+ T cell reaction upon ex vivo challenge with the same peptides b). Antigens used for restimulation 
are shown on abscissae. PHA, phytohemagglutinin; Th, T helper cell. Cumulative results of 6–10 mice are 
presented. Differences were considered significant for p 0.05 (indicated as *) and very significant for p 
0.01 (indicated as **) as determined by Mann-Whitney U test. 
 
 
As a specificity control, this experiment was additionally performed by the collaboration group of 
J. Bäcklund using mice transgenic for HLA-DRB1*04:01 as shown in Figure 4.39. Immunization 
of these mice with the same set of HLA-DRβ1*04:02–binding Dsg3 peptides did neither yield an 
IFN-+ (except of one mouse) nor IL-4+ T cell response upon ex vivo restimulation of splenic CD4+ 
T cells with human Dsg3. Upon both immunization and ex vivo challenge with the HLA-
DRβ1*04:02–binding Dsg3 peptides, both strong IFN-+ and IL-4+ T cell responses were induced, 
which was not observed upon ex vivo challenge with the HLA-DRβ1*04:02–non-binding Dsg3 
peptides or Col VII protein. Similarly, immunization of HLA-DRB1*04:01–tg mice with a set of five 
Dsg3 peptide that do not bind to HLA-DRβ1*04:02 did neither lead to an IFN-+ nor IL-4+ T cell 
reaction upon ex vivo restimulation with human Dsg3. Only again, both immunization and ex vivo 
challenge with the HLA-DRβ1*04:02–non-binding Dsg3 peptides resulted in a pronounced IFN-+ 
and IL-4+ T cell response. 
Application of the mitogens PHA and concanavalin A (ConA) served as a positive control for LN 
cell and splenic CD4+ T cell viability, respectively, whereas background stimulation of LN T cells 
from HLA-DRB1*04:02–tg mice was assessed by injection of mice with PBS and adjuvant only 
(Figure 4.40). 
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Figure 4.39: Dsg3-specific T cells from HLA-DRB1*04:01–transgenic mice did not recognize the Dsg3 
peptides. 
Splenic CD4+ T cells from HLA-DRB1*04:01–transgenic mice immunized with either a set of Desmoglein 3 
(Dsg3) peptides that bind or do not bind to HLA-DRβ1*04:02 only exhibited interferon (IFN)-+ (b) and 
interleukin (IL)-4+ (a) T cell reactivity upon ex vivo challenge with the respective set of Dsg3 peptides. 
Importantly, upon ex vivo challenge with Dsg3 protein, no T cell responses could be observed except of an 
IFN-+ T cell response of one mouse. Antigens used for restimulation are shown on abscissae. Col VII, 
Collagen VII; ConA, concanavalin A; Th, T helper cell. Cumulative results of 2–4 mice are presented. 
 
 
 
Figure 4.40: Background activity of lymph node T cells from HLA-DRB1*04:02–transgenic mice. 
Immunization of HLA-DRB1*04:02–transgenic mice with phosphate-buffered saline (PBS) and adjuvant 
(TiterMaxTM) alone did neither induce background interferon (IFN)-+ (b) nor interleukin (IL)-4+ (a) T cell 
responses upon ex vivo stimulation with the set of protein and peptide antigens used in this study. Application 
of phytohemagglutinin (PHA) served as a positive control. Antigens used for restimulation are shown on 
abscissae. Dsg3, Desmoglein 3; Col VII, Collagen VII. Cumulative results of two mice are presented. 
 
 
To summarize, only ex vivo challenge of LN T cells from HLA-DRB1*04:02–tg mice immunized 
with a set of five HLA-DRβ1*04:02–binding Dsg3 peptides with human Dsg3 protein or the same 
peptides yielded both an IFN-+ and IL-4+ T cell response. In addition, an IFN-+ T cell response 
was induced upon both immunization of these mice and ex vivo restimulation with the HLA-
DRβ1*04:02–non-binding Dsg3 peptides as a particularity. Contrariwise, splenic CD4+ T cells 
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from HLA-DRB1*04:01–tg mice generally merely responded to the respective Dsg3 peptides they 
were immunized with. 
These findings confirm the conclusions drawn from the reverse experiment described in 4.2.3.1 
of T cell recognition of human Dsg3 epitopes being tightly restricted by HLA-DRB1*04:02. 
 
 
4.2.4 Immunization of HLA-DR4–tg mice with Dsg3 peptides induces Dsg3-
specific IgG 
4.2.4.1 ELISA of sera from Dsg3 peptides-immunized HLA-DR4–tg mice 
Since the experiments described in 4.2.3.1 and 4.2.3.2 clearly demonstrated that in the HLA-
DRB1*04:02–transgenic mouse model of PV, CD4+ T cell recognition of the Dsg3 EC is tightly 
restricted by HLA-DRB1*04:02, we next addressed the question whether induction of Dsg3-
reactive IgG antibodies as well is regulated by HLA-DRB1*04:02. For this purpose, sera from 
HLA-DRB1*04:02–tg mice immunized according to the scheme presented in 3.2.1.2a with either 
a set of HLA-DRβ1*04:02–binding (2.5.2.1) or –non-binding (2.5.2.2) Dsg3 peptides were 
assayed for reactivity against recombinant human Dsg3 by ELISA (3.2.2.1). Mice sera were 
diluted in the ratio of 1:25 and OD of the colorimetric substrate was measured at 405 nm. 
Interestingly, as shown in Figure 4.41a, sera from HLA-DRB1*04:02–tg mice immunized with a 
set of five HLA-DRβ1*04:02–binding Dsg3 peptides displayed pronounced IgG reactivity against 
recombinant Dsg3 – approximately half of the antibody titer level achieved by immunization of 
mice with human Dsg3 protein. In contrast, immunization of these mice with a set of five Dsg3 
peptides that do not bind to HLA-DRβ1*04:02 did not result in the production of IgG antibodies 
recognizing Dsg3 protein. 
Intriguingly, opposed to HLA-DRB1*04:02–tg mice, sera from control mice transgenic for HLA-
DRB1*04:01 did not exhibit Dsg3-specific IgG antibody responses upon immunization with either 
the HLA-DRβ1*04:02–binding or –non-binding peptides as shown in Figure 4.41b. Analogous to 
HLA-DRB1*04:02–tg mice (OD of ca. 3.5), immunization of control mice with human Dsg3 protein 
(2.5.1) yielded a strong Dsg3-specific humoral immune response, although to a much lesser 
extent (OD of ca. 1.1). These findings clearly illustrate that HLA-DRB1*04:02–restricted CD4+ T 
cell recognition of specific Dsg3 epitopes is essential for the induction of Dsg3-reactive IgG 
antibodies. 
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Figure 4.41: Enzyme-linked immunosorbent assay of sera from HLA-DR4–transgenic mice 
immunized with Dsg3 peptides. 
Immunization of HLA-DRB1*04:02–transgenic (tg) mice with a set of HLA-DRβ1*04:02–binding Desmoglein 
3 (Dsg3) peptides induced immunoglobulin (Ig) G reactivity against recombinant human Dsg3 as shown by 
enzyme-linked immunosorbent assay using serum samples diluted in the ratio of 1:25. Contrariwise, 
immunization of mice with a set of HLA-DRβ1*04:02–non-binding peptides did not yield Dsg3-reactive IgG 
antibodies. Upon immunization of mice with Dsg3 protein, a robust antibody response was mounted (optical 
density [OD] 3.5). Cumulative results of three mice per experiment are presented (a). In contrast, sera from 
HLA-DRB1*04:01–tg mice diluted in the same ratio did not display Dsg3-specific IgG antibody induction 
upon immunization with neither the HLA-DRβ1*04:02–binding nor –non-binding peptides. Immunization with 
Dsg3 protein resulted in a pronounced, but compared to HLA-DRB1*04:02–tg mice much weaker IgG 
antibody response (OD 1.1) (b). Cumulative results of 2–4 mice are presented. 
 
 
4.2.4.2 IIF of sera from Dsg3 peptides-immunized HLA-DR4–tg mice 
In addition to binding to recombinant Dsg3 protein as determined by ELISA (3.2.2.1), serum 
samples of HLA-DRB1*04:02–tg mice immunized with a set of Dsg3 peptides that either bind 
(2.5.2.1) or do not bind (2.5.2.2) to HLA-DRβ1*04:02 according to the pattern shown in 3.2.1.2a 
were assayed for IgG reactivity against native Dsg3 protein expressed on monkey esophagus 
epithelium. Therefore, mice sera were diluted in the ratio of 1:25, incubated on epidermal 
keratinocytes, and binding of the FITC-tagged secondary antibody was detected by IIF 
microscopy (3.2.2.3). 
As presented in Figure 4.42a and b, immunization of mice with a set of HLA-DRβ1*04:02–binding 
Dsg3 peptides induced IgG antibodies that strongly interacted with native Dsg3 protein expressed 
by esophagus epithelium. Immunization of mice with control peptides however did not lead to the 
generation of anti-epithelial surface IgG, but only unspecific background staining (Figure 4.42c 
and d). 
Strikingly, immunization of HLA-DRB1*04:01–tg control mice with neither the HLA-DRβ1*04:02–
binding (Figure 4.43a) nor –non-binding (Figure 4.43b) peptides resulted in the “chicken wire” 
pattern typical of Dsg3-specific IgG tissue deposition. 
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Figure 4.42: Indirect immunofluorescence microscopy of sera from HLA-DRB1*04:02–transgenic 
mice immunized with Dsg3 peptides. 
Sera from HLA-DRB1*04:02–transgenic mice immunized with the Desmoglein 3 (Dsg3) peptides that bind 
to HLA-DRβ1*04:02 (a and b) displayed immunoglobulin (Ig) G reactivity against native Dsg3 as shown by 
indirect immunofluorescence microscopy. However, sera from mice immunized with the HLA-DRβ1*04:02–
non-binding peptides did not exhibit Dsg3-specific IgG tissue deposition (c and d). Mouse sera were diluted 
in the ratio of 1:25. Representative results of three mice are shown. 
 
 
 
Figure 4.43: Indirect immunofluorescence microscopy of sera from HLA-DRB1*04:01–transgenic 
mice immunized with Dsg3 peptides. 
Immunization of HLA-DRB1*04:01–transgenic mice with neither the HLA-DRβ1*04:02–binding (a) nor –non-
binding Desmoglein 3 (Dsg3) peptides (b) resulted in the production of antibodies recognizing native Dsg3 
protein as visualized by indirect immunofluorescence microscopy. Mouse sera were diluted in the ratio of 
1:25. Representative result of 2–4 mice are displayed. 
 
 
As shown in Figure 4.44, sera from mice transgenic for either HLA-DRB1*04:02 or –DRB1*04:01 
displayed high IgG reactivity against native Dsg3 upon immunization with human Dsg3 protein. 
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Figure 4.44: Indirect immunofluorescence microscopy of sera from HLA-DR4–transgenic mice 
immunized with human Dsg3 protein. 
Immunization of mice transgenic for HLA-DRB1*04:02 (a) or –DRB1*04:01 (b) with human Desmoglein 3 
(Dsg3) protein led to the generation of antibodies recognizing native Dsg3 protein present on monkey 
esophagus epithelium as detected by indirect immunofluorescence microscopy. Mouse sera were diluted in 
the ratio of 1:25. Representative result of 2–4 mice are displayed. 
 
 
Taken together, the here described findings confirmed those presented in 4.2.4.1 of only sera 
from HLA-DRB1*04:02–tg mice immunized with the HLA-DRβ1*04:02–binding Dsg3 peptides 
exhibiting IgG reactivity against both recombinant and native Dsg3 protein (Figures 4.41a, and 
4.42a and b). In contrast, immunization of HLA-DRB1*04:01–tg with neither the HLA-
DRβ1*04:02–binding nor –non-binding peptides induced IgG reactive against recombinant Dsg3 
protein (Figure 4.41b) or that expressed by monkey esophagus epithelium (Figure 4.43). Solely 
immunization of both HLA-DR–tg mice with human Dsg3 protein led to the production of 
antibodies interacting with recombinant (Figure 4.41) and native Dsg3 (Figure 4.44). 
 
 
4.2.5 IgG cross-reactivity of sera from human Dsg3-immunized HLA-DR4-tg mice 
4.2.5.1 WB of sera from human Dsg3-immunized HLA-DR4–tg mice 
Repetitive immunization of HLA-DRB1*04:02–tg mice with human Dsg3 protein (2.5.1) according 
to the scheme illustrated in 3.2.1.2a did not induce blisters and erosions of mucous membranes, 
the phenotype characteristic of PV. In order to assess whether the homology between the EC of 
human and mouse Dsg3 is ample for human Dsg3-reactive IgG antibodies to bind to recombinant 
murine Dsg3 ex vivo, serum samples from HLA-DRB1*04:02–tg mice immunized with human 
Dsg3 were tested for recognition of the mouse Dsg3 EC (2.5.1) by western blot (WB) analysis 
(3.2.2.2). As presented in Figure 4.45, IgG reactivity against the human Dsg3 EC (72 kDa) was 
pronounced, whereas it was markedly reduced against the murine Dsg3 EC (75 kDa). Binding of 
an anti-E Tag antibody served as a positive control and the NC1 of Col VII (2.5.1) was used as a 
noncross-reactive control protein. 
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Figure 4.45: Immunoblotting analysis of sera from HLA-DRB1*04:02–transgenic mice immunized 
with Dsg3 protein. 
Sera from HLA-DRB1*04:02–transgenic mice immunized with human Desmoglein 3 (hDsg3) exhibited 
robust immunoglobulin G reactivity against human Dsg3, but diminished reactivity against murine Dsg3 
(mDsg3) as determined by immunoblotting analysis. Recognition of proteins by an anti-E Tag antibody 
served as a positive control, whereas Collagen VII (Col VII) was used as control protein produced in the 
same expression system. Representative result of five mice is displayed. 
 
 
4.2.5.2 DIF of sera from human Dsg3-immunized HLA-DR4–tg mice 
As illustrated in Figure 4.45, immunoblotting analysis revealed weak recognition of the analog 
recombinant mouse Dsg3 EC by the anti-human Dsg3-specific IgG antibodies present in the sera 
of HLA-DRB1*04:02–tg mice immunized (3.2.1.2a) with human Dsg3 protein. In order to assess 
whether human Dsg3-responsive IgG antibodies also target murine Dsg3 under in vivo conditions, 
tissue samples from HLA-DRB1*04:02–tg mice immunized with human Dsg3 were assayed for 
binding of antibodies to both tongue and palatinal mucosa using DIF microscopy (3.2.2.3). 
As presented in Figure 4.46, tissue-bound IgG antibodies were present on neither mouse palate 
(a) nor tongue (b) epithelium. Lack of binding of anti-human Dsg3-reactive IgG antibodies to the 
murine Dsg3 EC may explain the absence of a blistering and erosive phenotype of HLA-
DRB1*04:02–tg mice upon immunization with human Dsg3 protein. 
 
 
 
Figure 4.46: Direct immunofluorescence microscopy analysis of sera from HLA-DRB1*04:02–
transgenic mice immunized with human Dsg3 protein. 
Palatinal (a) and tongue (b) mucosa from HLA-DRB1*04:02–transgenic mice immunized with human 
Desmoglein 3 (Dsg3) protein did not display tissue deposition of Dsg3-reactive antibodies as detected by 
direct immunofluorescence microscopy. Representative results of 5 mice are shown. 
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5 Discussion 
 
5.1 Human study 
Aim of the first part of this doctoral thesis was to investigate APC and APC-derived cytokines, as 
well as their relation to Th cell subsets and to the auto-ab response in the pathogenesis of 
pemphigus. 
Circulating IgG auto-ab are a characteristic hallmark of the rare, but potentially fatal autoimmune 
bullous skin disorder pemphigus and predominantly target the desmosomal cadherins Dsg1 and 
Dsg3, thereby causing loss of epidermal keratinocyte adhesion (Hertl and Veldman 2001; Amagai 
2002). Therefore, pemphigus is considered as a model for an auto-ab–mediated organ-specific 
disorder (Amagai 2002). To date, the precise immunological events involved in the initiation and 
perpetuation of this disease are not yet completely understood, confining therapeutic options 
primarily to broad systemic immunosuppression often associated with severe side effects and 
comorbidities (Frew, Martin, and Murrell 2011). Numerous studies provide evidence for 
autoreactive Dsg-specific CD4+ T cells playing a critical role in controlling self-destructive IgG 
auto-ab responses in the pathogenesis of pemphigus (Hertl, Amagai, et al. 1998a; Nishifuji et al. 
2000; Takahashi et al. 2008; Takahashi, Kuwana, and Amagai 2009; Eming et al. 2008; Amber 
et al. 2013). Since the activation of CD4+ T cells generally relies on the interaction with APC, the 
contribution of cytokines to disease development has been more and more analyzed in several 
studies (Giordano and Sinha 2012). However, the specific function of APC in the generation of 
autoreactive antibodies is largely unknown. 
Cohorts of clinically well characterized pemphigus patients, as well as HC were recruited for this 
cross-sectional study, whereas patients affected with the neuromuscular disorder MG served as 
a further unrelated auto-ab–mediated and organ-specific disease control. First of all, circulating 
populations of DC and monocytes were phenotypically characterized in peripheral venous blood 
of the test subjects, including markers for activation and migration. Functional properties of the 
blood monocyte compartment were investigated, including their ability to synthesize and release 
cytokines, as well as their capacity to internalize antigen. Beside APC of the innate immune 
response, the distribution of CD4+ T cell subpopulations, as well as serum autoantigen-specific 
IgG antibody titers were determined. These titers were finally related to the parameters assessed 
in both the APC and CD4+ T cell compartment in order to uncover novel potential relationships in 
the process of auto-ab production in pemphigus. 
The findings obtained in this study revealed altered DC behavior in active pemphigus patients, 
such as diminished frequencies of circulating mDC and pDC along with an increased CCR2 
expression of mDC, indicating enhanced migration activities of mDC into inflamed peripheral 
tissues. Furthermore, increased frequencies of blood CD16+ monocytes, among which the 
nonclassical subset was additionally elevated were found in active pemphigus patients, as well 
as augmented CCR2 expression of CD14+ monocytes. Yet, circulating monocytes from 
pemphigus patients did neither display increased stimulation-induced production of the 
proinflammatory cytokines IL-6 and TNF-α nor differences in maximum antigen uptake capacity. 
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Nevertheless, active pemphigus patients exhibited enhanced plasma levels of TNF-α and the 
immunomodulatory IL-27, of which the latter apparently rather exerts an inflammatory function. 
Although in active pemphigus patients, neither elevated frequencies of circulating Th1 nor Th2 
cells were detected, these patients displayed augmented populations of both Th17 cells and IL-
10–synthesizing T cells. 
Important for pemphigus pathology, a significant correlation was not only found between serum 
IgG auto-ab titers and the plasma levels of both IL-6 and TNF-α, but also between auto-ab titers 
and the plasma concentrations of IL-27. Furthermore, similarly augmented plasma levels of IL-21 
exerting a crucial function in B cell activation possibly indicate the mechanism of an IL-27–
mediated activation of IL-21–producing Tfh cells (Batten et al. 2010). 
 
5.1.1 Role of dendritic cells in pemphigus 
An initial focus was put on the APC of the innate immune system, to which the circulating subsets 
of DC and monocytes belong. The broad family of DC discovered by Steinman et al. in 1973 holds 
a central position in the immune system because they represent specialized sentinels connecting 
the innate and adaptive immune responses without directly engaging in effector activities, such 
as the eradication of pathogens (Steinman and Cohn 1973a; Ganguly et al. 2013). Following 
recognition and procession of the pathogen, DC instantly migrate to the T cell areas of lymphoid 
organs, where they present pathogen-derived antigens to the respective antigen-specific T cells 
(Ganguly et al. 2013). 
Human circulating DC comprise two major classes with different appearance, function, cytokine 
profile, as well as expression of pathogen-sensing receptors and cell surface markers, the CD14-
CD11c++ mDC and pDC that may represent the precursors of the DC located in tissues and LN 
(Collin, McGovern, and Haniffa 2013). Recently, an additional highly proinflammatory subset of 
DC within the heterogeneous population of blood CD16+CD14- inflammatory monocytes termed 
slanDC was identified by Schaekel et al. that was also found to be present in the inflammatory 
infiltrate in psoriasis, RA, and CD (Schakel et al. 2002; Schakel 2009). 
The engagement of DC in tolerance and autoimmunity is considered to be complex and 
dichotomous since on the one hand, DC establish and maintain immune tolerance through various 
mechanisms, such as the induction of both Treg cells and T cell anergy. On the other hand, the 
extraordinary T cell stimulatory capacity of DC may also facilitate the priming and differentiation 
of autoreactive T cells, a consequence of either misguided activation stimuli or a cell-specific 
disruption of negative regulation. Accordingly, a potential involvement of a qualitatively or 
quantitatively altered DC compartment in disease pathogenesis has been implicated in several 
autoimmune disorders, including autoimmune myocarditis, MS, psoriasis, TID, and SLE 
(Eriksson, Ricci, et al. 2003; Eriksson, Kurrer, et al. 2003; Serafini et al. 2000; Greter et al. 2005; 
Karni et al. 2006; Lande et al. 2008; Schwab et al. 2010; Calderon et al. 2008; Tortola et al. 2012; 
Guiducci et al. 2010; Turley et al. 2003; Ronnblom and Alm 2001; Bave et al. 2003; Means et al. 
2005). 
In our study, active pemphigus patients displayed reduced frequencies of circulating mDC with 
significance close to the threshold (p= 0.0875) compared to HC, and significantly versus MG 
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controls (Figure 4.8a). Interestingly, this diminution of mDC concurred with a significantly 
augmented expression of CCR2 (Figure 4.11a). In addition, blood pDC were also found to be 
decreased in active pemphigus patients (Figure 4.8b), whereas slanDC numbers did not vary 
between the test subject groups (Figure 4.9). 
The capacity of DC to instruct adaptive immune responses is a consequence of their localization 
within tissues and their specialized ability for mobilization (Randolph, Ochando, and Partida-
Sanchez 2008). In order to enter nonlymphoid peripheral tissues and move within them, mDC 
express chemokine receptors indicating an immature immunogenicity status, such as CCR2 
(Geissmann, Jung, and Littman 2003; Merad et al. 2002), CCR5 (Stumbles et al. 2001; Yamagami 
et al. 2005), and CCR6 (Merad et al. 2004). Upon activation induced by the recognition of PAMP 
or danger-associated signals, DC downregulate their responsiveness to the respective 
inflammatory chemokines (Alvarez, Vollmann, and von Andrian 2008). Instead they upregulate 
CCR7 (Forster, Davalos-Misslitz, and Rot 2008), thereby acquiring a migratory phenotype, and 
express structures associated with maturation, including CD40, CD80, CD86, and HLA-DR 
(Randolph, Ochando, and Partida-Sanchez 2008). 
The reduced circulating population size and instantaneous upregulation of CCR2 of mDC in 
pemphigus patients is likely interpreted by mDC being recruited from the circulation into the 
inflamed skin. Although the CCR2 ligands, CCL2 and CCL7 are marginally expressed in resting 
tissues, epidermal keratinocytes of the skin produce considerable amounts of these chemokines 
under inflammatory conditions (Merad et al. 2004; Vanbervliet et al. 2002). In pemphigus, the 
scenario of CCR2-mediated skin infiltration of mDC is underpinned by the findings by Chiossi et 
al. of dermal DC numbers correlating with the serum IgG auto-ab titers in a cohort of Brazilian PF 
patients (Chiossi, Costa, and Roselino 2004). In addition, Picut et al. found the local presence of 
DC being associated with intraepidermal cleft formation in skin biopsies from PV patients and 
suggested that these DC represented functionally active APC possibly contributing to the 
development of lesions (Picut et al. 1987). 
According to these observations in pemphigus, a study by Clarkson et al. reported of an 
accumulation of DC in the central nervous system (CNS) in experimental MS and this effect was 
dependent on CCR2. Furthermore, CCR2-expressing DC were demonstrated to be critical for 
effector T cell restimulation and progression of the disease (Clarkson et al. 2015). Similarly, the 
work by Dogan et al. observed in a murine model of EAE glia-derived CCL2 attracting TNF– and 
nitric oxide synthase (NOS)-expressing macrophages and mDC to the CNS (Dogan, Elhofy, and 
Karpus 2008). Moreover, the work by Henkel et al. demonstrated in spinal cord tissues from 
patients affected with amyotrophic lateral sclerosis (ALS) an enrichment of DC concurrent with 
an increased expression of CCL2. In addition, ALS patients with a higher extent of DC 
accumulation in neurological tissues exhibited an accelerated progression of the disease 
compared to those with a reduced local involvement of DC (Henkel et al. 2006). Apart from that, 
human pancreatic islets were shown to constitutively produce CCL2 being upregulated by the 
presence of proinflammatory cytokines, such as TNF-α and IL-1β (Piemonti et al. 2002). Owing 
to their expression of CCR2, blood monocytes and mDC might be directed to the islets by locally 
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secreted CCL2 and this way contribute to the perpetuation of the autoimmune response in TID 
(Penna, Sozzani, and Adorini 2001). 
Interestingly, in concordance with our findings in pemphigus, a study by Nieminen et al. also 
observed decreasing frequencies of circulating mDC and pDC populations in recent-onset 
pediatric TID. Yet, they detected a reduced surface expression of CCR2 on both mDC and pDC 
from these patients (Nieminen et al. 2012). In the pathogenesis of SLE, Khan et al. reported of a 
decrease of circulating mDC in patients affected with active disease, although they did not 
investigate whether this reduction concurred with an altered expression of CCR2 (Khan et al. 
2013). In accordance with that, further studies also found in lupus patients a decreased frequency 
of circulating mDC (Scheinecker et al. 2001; Migita et al. 2005; Fiore et al. 2008; Jin et al. 2008). 
Furthermore, in psoriasis, the work of Prignano et al. similarly identified a diminished population 
of peripheral DC, including mDC and pDC in untreated patients and also assumed an augmented 
recruitment of DC into cutaneous plaques in these patients (Prignano et al. 2012). In primary SS, 
the number of blood DC was as well observed to be decreased, particularly that of the CD1a+ 
subset. Interestingly, they detected a local increase of mononuclear cells in the patients’ salivary 
glands, again suggesting trafficking of DC into peripheral sites of inflammation (Ozaki et al. 2001). 
Of note, a protective function of DC-expressed CCR2 has also been observed in autoimmune 
conditions, such as murine RA (Quinones et al. 2004). 
To summarize, our hypothesis of CCR2-mediated migration into the inflamed skin based on the 
detected reduced circulating frequencies of mDC and augmented expression of CCR2 in active 
pemphigus is supported by similar findings in other autoimmune diseases. Accordingly, not only 
in autoimmune disorders with mainly auto-ab–induced pathology, such as SLE (Khan et al. 2013), 
TID (Nieminen et al. 2012), and SS (Ozaki et al. 2001) blood mDC populations were found to be 
diminished, but also in psoriasis (Prignano et al. 2012). Further human and experimental studies 
observed an enrichment of DC populations in the respective organ targeted, i.e. the CNS in EAE 
(Clarkson et al. 2015; Dogan, Elhofy, and Karpus 2008) and ALS (Henkel et al. 2006), as well as 
the pancreatic islands in TID (Penna, Sozzani, and Adorini 2001), with migration depending on 
CCR2 in both EAE and TID. The found increased expression levels of CCL2 in EAE (Dogan, 
Elhofy, and Karpus 2008), ALS (Henkel et al. 2006), and TID (Piemonti et al. 2002) thereby 
provide indirect evidence for a central role of CCR2 in the migration of DC in autoimmune disease. 
Interestingly, the extent of DC accumulation within the affected tissue was also found to be critical 
for disease progression in both EAE (Clarkson et al. 2015) and ALS (Henkel et al. 2006). 
 
Like mDC, circulating pDC are also able to enter inflamed tissues although their responsiveness 
towards proinflammatory chemokines, such as CCL2, CCL5, and CCL20 is considerably reduced 
despite their chemokine receptor profile resembling that of mDC, including CCR2, CCR5, CXCR3, 
CXCR4, and CCR7 (Penna, Sozzani, and Adorini 2001). In the steady state, pDC rather migrate 
to secondary lymphoid organs attracted by the two CCR7-related chemokines CCL19 and CCL21 
(Penna, Sozzani, and Adorini 2001). 
Several autoimmune disorders are associated with an accumulation of pDC in lymphoid and 
peripheral tissues, such as SLE, psoriasis, and RA, as well as allergic diseases (Sozzani et al. 
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2010). In normal skin, pDC are absent, yet, in some inflammatory dermatoses, such as lupus 
erythematosus (LE) (Banchereau and Pascual 2006) and psoriasis (Nestle et al. 2005), pDC 
infiltrate the skin, in which they orchestrate local immune responses. In LE skin lesions, pDC were 
found to persist throughout the whole progression of the disease and to specifically locate to the 
dermis and dermo-epidermal junction where epithelial damage takes place (Vermi et al. 2009). 
Cytotoxic damage is a key pathological event in the interface dermatitis of LE and might be 
perpetuated by the local release of cytotoxic molecules by pDC (Sozzani et al. 2010). However 
in psoriasis, the infiltration of pDC is predominantly confined to the dermis and occurs during the 
early phases of the disease (Nestle et al. 2005). 
Apart from skin autoimmune diseases, a study by Lande et al. reported of immature pDC being 
recruited to both synovial fluid and tissue of RA patients. Expression of the IFN-α–inducible 
protein MxA in RA synovial tissue thereby suggested local production of type I IFN by mature 
pDC (Lande et al. 2004). In human nasal allergy, experimental challenge with allergen resulted 
in a pronounced increase of pDC in nasal mucosa. Moreover, adhesion molecules were found to 
be upregulated on pDC, normally allowing for leukocyte extravasation in organized lymphoid 
tissue (Jahnsen et al. 2000). 
In addition, a study by Baumgart et al. identified in patients with active IBD enhanced frequencies 
of pDC in the inflamed colonic mucosa and mesenteric LN (Baumgart et al. 2011). Similar to 
pemphigus, the enrichment of gut mucosal pDC was associated with declining numbers of 
peripheral immature pDC that also correlated with the severity of the disease (Baumgart et al. 
2005). Furthermore, patients with active IBD not only exhibited a significant drop of blood pDC, 
but also immature mDC. Likewise, a study by Chen et al. observed significantly reduced 
frequencies of pDC in the peripheral blood of TID patients (Chen et al. 2008). 
Altogether, analogous to our results of decreasing circulating pDC in active pemphigus patients, 
a diminished population of blood pDC was similarly found in patients with TID (Chen et al. 2008) 
and IBD with concurrent accumulation of pDC in the colonic mucosa (Baumgart et al. 2011). In 
pemphigus, pDC may possibly as well infiltrate the skin and cause damage by cytokine production 
as it was shown for patients with LE (Vermi et al. 2009) and psoriasis (Nestle et al. 2005). 
Interestingly, human pDC are weak APC, but upon activation by for instance viral nucleic acids 
acquire full DC morphology and phenotype (Liu 2005). Although less efficiently than classical 
mDC, they in this state present antigen to CD4+ T cells, as well as cross-prime CD8+ T cells 
(Villadangos and Young 2008; Hoeffel et al. 2007). The capacity of pDC to activate Dsg3-specific 
CD4+ T cells in pemphigus has not yet been investigated. 
 
The circulating population of slanDC was quantitatively characterized using a combination of two 
blood samples, and analysis of both data sets together revealed no significant differences 
between the test subject groups (Figure 4.9). Since in several autoimmune disorders, including 
psoriasis (Schakel 2009), MS (Thomas et al. 2014), RA (Schakel et al. 2006), and CD (de Baey 
et al. 2003), slanDC have been reported to be present in the inflammatory infiltrate, slanDC may 
likewise accumulate in the skin of pemphigus patients. 
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Interestingly, functional analysis indicated a close relationship of slanDC with rather nonclassical 
monocytes instead of DC, as they similarly possessed a superior ability to produce TNF-α 
(Schakel et al. 2002). In addition, treatment with glucocorticoids resulted in their depletion 
(Thomas et al. 2014), which we also observed in our patients (data not shown). 
In order to assess the state of maturity/immunogenicity of slanDC we as well determined their cell 
surface expression of HLA-DR and the costimulatory molecule CD86. Against our expectations, 
the distribution intensities of neither HLA-DR nor CD86 were elevated on blood slanDC from 
active pemphigus patients (Figure 4.12). We suggest that activation of slanDC rather occurs at 
the site of inflammation, where large amounts of skin-derived autoantigens are present and is 
thus not detectable in the circulation. This explanation may be in line with the observed increased 
expression of the inflammatory CCR2 on mDC from active pemphigus patients (Figure 4.11a), 
indicating an immature immune status. 
 
Interesting for pemphigus pathogenesis, numerous DC subsets that populate the human skin 
have been shown to shape both cellular and humoral immune responses in health and disease 
(Klechevsky 2013). Epidermal LC not only are particularly efficient at priming and cross-priming 
naïve CD8+ T cells into potent cytotoxic T cells, but also orchestrate CD4+ T cell responses 
(Klechevsky et al. 2008). Besides differentiating naïve T cells into cells releasing Th1 and Th2 
cell signature cytokines, LC also initiate Th17 responses in vitro (Mathers et al. 2007). In addition, 
LC were demonstrated to be eminently adept at differentiating naïve CD4+ T cells into IL-22– and 
IL-21–secreting cells (Penel-Sotirakis et al. 2012). 
In contrast to LC, CD14+ dermal DC can directly activate B cells into IgM-secreting plasma cells, 
partly by their secretion of IL-12 (Klechevsky et al. 2008). Moreover, CD14+ DC differentiate CD4+ 
T cells into T cells exhibiting a Tfh cell phenotype (Klechevsky et al. 2008). 
In this study, we found in active pemphigus patients increasing frequencies of circulating Th17 
cells (Figure 4.23c), which according to the findings above may be primed by LC of the epidermis. 
Correspondingly, elevated amounts of IL-21 in the plasma of active pemphigus patients (Figure 
4.29) may originate from either epidermal LC or CD14+ dermal DC primed Tfh cells. These 
presumptions have not yet been clarified in the pathogenesis of pemphigus. 
 
Taken together, active pemphigus patients exhibited reduced frequencies of both circulating mDC 
and pDC concurrent with an increased expression of CCR2 on mDC, indicating an elevated 
migration activity of these cells into the inflamed skin. Finally, we did not find clears signs of blood 
DC playing a dominant role in pemphigus pathogenesis, in contrast to observations in the disease 
development of other auto-ab–mediated autoimmune disorders, such as SLE (Means et al. 2005). 
Of note, differing identification strategies used for a marginal blood cell population, as well as a 
possible impact of medication may aggravate the quantitative and phenotypic comparison of DC 
subsets between individual studies. 
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5.1.2 Role of monocytes in pemphigus 
Beside DC with their unique extraordinary T cell stimulatory capacity (Steinman 2012), monocytes 
contribute to the maintenance of immune homeostasis and defense by various both direct and 
indirect effector functions (Auffray, Sieweke, and Geissmann 2009). Human monocytes constitute 
a heterogeneous population of accessory cells composed of several functionally discrete subsets 
and they are also able to both stimulate and suppress T cell responses in infectious and 
autoimmune diseases (Serbina et al. 2008; Evans et al. 2009; Movahedi et al. 2008; Geissmann 
et al. 2010). 
So far, only sporadic data exist concerning the role of monocytes in the evolvement and 
progression of pemphigus. In 2000, González et al. claimed a correlation between the population 
size and the phenotype of circulating mononuclear cells and the severity of PV disease, but the 
study suffered from a rather small cohort of patients (Gonzalez et al. 2000). In order to specify 
the relevance of monocytes in pemphigus more systematically, we firstly examined the distinct 
decomposition of the two major functionally discrete monocyte subsets distinguished by the 
expression of CD16 (Auffray, Sieweke, and Geissmann 2009). Unlike the predominant 
subpopulation of classical monocytes being devoid of CD16, CD16+ monocytes display a higher 
level of HLA-DR expression, entailing an enhanced APC and T cell stimulatory activity (Passlick, 
Flieger, and Ziegler-Heitbrock 1989) and are capable of inducing TNF-α upon stimulation with 
bacterial LPS (Belge et al. 2002). In the setting of nonautoimmune disease, CD16+ monocytes 
were reported to be augmented in the blood of patients with acute inflammation and infectious 
diseases (Mizuno et al. 2005; Fingerle-Rowson, Auers, et al. 1998; Horelt et al. 2002). 
Indeed, we also found for active pemphigus patients a significantly increased proportion of CD16+ 
monocytes and in addition, elevated values for MG patients who were used as a further unrelated 
antibody-mediated autoimmune disorder control (Figure 4.10a). But a correlation between 
frequencies of CD16+ monocytes and the occurrence of disease-associated subpopulations of 
CD4+ T cells could not be found. 
An increase of CD16+ monocytes was similarly observed in other autoimmune inflammatory 
conditions, including RA (Ziegler-Heitbrock 2007). In peripheral blood of RA patients, CD16+ 
monocyte numbers were not only found to be augmented, but also correlated with RBC 
sedimentation rate and plasma levels of C-reactive protein (Baeten et al. 2000). In addition, 
numerous studies reported of frequencies of CD16+ monocytes rising with RA activity (Kawanaka 
et al. 2002; Hepburn, Mason, and Davies 2004; Iwahashi et al. 2004; Cooper et al. 2012; Rossol 
et al. 2012; Yoon et al. 2014). 
Interestingly, systemic treatment of RA patients with corticosteroids resulted in a diminution of the 
circulating CD16+ monocyte population, possibly by selective apoptosis, whilst the population of 
classical monocytes even increased in a dose-dependent manner (Fingerle-Rowson, Angstwurm, 
et al. 1998; Dayyani et al. 2003). Consequently and crucial for validation of our data, increased 
frequencies of CD16+ monocytes in both active pemphigus patients and MG patients did not rely 
on the intake of immunosuppressive agents of individual patients. 
Similar to RA, an expansion of blood CD16+ monocytes producing TNF-α has also been observed 
in complication-free TID patients (Mysliwska et al. 2012), as well as in both peripheral blood and 
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salivary glands of SS patients (Ciccia et al. 2013). Contrariwise, SLE patients displayed reduced 
numbers and functionally impaired peripheral blood CD16+ monocytes, possibly pointing to a 
different function of this cell population in disease pathogenesis (Burbano, Vasquez, and Rojas 
2014). 
In summary, the rise of blood CD16+ monocytes in both active pemphigus and MG patients was 
observed in several other autoimmune disorders, including RA (Baeten et al. 2000), TID 
(Mysliwska et al. 2012), and SS (Ciccia et al. 2013), which points to a rather disease-unspecific, 
common inflammatory effect. 
 
Regarding the function of CD16+ monocytes, these cells are located within blood vessels, where 
they patrol healthy tissues for damage or pathogenic microbes by continually crawling long-range 
onto the endothelium (Auffray et al. 2007). Following extravasation into the tissue, CD16+ 
monocytes differentiate into macrophages and elicit an innate immune response (Auffray et al. 
2007). Accordingly, Hepburn et al. suggested for RA that the elevation of the circulating CD16+ 
monocyte subset represented an activation of the monocyte/macrophage system and that these 
cells might possess the ability of differentiating into macrophages in the synovium, where they 
would act as potent producers of proinflammatory cytokines (Hepburn, Mason, and Davies 2004). 
In the pathogenesis of IBD, CD16+ monocytes have been proposed to exert a similar function as 
they have been found to particularly accumulate within the active inflamed regions of the mucosa, 
in which high levels of TNF-α have been linked with disease progression (Koch et al. 2010; Hanai 
et al. 2008; Komatsu et al. 2001; Papadakis and Targan 2000). In addition, an expansion of 
activated CD16+ monocytes has also been observed in patients affected with the demyelinating 
autoimmune disorder MS (Chuluundorj et al. 2014). 
In active pemphigus patients, elevated plasma levels of the proinflammatory cytokines IL-6 and 
TNF-α (Figure 4.19) may as well originate from the expanded circulating population of CD16+ 
monocytes as discussed later on. 
 
Based on the expression level of CD14, CD16+ monocytes can be further subdivided into two 
functionally discrete subsets with the designated nonclassical and intermediate monocytes 
exhibiting reduced and high levels of CD14, respectively (Grage-Griebenow, Flad, and Ernst 
2001). Possibly in transition from the classical to the nonclassical subset (Ziegler-Heitbrock and 
Hofer 2013), CD14+CD16+ intermediate monocytes constitute a marginal population with unique 
properties that was observed to be expanded under inflammatory conditions (Rossol et al. 2012; 
Moniuszko et al. 2009). 
Similarly, the population of CD14dimCD16+ nonclassical monocytes has been implicated in the 
pathogenesis of autoimmune disorders. For instance, TLR7- and TLR8-mediated recognition of 
immune complexes containing nucleic acids by nonclassical monocytes resulted in the production 
of proinflammatory cytokines, including TNF-α (Cros et al. 2010). In addition, a very recent study 
identified nonclassical monocytes as the primary proinflammatory CD16+ monocyte subset. Upon 
stimulation with LPS, these cells not only secreted elevated amounts of IL-1β and TNF-α 
compared to the intermediate subset, but were also expanded in patients with sepsis and SLE 
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(Mukherjee et al. 2015). Interestingly, sepsis patients as well exhibited enhanced frequencies of 
intermediate monocytes, whilst an increase of the nonclassical subset was confined to patients 
with SLE, possibly due to their status of chronic inflammation (Grage-Griebenow, Flad, and Ernst 
2001). 
In our study, active pemphigus patients displayed augmented numbers of circulating 
CD14dimCD16+ nonclassical monocytes with significance close to the threshold (Figure 4.10b). 
This observation is in concordance with the findings by Baeten et al. of elevated frequencies of 
CD16+ monocytes that expressed a specific autoantigen of RA and exhibited diminished levels of 
CD14 in both peripheral blood and synovial tissue from RA patients. Furthermore, the presence 
of these cells in synovial tissue correlated with the extent of joint destruction, suggesting a local 
involvement of nonclassical, but not intermediate monocytes in the pathogenesis of RA (Baeten 
et al. 2000). A study by Rossol et al. however identified a selective expansion of the intermediate 
monocyte subset in peripheral blood of RA patients (Rossol et al. 2012), so data concerning the 
quantitatively predominant CD16+ monocyte subtype in RA is still controversial. 
In contrast to our observation of increasing nonclassical monocytes in active pemphigus patients, 
augmented circulating frequencies of the intermediate subtype were reported in several other 
autoimmune disorders, such as CD (Grip et al. 2007) and Eales’ disease (ED) (Sen et al. 2011). 
A possible explanation for the more frequently detected expansion of the intermediate subset in 
inflammatory and autoimmune conditions was very recently provided by Liu et al. Analogous to 
the findings in CD (Grip et al. 2007), ED (Sen et al. 2011), and RA (Rossol et al. 2012), patients 
with autoimmune uveitis (AU) as well displayed augmented circulating intermediate monocytes, 
but importantly, this effect was associated with glucocorticoid therapy (Liu et al. 2015). Moreover, 
according to the work by Mukherjee et al., purification of PBMC by density gradient centrifugation 
critically changed surface expression of CD14 and CD16 on monocytes towards a nonclassical 
monocyte phenotype (Mukherjee et al. 2015). 
Since we only included patients with no or minimal intake of Pred in our study, as well as used 
whole blood for the phenotypic characterization of CD16+ monocytes, the observed expansion of 
the nonclassical subset in active pemphigus patients was not induced by medication or density 
gradient centrifugation. 
Altogether, active pemphigus patients displayed in peripheral blood a selective expansion of the 
nonclassical subset within CD16+ monocytes as similarly reported in patients with RA (Baeten et 
al. 2000), sepsis, and SLE (Grage-Griebenow, Flad, and Ernst 2001). Importantly, therapy with 
glucocorticoids as well as the respective cell isolation method selected may critically impact the 
frequencies of nonclassical monocytes, which has to be considered upon comparison of different 
study results. 
 
It has long been known that there is a local accumulation of mononuclear APC, including 
monocytes, macrophages, and the skin-resident LC in both lesional and perilesional skin biopsies 
obtained from PV patients (Nestor, Cochran, and Ahmed 1987; Mashkilleyson, Konttinen, and 
Visa 1989; Chiapa-Labastida et al. 2011). The migration of circulating monocytes into the 
periphery underlies distinct trafficking mechanisms, with the classical CD16- population being 
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recruited via the CCL2/monocyte chemoattractant protein-1 (MCP-1)–CCR2 axis, whilst CD16+ 
monocytes are largely devoid of CCR2 (Geissmann, Jung, and Littman 2003). Under 
inflammatory conditions, this route enables classical monocytes to exit the blood stream and 
access peripheral nonlymphoid tissues (Boring et al. 1997; Kurihara et al. 1997; Maus et al. 2003; 
Kuziel et al. 1997). This may also explain why blocking CCR2 was effective in attenuating disease 
in models of atherosclerosis, MS, and RA with known monocyte-induced pathology (Viola and 
Luster 2008; Boring et al. 1998; Izikson et al. 2000; Gong et al. 1997). 
Interestingly, CCR2 expression of monocytes was elevated in active pemphigus patients and 
similarly also in MG controls (Figure 4.11b), and the associated CCR2-mediated monocyte 
migration in the state of inflammation may be likewise linked to pemphigus pathogenesis. In 
support of this hypothesis, there is great evidence for a pathogenic role of CCL2/CCR2-mediated 
migration of monocytes in other autoimmune disorders. 
Accordingly, CCR2-dependent infiltration of mononuclear cells induced inflammation and 
destruction of the retina in a spontaneous mouse model of AU. Depletion of functional CCR2 
however efficiently prevented induction of the disease phenotype, probably by an impaired 
monocyte-mediated recruitment of autoreactive CD4+ T lymphocytes (Chen et al. 2014). In 
experimental TID, in which monocytes infiltrating the islets contribute to disease pathogenesis, 
CCR2 deficiency similarly resulted in a delayed onset of diabetes pathology (Solomon, Balasa, 
and Sarvetnick 2010). Furthermore, loss of CCR2 also resulted in diminished renal disease and 
prolonged survival in experimental SLE (Perez de Lema et al. 2005). 
Concerning human studies, Vestergaard et al. found in patients afflicted with the skin autoimmune 
diseases atopic dermatitis (AD) and psoriasis a slight, but significant overexpression of CCR2 on 
peripheral blood monocytes compared to HC (Vestergaard et al. 2004). Moreover, rising levels of 
CCL2 were detected within the colon of IBD patients that might attract CCR2-bearing monocytes 
into the inflamed mucosal tissue. In addition, local CCL2 expression also correlated with the 
activity of the disease (Banks et al. 2003). 
CCL2 is a potent attractor for monocytes and DC (Nakamura, Williams, and Kupper 1995), as 
well as both Th1 and Th2 cells (Sebastiani et al. 2001), and was present in the basal layer of 
lesions from patients with AD and psoriasis (Giustizieri et al. 2001). While CCL2 was undetectable 
in resting keratinocytes, a study by Li et al. observed expression of CCL2 in both oral and skin 
keratinocytes depending on TNF-α and/or IFN- (Li, Farthing, and Thornhill 2000). Interestingly, 
the work by Feliciani et al. revealed in both lesional and perilesional skin areas from PV patients 
an overexpression of IL-1α and TNF-α by keratinocytes. In addition, keratinocyte synthesis of the 
IL-1α and TNF-α transcripts was induced by autoreactive IgG antibodies in vitro, and mice 
deficient in either cytokine exhibited reduced pemphigus pathology upon passive transfer of 
pemphigus (Feliciani et al. 2000). Apart from that, a study by Chiapa-Labastida et al. found in PV 
patients apoptotic keratinocytes to accumulate in both dermis and epidermis that induce 
monocytes to release TNF-α during phagocytosis of these cells (Chiapa-Labastida et al. 2011). 
To summarize, active pemphigus patients displayed an upregulation of CCR2 on classical 
monocytes, suggesting a potential role of CCL2/CCR2-mediated migration of monocytes into the 
inflamed skin. This scenario is supported by several studies in other autoimmune disorders, 
101 
 
including experimental AU (Chen et al. 2014), TID (Solomon, Balasa, and Sarvetnick 2010), and 
SLE (Perez de Lema et al. 2005), in which depletion of functional CCR2 resulted in an 
amelioration of disease pathology. Moreover, increasing levels of the CCR2-associated CCL2 
were detected in the colon of IBD patients (Banks et al. 2003), as well as lesional skin of patients 
with AD and psoriasis (Giustizieri et al. 2001). Interestingly, CCL2 expression of keratinocytes 
was found to be induced by TNF-α and/or IFN- (Li, Farthing, and Thornhill 2000), and IgG auto-
ab from pemphigus patients induced keratinocytes to synthesize the transcripts of IL1α and TNF-
α in vitro. Hence, auto-ab–mediated production of TNF-α of keratinocytes may stimulate the local 
expression of CCL2 attracting CCR2-bearing blood monocytes to the site of inflammation in 
pemphigus. 
 
In order to assess the status of immunogenicity of monocytes from pemphigus patients, we 
specifically determined their capacity to secrete the proinflammatory cytokines IL-6 and TNF-α 
upon stimulation with LPS. Although the intensity of intracellular IL-6 and TNF-α expression was 
not significantly increased in active pemphigus patients, they displayed a gradual elevation of 
TNF-α synthesis (Figure 4.15b) and a shift to higher IL-6 and TNF-α individual values (Figure 
4.15c). Considering the relationship between both IL-6 and TNF-α yielded an even enhanced 
separation between active pemphigus patients and HC (Figure 4.15c). 
Upon analysis of proinflammatory cytokine synthesis, we did not specify CD14+ monocytes by 
additional expression of CD16. Yet, according to the findings by Mukherjee et al. we assume that 
the nonclassical CD16+ monocyte subset is the primary source of TNF-α that we also found to be 
expanded in active pemphigus patients (Figure 4.10b). 
 
Several studies reported of significantly elevated levels of circulating, i.e. released TNF-α in PV 
patients (Ludwig and Schmidt 2009; Keskin et al. 2008; Alecu et al. 1999; Lopez-Robles et al. 
2001). Moreover, D’Auria et al. detected increasing levels of both TNF-α and IL-6 in the sera of 
PV patients, which also correlated with the activity of the disease. In addition, systemic therapy 
with corticosteroids resulted in a diminution of both cytokine serum concentrations, as well as 
clinical manifestations (D/'Auria, Bonifati, and Mussi 1997). Furthermore, Narbutt et al. observed 
in both active and remittent stage of PV elevated serum concentrations of IL-6, as well as a 
negative correlation between TNF-α levels and IgG auto-ab titers in remittent PV patients (Narbutt 
et al. 2008). 
In our study, the plasma concentrations of TNF-α in active pemphigus patients were significantly 
augmented (Figure 4.19b). An elevation may also be valid for the IL-6 plasma levels of the active 
pemphigus patients, although only a nonsignificant elevation was observed, but the significance 
level was possibly affected by the two extreme IL-6 values within the HC group (Figure 4.19a). 
Noteworthy, the plasma levels of both TNF-α and IL-6 of the three remittent patients assumed 
similar values as the HC (Figures 4.19). Important for pemphigus pathology, high titers of anti-
Dsg IgG antibodies were found in patients with high levels of both TNF-α (Figure 4.26a and b) 
and IL-6 (Figure 25a and b) as revealed by the correlation of these parameters. However, 
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according to a recent study by Hall et al., application of the mAb Infliximab targeting TNF-α did 
not prove effective for the treatment of patients with PV (Hall et al. 2015). 
In summary, we could not detect significant differences in IL-6 and TNF-α production by CD14+ 
monocytes between active pemphigus patients and control groups. Yet, we observed in active 
pemphigus patients increasing levels of both IL-6 and TNF-α, which is in line with other respective 
reports in the literature (Ludwig and Schmidt 2009; D/'Auria, Bonifati, and Mussi 1997). Important 
for pemphigus pathology, we observed a correlation between both IL-6 and TNF-a plasma levels 
and serum IgG auto-ab titers in pemphigus patients, indicating a contribution of these cytokines 
to auto-ab induction. 
 
The capability to take up and process antigen belongs to the most important functions of APC, 
including monocytes (Auffray, Sieweke, and Geissmann 2009). In order to assess whether this 
property is altered in pemphigus, PBMC were exposed to fluorescently labeled recombinant 
human Dsg3 protein, and the maximum antigen uptake capacity, as well as kinetics of take up 
were determined. 
In active pemphigus patients, neither the antigen uptake ability of CD16+ (Figure 4.18a) nor 
classical monocytes (Figure 4.18b) significantly differed from that of HC. In addition, no 
differences in the velocity of protein internalization were found between active pemphigus patients 
and HC (Figure 4.18c). Thus, we could not observe pemphigus-specific particularities concerning 
the antigen uptake capacity of monocytes. 
In agreement with the report by Mukherjee et al., we similarly identified classical monocytes as 
the primary subset specialized in phagocytosis compared to CD16+ monocytes (Mukherjee et al. 
2015). Equipped with high expression of the scavenger receptors CD36 and CD163, as well as a 
high intracellular concentration of myeloperoxidase and lysozyme, classical monocytes represent 
excellent phagocytes (Mysliwska et al. 2012). 
 
5.1.3 Role of CD4+ T cells in pemphigus 
Although the pathology of pemphigus is linked to the generation of mainly Dsg-specific IgG auto-
ab, the critical role of autoreactive CD4+ T cells in the induction of these humoral responses has 
been analyzed and highlighted in numerous studies (Hertl, Eming, and Veldman 2006). 
In 1997, Lin et al. developed Dsg3-reactive CD4+ T cell lines and clones from PV patients that 
upon stimulation secreted Th2 cell signature cytokines, and whose response to recombinant Dsg3 
fusion proteins was restricted to HLA-DR (Lin, Swartz, and Lopez 1997). Using Dsg3-specific T 
cell lines and clones from PV patients, a study from our group found in chronic active PV patients 
frequencies of autoreactive Th1 cells surpassing those of autoreactive Th2 cells, as well as T cell 
recognition of the Dsg3 ectodomain being restricted to both HLA-DRB1*04:02 and HLA-
DQB1*05:03 (Veldman et al. 2003b). In addition, Rizzo et al. observed in PV patients a significant 
association of Dsg3-specific Th2 activity with overt disease, whereby this Th2 activity also 
correlated with the Dsg3-specific IgG titers of the patients (Rizzo et al. 2005). 
Considering the observed increased production of APC-derived proinflammatory cytokines in 
pemphigus patients (Figures 4.19), we as well sought to assess whether the polarization of CD4+ 
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T cells is affected. Yet, in our study, the circulating frequencies of neither Th1 nor Th2 cells 
significantly varied between active pemphigus patients and control groups as illustrated in Figure 
4.23a and b. Zhu et al. similarly observed for Th2 cells no significant differences between HC, 
active and remittent PV patients, but differing from our findings a significantly reduced subset of 
Th1 cells in active PV patients (Zhu et al. 2012). 
 
Based on the Th2 cell bias observed in active PV patients (Rizzo et al. 2005), we additionally 
determined the levels of the Th2 cell-related IL-33 in the plasma of pemphigus patients and 
controls. IL-33, identified as a member of the IL-1 cytokine family in 2005 (Schmitz et al. 2005) 
predominantly induces Th2 cell responses and has also been implicated in the pathogenesis of 
allergy and several autoimmune diseases, such as RA, SLE, and MS (Pei et al. 2014; Tang et al. 
2013; Li, Lin, and Zheng 2014; Christophi et al. 2012). In addition, IL-33 functions as an alarmin 
upon cellular stress or damage (Cayrol and Girard 2014). 
In active pemphigus patients, the plasma levels of IL-33 tended to be enhanced (p= 0.1687) 
compared to HC and additionally, MG patients also exhibited elevated (p= 0.1171) values, 
although without reaching significance (Figure 4.20a). A very recent publication by Tirado-
Sanchez et al. indeed detected in the sera of PV patients significantly elevated levels of IL-33 and 
its respective soluble receptor sST2, with these two parameters also correlating with both Dsg3-
specific IgG titers and the clinical activity of the disease (Tirado-Sanchez, Bonifaz, and Ponce-
Olivera 2015). 
 
Interestingly, active pemphigus patients exhibited a clearly elevated subpopulation of Th17 cells, 
which was also the case to a lower extent in MG controls (Figure 4.23c). Th17 cells are a discrete 
subset of CD4+ T cells that is considered as proinflammatory and that has been implicated in the 
pathogenesis of various autoimmune disorders, including psoriasis, RA, IBD, and MS (Yang et 
al. 2014). Our finding is in accordance with the study by Xu et al. who demonstrated significantly 
elevated numbers of circulating Th17 cells particularly in both acute onset and chronic active PV 
patients (Xu et al. 2013). A recent study by Asothai et al. similarly observed increasing frequencies 
of Th17 cells in the blood of PV patients (Asothai et al. 2015). In addition, a study by Arakawa et 
al. reported of an accumulation of lesional Th17 cells in PV patients, while neither the Dsg3-
specific antibody titers nor the severity of the disease correlated with the proportion of IL-17+ cells 
present in the skin lesions (Arakawa et al. 2009). Identification of the precise function of Th17 
cells in the pathogenesis of pemphigus still requires further investigation. Yet, the finding of 
elevated frequencies of Th17 cells in MG patients is in concordance with very recent results in an 
experimental animal model of MG by Schaffert et al. who demonstrated the production of AChR-
specific IgG antibodies relying on Th17 cells in their in vivo model (Schaffert et al. 2015).  
Of note, a study by Iwamoto et al. reported of TNF-α inducing Th1 and Th17 cell responses by 
mediating the differentiation of LPS-stimulated CD14+ monocytes into mature DC (Iwamoto et al. 
2007). Nonclassical CD16+ monocytes being expanded in peripheral blood of both pemphigus 
and MG patients (Figure 4.10b) potently produce TNF-α upon stimulation (Mukherjee et al. 2015; 
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Belge et al. 2002), this way possibly contributing to the formation of Th17 cells in the pathogenesis 
of pemphigus and MG. 
 
Remarkably, active pemphigus patients exhibited slightly augmented subpopulations of IL-10–
producing CD4+ T cells unlike MG controls showing diminished percentages of these cells (Figure 
4.23d). Although various studies demonstrated reduced immunoregulatory CD4+ T cell numbers 
in PV patients (Veldman, Hohne, et al. 2004; Hertl, Eming, and Veldman 2006; Sugiyama et al. 
2007; Xu et al. 2013), this discrepancy might be explained by Th2 cells as well secreting IL-10, 
since we did not assess a suppressive function of these cells. Otherwise, the augmented 
proportion of IL-10–producing CD4+ T cells may represent a population of Tr1 cells in transition 
to Th17 cells under the influence of proinflammatory cytokines, including IL-6, IL-1β, and TNF-α, 
as it has already been demonstrated for other skin diseases (Bovenschen et al. 2011). 
Alternatively, increasing frequencies of IL-10–secreting Th cells may also represent a 
compensatory mechanism triggered by the misguided immune response in pemphigus. 
Moreover, this observed rise possibly depends on IL-27, which we found to be augmented in the 
plasma of pemphigus patients (Figure 4.20b) and which is known to propagate the IL-10 
secretion of effector CD4+ T cells (Neumann et al. 2014; Batten et al. 2008). The potential function 
of IL-27 in the pathogenesis of pemphigus will be further discussed in the following section. 
 
Altogether, since in active pemphigus patients, we did not find an increase of circulating Th2 cells, 
we conclude that the Th2 cell bias reported in pemphigus is rather confined to Dsg-specific CD4+ 
T cells (Rizzo et al. 2005). Interestingly, and according to findings in the literature (Xu et al. 2013; 
Asothai et al. 2015), active pemphigus patients displayed a pronounced elevation of peripheral 
Th17 cells, which may be induced by the observed expanded population of CD16+ monocytes 
(Mukherjee et al. 2015). Unexpectedly, active pemphigus patients as well exhibited augmented 
frequencies of IL-10–producing T cells, which is opposed to the findings of other respective 
studies (Veldman, Hohne, et al. 2004; Xu et al. 2013). Possibly, since we did not test for a 
suppressive capacity of these cells, this detected increase is due to Th2 cells as well secreting 
IL-10, transitional Th cell plasticity, immune compensatory mechanisms, or an effect depending 
on IL-27, which we also found to be elevated in the plasma of active pemphigus patients. 
 
5.1.4 Role of IL-21–producing T cells in pemphigus 
Neutralizing antibodies are an essential factor in the development of protective immunity to most 
pathogenic threats. However, B cell dysfunction can result in the generation of autoreactive 
antibodies and the formation of immune complexes, which induce local inflammatory reactions 
and tissue damage (Martin and Chan). Pemphigus is considered as a prototypical auto-ab–
mediated organ-specific disorder and when monitored in individual patients, the titers of serum 
Dsg-reactive IgG antibodies generally correlate with disease activity (Ishii et al. 1997; Sams and 
Jordon 1971). In accordance with that, predominantly active PV patients of our cohort displayed 
elevated Dsg3-specific serum IgG titers, which varied within a wide range (Figure 4.24). 
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Interestingly, beside IgG auto-ab titers correlating with both circulating TNF-α (Figure 4.26a and 
b) and IL-6 (Figure 25a and b), we also found for pemphigus and solely PV patients a strong 
correlation between the presence of serum Dsg-responsive antibodies and the plasma levels of 
IL-27 (Figure 27a and b). Moreover in pemphigus patients, the plasma levels of IL-27 not only 
strongly correlated with the production of circulating auto-ab, but were also significantly elevated 
in individuals with active disease (Figure 4.20b). Similarly, MG patients exhibited enhanced 
plasma concentrations of IL-27 (Figure 4.20b), which yet in contrast to pemphigus patients did 
not relate to the serum titers of anti-AChR IgG (Figure 4.27c), suggesting a disease-specific 
function of IL-27 in the pathogenesis of pemphigus. 
 
IL-27, a heterodimeric cytokine recently discovered by Pflanz et al. is evolutionary related to IL-
12 and is mainly expressed by activated APC (Pflanz et al. 2002). IL-27 exerts key modulatory 
effects on both T and B cells with its regulatory activities comprising the induction of inhibitory 
receptor PD ligand 1 (PD-L1) upregulation and the secretion of IL-10 by several CD4+ T cells. To 
its inflammatory properties belong the development of cytotoxic CD8+ T cells, the capacity to 
directly support B cell production of antibodies (Hunter and Kastelein 2012), and the promotion 
of Tfh cells (Batten et al. 2010; Gringhuis et al. 2014). Interestingly, a disease-propagating 
function of IL-27 has been described in several disorders of autoimmune etiology, such as IBD 
(Schmidt et al. 2005; Cox et al. 2011), RA (Goldberg, Wildbaum, et al. 2004; Cao et al. 2008 ; 
Shen et al. 2011), EAE (Goldberg, Zohar, et al. 2004; Li et al. 2005), psoriasis (Shibata et al. 
2010; Shibata et al. 2013), TID (Wang et al. 2008), and SS (Xia et al. 2012). For instance, 
Goldberg et al. suppressed an ongoing disease in mouse models of both RA and MS via the 
neutralization of the p28 subunit of IL-27 (Goldberg, Wildbaum, et al. 2004; Goldberg, Zohar, et 
al. 2004). In our study, we observed in pemphigus patients a strong correlation of IL-27 plasma 
concentrations with TNF-α, which might support an additional proinflammatory role of IL-27 in 
pemphigus pathogenesis (Figure 4.28a). 
Recently, Batten et al. demonstrated that IL-27 signaling in T cells resulted in the production of 
IL-21 and in addition that IL-27 was able to enhance both the survival of activated CD4+ T cells 
and the expression of the Tfh cell markers CXCR5, PD-1, and ICOS. Moreover, loss of IL-27 
signaling was shown to ameliorate disease in a murine model of SLE (Batten et al. 2010). Tfh 
cells represent specialized and essential providers of B cell help both to form and maintain GC 
and to regulate the differentiation of B cells into memory B cells and antibody-secreting plasma 
cells. The characteristic expression of CXCR5 defines the localization of Tfh cells to B cell follicles 
within secondary lymphoid tissues, including GC. During the process of affinity maturation, 
CD4+CXCR5+ Tfh cells efficiently induce both class switching and antibody secretion of B cells 
(Tangye et al. 2013). Owing to their capacity to control the induction of high-affinity humoral 
immune responses, alterations in the peripheral Tfh cell compartment have been found in several 
antibody-mediated autoimmune disorders, like SLE and RA, in which the expansion of blood Tfh 
cells (defined as CD4+CXCR5+PD-1+ICOS+ T cells) could be linked to disease activity (Simpson 
et al. 2010; Wang et al. 2013). Moreover, a study by Gringhuis et al. observed fucose-based 
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stimuli inducing DC to potently produce IL-27, which can drive Tfh cell generation and T cell-
dependent IgG production by B cells (Gringhuis et al. 2014). 
In order to assess whether the above mentioned axis of IL-27-induced promotion of Tfh cells may 
also be relevant in pemphigus, we determined the plasma levels of IL-21 being robustly produced 
by Tfh cells (Luthje et al. 2012) and exerting an essential function in B cell differentiation into 
class-switched plasma cells (Linterman et al. 2010). Indeed, active pemphigus patients and MG 
controls displayed significantly elevated plasma concentrations of IL-21 (Figure 4.29). Increasing 
amounts of circulating IL-21 have been previously observed in MG (Yilmaz et al. 2015; Li et al. 
2014) and other antibody–mediated autoimmune disorders, such as RA (Liu et al. 2012) and SLE 
(Dolff et al. 2011), suggesting that IL-21 is produced by autoreactive Tfh cells during an ongoing 
auto-ab response. Interestingly, an increase of both IL-21 levels and Tfh cells has also been found 
in patients with the pemphigus-related AIBD BP (Li et al. 2013). 
In order to trace the cellular source of the circulating IL-21 and to underpin the hypothesis of an 
IL-27–mediated propagation of Tfh cells, we additionally quantified the circulating population of 
Tfh cells in a further cohort of pemphigus and MG patients, as well as HC (Hennerici et al. 2016). 
According to the findings by Morita et al., circulating counterparts of Tfh cells can be detected by 
the expression of CXCR5 in peripheral blood (Morita et al. 2011). Of note, a few pemphigus 
patients used in this analysis received systemic immunosuppressive treatment, which however 
was reported to induce a decline of both peripheral Tfh cells and IL-21 plasma levels (Jin et al. 
2014; Liu et al. 2014). 
Indeed, the frequency of CD4+CXCR5+ circulating Tfh cells was significantly increased in 
pemphigus patients. Yet, in contrast to previous studies in MG (Tackenberg et al. 2007; Saito et 
al. 2005; Luo et al. 2013), we did not detect elevated numbers of peripheral Tfh cells in our cohort 
of MG patients, which is possibly due to the rather mild to moderate disease activity of the study 
patients. In addition, since almost all MG patients were under either immunomodulatory or 
immunosuppressive therapy at the time of analysis, a potential therapeutic effect cannot be 
excluded. Furthermore, we identified in the investigated pemphigus patients Dsg3-specific IL-21–
producing cells in a significantly higher frequency compared to HC by ELISPOT assay. These 
findings indicate that autoreactive Dsg3-specific IL-21–producing T cells are involved in the 
induction of Dsg3-specific auto-ab by providing help to autoreactive B cells. However, the effect 
of IL-27 on promoting peripheral Tfh cell rather occurs in a timely delayed manner because we 
could not find a correlation between circulating Tfh cells and IL-27 plasma levels. 
Of note, IL-21 is also produced by Th17 cells (Zhou et al. 2007), which we noticed to be enhanced 
in the blood of both active pemphigus and MG patients (Figure 4.23c). IL-21 induces the 
differentiation of Th17 cells in a STAT3-depending manner, this way possibly providing autocrine 
stimulation for the maintenance of Th17 cells (Wei et al. 2007; Korn et al. 2007). In this respect, 
we conclude that IL-21 in pemphigus is partially released by activated Th17 cells, which is also 
confirmed by the detection of IL17/IL-21 double positive T cells in pemphigus patients. Yet, IL-
21–producing Th17 cells only displayed a minor T cell population in the analyzed pemphigus 
patients with IL-21 single positive T cells being over 20 times more frequent. 
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Taken together, increasing plasma levels of IL-27, which strongly correlated with Dsg-specific IgG 
auto-ab titers, as well as elevated plasma levels of IL-21 concurrent with augmented frequencies 
of circulating Tfh and Th17 cells imply a potential contribution of IL-27 and IL-21–producing T 
cells to the pathogenesis of pemphigus. Hence, the antagonization of IL-27 and other factors 
involved in Tfh cell function, like IL-21 may represent a novel therapeutic option in pemphigus. 
 
5.1.5 Summary 
Aim of the first part of this doctoral thesis was to investigate antigen-presenting cells and APC-
derived cytokines, as well as their relation to Th cell subsets and the auto-ab response in the 
pathogenesis of pemphigus. Concerning the APC compartment, we found quantitative alterations 
with the frequencies of both blood mDC and pDC being diminished in active pemphigus patients. 
This reduction concurred with a significantly augmented expression of CCR2 on circulating mDC, 
an effect that we similarly observed on CD14+ monocytes, possibly suggesting an increased 
migration of APC into the inflamed skin. Moreover, circulating frequencies of CD16+ monocytes 
were significantly elevated in active pemphigus patients, as well as MG controls, of which the 
nonclassical CD16+ subset identified by a reduced expression of CD14 was specifically expanded 
in active pemphigus patients. With regard to the function of APC, active pemphigus patients 
displayed slightly and significantly augmented plasma concentrations of IL-6 and TNF-α, 
respectively. Moreover, plasma levels of the Th2 cell-linked IL-33 were slightly enhanced in active 
pemphigus patients without reaching significance. Interestingly, pemphigus patients with active 
disease exhibited significantly elevated circulating frequencies of Th17 cells and IL-10–producing 
T cells. 
Furthermore, a strong correlation between IL-27 plasma levels and Dsg-specific IgG auto-ab 
titers, as well as elevated plasma levels of IL-21 along with increased frequencies of peripheral 
Tfh and Th17 cells suggest a potential implication of IL-27 and IL-21–producing T cells in the 
pathogenesis of pemphigus. 
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5.2 Mouse study 
The second part of this doctoral thesis deals with a novel HLA-DRB1*04:02–tg mouse model of 
PV, in which we characterized Dsg3-specific cellular and humoral immune responses. This model 
was created based on a high prevalence of distinct HLA class II alleles in pemphigus patients, 
including HLA-DRB1*04:02, –DRB1*14:01, and –DQB1*05:03 (Tron et al. 2006). Detailed 
epidemiological analysis revealed the association of PV with HLA-DRB1*04:02 and –DQB1*05:03 
being primary, whereas the increased occurrence of –DRB1*14:01 and –DQB1*03:02 is due to a 
linkage disequilibrium with the respective primary allele (Lee et al. 2006). The pathogenesis of 
pemphigus being linked to the presence of specific HLA class II alleles implies autoreactive CD4+ 
T cells exerting a critical function in the initiation and maintenance of this disease, for which 
numerous studies have provided evidence (Hertl, Amagai, et al. 1998a; Nishifuji et al. 2000; 
Takahashi et al. 2008; Takahashi, Kuwana, and Amagai 2009; Eming et al. 2008; Amber et al. 
2013). 
In this study, the HLA-DRB1*04:02–tg mouse model of PV served as a means to investigate APC-
mediated activation of CD4+ T cells, as well as CD4+ T cell-mediated induction of IgG antibody 
production in a Dsg3-specific manner, respecting the strong genetic association of this 
autoimmune disorder. In order to assess Dsg3-specific antibody production, we at first immunized 
these mice with human Dsg3 protein and assayed IgG reactivity against both recombinant and 
native Dsg3. Subsequently, we tested for the HLA-DRB1*04:02–restricted activation of Dsg3-
specific CD4+ T cells using APC equipped with epitopes of the Dsg3 ectodomain, which 
specifically bind to HLA-DRβ1*04:02. In the reverse experiment, HLA-DRB1*04:02–dependent T 
cell recognition of human Dsg3 was determined by in vivo immunization of mice with the HLA-
DRβ1*04:02–binding Dsg3 epitopes and ex vivo restimulation of activated T cells with the full 
Dsg3 ectodomain. Furthermore, in order to test whether Dsg3-specific production of IgG 
antibodies was similarly regulated by HLA-DRB1*04:02, we additionally immunized mice with 
Dsg3 epitopes, which bind to HLA-DRβ1*04:02 and checked for reactivity against both 
recombinant and native Dsg3 protein. Finally, we analyzed whether the IgG induced in mice by 
immunization with the human Dsg3 ectodomain displayed cross-reactivity against recombinant 
and native murine Dsg3 in both ex vivo and in vivo experiments. 
In order to specify the findings obtained in this study for HLA-DRB1*04:02, some of the 
experiments were additionally performed in mice transgenic for HLA-DRB1*04:01 by the 
collaboration group of J. Bäcklund. Unlike HLA-DRB1*04:02, the HLA-DRB1*04:01 allele strongly 
relates to the prevalence of RA. 
 
In our HLA-DRB1*04:02–tg mouse model of PV, we could demonstrate that induction of human 
Dsg3-specific IgG antibodies depended on prior activation of Dsg3-reactive CD4+ T cells. T cell 
activation thereby critically relied on the recognition of epitopes of the Dsg3 ectodomain, which 
specifically bind to HLA-DRβ1*04:02. Thus, polymorphisms of peptide-binding motifs of distinct 
PV-linked HLA class II alleles tightly regulated CD4+ T cell-mediated induction of Dsg3-reactive 
IgG antibodies. However, human Dsg3-specific IgG antibodies only displayed weak cross-
reactivity with the murine analogue protein ex vivo and did not interact with native protein in mice 
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immunized with human Dsg3 protein. This might explain why this mouse model did not develop 
the clinical PV phenotype, but reliably reproduced HLA-DRB1*04:02–restricted human Dsg3-
specific immune responses on both the CD4+ T cell and B cell level. 
 
5.2.1 T cell recognition of human Dsg3 is tightly HLA-DRB1*04:02–restricted 
The pathology of pemphigus is primarily caused by the presence of Dsg-specific IgG auto-ab 
causing loss of epidermal keratinocyte adhesion, which manifests clinically in blister and erosion 
formation of the skin and mucous membranes (Kneisel and Hertl 2011a; Stanley and Amagai 
2008). Yet, multiple studies have provided evidence for these humoral immune responses being 
controlled by autoreactive CD4+ T cells (Hertl, Amagai, et al. 1998a; Nishifuji et al. 2000; 
Takahashi et al. 2008; Takahashi, Kuwana, and Amagai 2009; Eming et al. 2008; Amber et al. 
2013). 
The epidemiological observation that the prevalence of pemphigus is highly associated with 
distinct HLA class II alleles, HLA-DRB1*04:02, –DRB1*14:01, and –DQB1*05:03 (Tron et al. 
2006), is strongly indicative of the interaction between APC and T cells being critically involved in 
the pathogenesis of this disease. Accordingly, the work by Wucherpfennig et al. investigated the 
structural basis for this relation and revealed that HLA-DRβ1*04:02 displayed the 
physicochemical properties required for efficient positioning of antigenic Dsg3 peptides in the 
HLA-DR pocket. The β-chain of the HLA-DRβ1*04:02 binding groove carries the negatively 
charged amino acid residues aspartic acid (D70) and glutamic acid (E71) at P4, so that peptides 
with a positively charged amino acid at the same position were efficiently bound and preferentially 
presented to CD4+ T cells. This facilitated activation of autoreactive CD4+ T cells by this specific 
HLA-DR–peptide complex (Wucherpfennig et al. 1995). Upon the development of atomic models 
of the PV-associated HLA class II alleles, Tong et al. confirmed HLA-DRβ1*04:02 exerting a 
crucial function in selecting specific self-peptides (Tong et al. 2006). 
Analogous to HLA-DRB1*04:02, HLA-DQB1*05:03 as well interacted with the same set of Dsg3 
epitopes (Tong et al. 2006), underpinning recent experimental data from our group of both HLA 
class II alleles restricting T cell recognition of identical epitopes of Dsg3 (Veldman, Gebhard, et 
al. 2004). The finding of T cell recognition of the Dsg3 ectodomain being restricted by HLA-
DRB1*04:02 and –DQB1*05:03 was already observed in former studies (Hertl, Amagai, et al. 
1998a; Hertl, Karr, et al. 1998). Interestingly, data from our group not only identified in PV patients, 
but also healthy carriers of the pemphigus-linked alleles T cell clones that recognized the Dsg3 
peptides, which bound to HLA-DRβ1*04:02, and which all shared either a positively charged 
lysine (K) or arginine (R) at P4 (Veldman, Gebhard, et al. 2004). 
The observation of healthy individuals displaying Dsg3-specific T cell reactivity (Veldman et al. 
2003b; Hertl, Amagai, et al. 1998a), as well as healthy, immediate relatives of PV patients 
exhibiting Dsg3-reactive IgG auto-ab (Kricheli et al. 2000) testifies of additional regulatory 
mechanisms preventing disease in these subjects. In this respect, a study from our group 
identified an increasing frequency of Dsg3-specific IL-10–producing Tr1 cells with constitutive 
expression of FOXP3 in healthy carriers of the PV-linked HLA class II alleles compared to PV 
patients (Veldman, Hohne, et al. 2004). In concordance with that, Sugiyama et al. observed in PV 
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patients markedly reduced circulating Treg cells along with both decreased gene and protein 
expression of FOXP3 in CD4+CD25+ T cells (Sugiyama et al. 2007). Moreover, Treg cells in acute 
onset PV patients also appeared to numerically surpass those in patients with remittent stage of 
disease (Xu et al. 2013). Finally, the work by Yokoyama et al. demonstrated in experimental PV 
that Treg cells induced in Dsg3-deficient mice prevented induction of an anti-Dsg3 IgG response 
upon transfer into mice with active production of auto-ab, highlighting the therapeutic potential of 
Treg cells in pemphigus (Yokoyama et al. 2011). 
Concerning a PV-specific polarization of Th cells, a study by Lin et al. showed that upon 
stimulation, Dsg3-reactive CD4+ T cell lines and clones from PV patients produced Th2 cell-
related cytokines and that their response to Dsg3 fusion proteins was also restricted to HLA-DR 
(Lin, Swartz, and Lopez 1997). Furthermore, using Dsg3-responsive T cell lines and clones from 
PV patients, a study from our group revealed that Dsg3-specific autoreactive Th cells mainly 
belonged to the Th2 cell lineage, whilst those in healthy individuals predominantly represented 
Th1 cells (Veldman et al. 2003b). In addition, Rizzo et al. observed Dsg3-specific Th2 cell activity 
being significantly associated with PV patients suffering from active disease, as well as the extent 
of Th2 cell activity correlating with the Dsg3-specific auto-ab titers of the patients (Rizzo et al. 
2005). In concordance with these findings, the IgG4 subclass prevailed in active pemphigus 
patients, being linked with Th2 cell activation, in contrast to IgG1 being related to a Th1 cell-
dominated immune response (Ayatollahi et al. 2004; Romagnani 1992). 
Apart from that, data from an active mouse model of PV provided evidence for autoreactive Th2 
cells priming naïve B cells to produce pathogenic Dsg3-specific IgG. In this model, release of the 
Th2 cell signature cytokine IL-4 by a single Dsg3-reactive T cell clone critically contributed to the 
formation of pathogenic IgG auto-ab, and in vivo blockade of IL-4 was effective in preventing 
development of the pemphigus phenotype (Takahashi et al. 2008). Similarly, in an unrelated 
mouse model, immunization of mice with human Dsg3 resulted in the generation of Dsg3-reactive 
Th2 cells, which induced unprimed B cells to produce Dsg3-specific IgG (Zhu et al. 2012). 
 
In our HLA-DRB1*04:02–tg mouse model of PV, we clearly demonstrated that T cell recognition 
of human Dsg3 protein is tightly restricted by HLA-DRB1*04:02 since solely T cells from mice 
immunized with a set of HLA-DRβ1*04:02–binding Dsg3 peptides displayed ex vivo reactivity 
against Dsg3 (Figure 4.38). In contrast, immunization of mice with a set of Dsg3 peptides, which 
do not bind to HLA-DRβ1*04:02 did not induce Dsg3-specific T cell responses (Figure 4.38). 
As a specificity control, mice transgenic for the unrelated RA-associated HLA class II allele 
DRB1*04:01 were selected and as expected, immunization of these mice with T cell epitopes of 
human Dsg3, which bind or not bind to HLA-DRβ1*04:02, respectively, only resulted in an immune 
response directed against the respective peptides they were injected with (Figure 4.39). As 
investigated by Wucherpfennig et al., the peptide binding cleft of the HLA-DRβ1*04:01 protein 
structurally differs from the PV-associated DR4 subtype by the β-chain carrying the neutral and 
positively charged amino acid residues glutamine (Q70) and lysine (K71) at P4, respectively. The 
P4 pocket of the HLA-DR4 molecule is situated in the center of the HLA-DR peptide binding 
groove and the physicochemical properties of its polymorphic surface residues critically determine 
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the binding of antigenic peptides, whilst flanking residues function as primary TCR contact site 
(Wucherpfennig et al. 1995). 
Similarly, in the reverse in vitro experiment of APC presenting the Dsg3 peptides to Dsg3-specific 
T cells, only presentation of a set of HLA-DRβ1*04:02–binding Dsg3 peptides yielded a 
proliferative response of Dsg3-specific murine CD4+ T cells (Figure 4.36a), which is in 
concordance with the described peptide binding algorithm for HLA-DRB1*04:02 proposed by 
Wucherpfennig et al. (Wucherpfennig et al. 1995). Accordingly, stimulation of Dsg3-reactive T 
cells with a set of Dsg3 peptides, which do not interact with HLA-DRβ1*04:02 only resulted in a 
response to the extent of background proliferation (Figure 4.36b). Consequently, the findings 
obtained in our in vitro and in vivo studies documented well the high level of specificity of the HLA-
DRB1*04:02–restricted CD4+ T cell response to human Dsg3. 
 
Considering an algorithm for anchor motifs of the Dsg3 peptides and the charge of critical peptide 
binding pockets of HLA-DRβ1*04:02, Wucherpfennig et al. defined several T cell epitopes of 
Dsg3, of which three located within the Dsg3 ectodomain induced activation of peripheral 
lymphocytes from PV patients (Wucherpfennig et al. 1995). In line with this, a study from our 
group demonstrated in PV patients that carried the HLA-DRB1*04:02 allele T cell reactivity 
against these HLA-DRβ1*04:02–binding Dsg3 peptides using Dsg3-reactive CD4+ T cell clones 
(Veldman, Gebhard, et al. 2004). As expected, those Dsg3 peptides, which do not bind to HLA-
DRβ1*04:02 did not induce a proliferative T cell response (Veldman, Gebhard, et al. 2004). 
According to the findings by Wucherpfennig et al. (Wucherpfennig et al. 1995), the identified T 
cell epitopes of Dsg3 specifically fulfilled the requirements for efficient binding to the peptide 
binding groove of HLA-DRβ1*04:02 and exhibited shared anchor motifs at P1, P4, and P6, 
including a positively charged residue at P4 (Veldman, Gebhard, et al. 2004).  
 
Altogether, the HLA-DRB1*04:02–tg mouse model clearly reproduced the algorithm proposed 
(Wucherpfennig et al. 1995) and ascertained (Tong et al. 2006) for peptide interaction with HLA-
DRβ1*04:02 as observed in PV patients (Veldman, Gebhard, et al. 2004). 
 
5.2.2 Dsg3 peptide immunization of HLA-DRB1*04:02–tg mice induces Dsg3-
specific IgG 
Pathogenic Dsg3-specific IgG auto-ab, which induced dissociation of epidermal keratinocyte 
adhesion represents a key finding in PV (Amagai 2008). Repetitive immunization of our HLA-
DRB1*04:02–tg mice with human Dsg3 protein resulted in a robust antigen-specific IgG antibody 
response, recognizing both recombinant (Figure 4.32) and native human Dsg3 epitopes (Figure 
4.33). Owing to limited cross-reactivity with the analogous mouse protein, immunization of these 
mice with the human Dsg3 ectodomain failed to induce a clinical phenotype, which will be 
discussed in more detail in the following section of this discussion. However, as determined by 
our group, sera from human Dsg3-immunized mice caused loss of adhesion of human epidermal 
keratinocytes under in vitro conditions. Furthermore, injection of these sera into human skin 
specimens resulted in antiepithelial surface IgG deposits, as well as intraepidermal loss of cell 
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adhesion, providing clear evidence for the pathogenicity of these IgG antibodies. Interestingly, 
sera from HLA-DRB1*04:02–tg mice immunized with human Dsg3 protein induced dissociation 
of human epidermal keratinocyte monolayers to a greater extent than did the sera from Dsg3-
immunized HLA-DR-B1*04:01–tg mice (Eming et al. 2014). This finding is in line with the 
observation of autoreactive CD4+ T cells regulating production of pathogenic IgG auto-ab in the 
pathogenesis of PV as demonstrated by numerous studies (Hertl, Amagai, et al. 1998a; Nishifuji 
et al. 2000; Takahashi et al. 2008; Takahashi, Kuwana, and Amagai 2009; Eming et al. 2008; 
Amber et al. 2013). 
 
In our PV model, further evidence for the generation of Dsg3-responsive IgG antibodies relying 
on the activation of autoreactive T cells is provided by the finding of only sera from mice 
immunized with the HLA-DRβ1*04:02–binding Dsg3 peptides showing reactivity against human 
recombinant (Figure 4.41a) and native monkey Dsg3 protein (Figure 4.42a and b). However, 
immunization of mice with a set of Dsg3 peptides, which do not efficiently bind to HLA-
DRβ1*04:02 did not yield IgG antibodies reactive against both recombinant (Figure 4.41a) and 
native epitopes of Dsg3 expressed by monkey esophagus epithelium (Figure 4.42c and d). In 
line with the observation of defying restriction by HLA-DRB1*04:02 on the T cell level (Figure 
4.39b), sera from mice transgenic for the RA-associated HLA-DRB1*04:01 allele did neither 
display reactivity against recombinant (Figure 4.41b) nor native (Figure 4.43a) Dsg3 upon 
immunization with the HLA-DRβ1*04:02–binding Dsg3 peptides. 
Of note, sera from both HLA-DRB1*04:02–tg and –DRB1*04:01–tg mice immunized with the full 
Dsg3 ectodomain displayed IgG reactivity against recombinant Dsg3 (Figure 4.41). However, 
compared to HLA-DRB1*04:02–tg mice, Dsg3-reactive IgG from HLA-DRB1*04:01–tg mice were 
found to be reduced in pathogenicity as determined by human epidermal keratinocyte dissociation 
assay (Eming et al. 2014). This indicates that the human Dsg3 protein additionally contains CD4+ 
T cell epitopes that bind to HLA-DRβ1*04:01, which finally results in the production of human 
Dsg3-specific IgG antibodies. 
 
The interaction between CD4+ T cells and B cells being required for the induction of human Dsg3-
reactive antibodies is further demonstrated by blockade of CD4+ T cells efficaciously abrogating 
the formation of anti-Dsg3 IgG in HLA-DRB1*04:02–transgenic mice. In addition, application of 
an anti-CD154 mAb disturbing T cell-mediated activation of B cells similarly impeded induction of 
Dsg3-specific IgG antibodies (Eming et al. 2014). Interestingly, there is also clinical proof for CD4+ 
T cell–B cell interaction being critical in the formation of Dsg3-reactive auto-ab since application 
of the anti-CD20 mAb Rituximab not only entailed a rapid clearance of peripheral B cells, but 
additionally resulted in a swift reduction of IL-4–producing Dsg3-reactive Th2 cells in the 
circulation (Eming et al. 2008). Likewise, medical treatment of PV patients with Rituximab led to 
a significant decline of Dsg3-specific serum IgG auto-ab. Of note, the diminution of Dsg3-reactive 
T cells was also linked with an immediate amelioration of clinical symptoms before anti-Dsg3 
serum auto-ab were reduced (Eming et al. 2014). These observations imply the relevance of 
autoantigen presentation by B cells in the activation of Dsg3-reactive CD4+ T cells. 
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Interestingly, Nishifuji et al. quantitatively determined Dsg3-specific IgG auto-ab production of 
circulating B cells by ELISPOT assay. In order to not only detect peripheral Dsg3-reactive 
activated, but also memory B cells, PBMC were additionally stimulated with recombinant Dsg3 
protein ex vivo. Importantly, the anti-Dsg3 antibody production was abolished upon depleting the 
PV patients’ lymphocytes of CD4+ T cells, highlighting the critical function of autoreactive CD4+ T 
cells in auto-ab induction (Nishifuji et al. 2000). 
 
The currently most established mouse model to study pathoimmunological mechanisms of PV in 
vivo was developed by Amagai et al. in 2000. In this model, active autoimmune disease can be 
reproduced by using a Dsg3-deficient mouse created by Koch et al. (Koch et al. 1997), which 
lacks acquired tolerance against Dsg3 and displays a phenotype reminiscent of PV. As the target 
protein is not expressed, immunization of these mice with murine Dsg3 induces a Dsg3-specific 
IgG response, which does not cause appearance of PV clinical symptoms. Yet, adoptive transfer 
of these Dsg3-reactive lymphocytes into immunodeficient Rag2-/- mice competent of epithelial 
Dsg3 expression results in the generation of anti-Dsg3 IgG auto-ab and manifestation of the PV 
phenotype (Amagai et al. 2000). 
Using this active autoimmune disease mouse model of PV, a study by Tsunoda et al. 
demonstrated that Dsg3-specific loss of tolerance was required in both T cells and B cells for 
efficient production of pathogenic IgG auto-ab, as well as induction of PV-like clinical signs. While 
adoptive transfer of purified T and B cells from Dsg3+/- or Dsg3+/+ mice into Rag2-/- mice did not 
induce pathogenic anti-Dsg3 IgG production, only a combination of both Dsg3-/- T and Dsg3-/- B 
cells was successful at causing the autoimmune state of PV. Furthermore, the single transfer of 
solely Dsg3-/- CD4+ T cells or B cells into Rag2-/- mice was not efficient at inducing anti-Dsg3 IgG 
and/or a clinical phenotype, underpinning the collaboration of Dsg3-specific CD4+ T cells being 
essential for the generation of pathogenic anti-Dsg3 auto-ab (Tsunoda et al. 2002). 
Using the same animal model, Aoki-Ota et al. later provided evidence for the induction of 
pathogenic anti-Dsg3 IgG critically relying on CD40–CD154 interaction, as its antagonization 
almost entirely abrogated auto-ab production and prevented blister formation in the recipient mice 
(Aoki-Ota et al. 2006). T cell-mediated activation of B cells requires binding of CD154 on activated 
T cells with CD40 expressed on B cells (Lougaris et al. 2005). Interestingly, administration of an 
anti-CD154 mAb was found to expand Treg cells in allograft transplant patients (Zhai et al. 2006). 
Interestingly, Takahashi et al. established in this active mouse model a novel system for the 
evaluation of the in vivo pathogenicity of Dsg3-responsive T cells at a clonal level. Therefore, 
Dsg3-specific CD4+ T cell lines generated in vitro were adoptively transferred into Rag2-/- mice 
combined with primed B cells from Dsg3-immunized Dsg3-deficient mice. Analysis of pathogenic 
T cell lines, which induced in recipient mice an anti-Dsg3 IgG response and a clinical phenotype 
identified the capacity of IL-4 production as a potential factor linked with pathogenicity (Takahashi 
et al. 2008). In a following study, Takahashi et al. demonstrated in this model that a single potent 
Dsg3-reactive T cell clone sufficed to render naïve B cells capable of secreting pathogenic anti-
Dsg3 IgG auto-ab, which induced the clinical PV phenotype (Takahashi, Kuwana, and Amagai 
2009). 
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Although the active disease model reliably imitates ongoing autoimmune responses in PV 
(Amagai 2008), it does not take into account the strong association of distinct HLA class II alleles 
in pemphigus patients. Thus, we show in our HLA-DRB1*04:02–tg mouse model for the first time 
that pathogenic anti-Dsg3 IgG antibody generation tightly depends on activation of autoreactive 
T cells under the immunogenetic restriction by HLA-DRB1*04:02. 
 
5.2.3 IgG cross-reactivity of sera from human Dsg3-immunized HLA-DR4–tg 
mice 
In the HLA-DRB1*04:02–tg mouse model of PV, we demonstrated that the activation of Dsg3-
specific CD4+ T cells and B cells leading to the production of pathogenic Dsg3-reactive IgG 
antibodies is tightly restricted by HLA-DRB1*04:02. Accordingly, immunization of these mice with 
T cell epitopes of human Dsg3, which bind to HLA-DRβ1*04:02 was efficient at inducing a marked 
anti-Dsg3 IgG response reactive against both recombinant (Figure 4.41a) and native Dsg3 
protein (Figure 4.42a and b). 
Since mice immunized with human Dsg3 did not display a clinical phenotype, we further assessed 
cross-reactivity of human Dsg3-specific IgG against murine Dsg3. Apparently, sera from these 
mice only displayed a diminished interaction with murine Dsg3 ex vivo (Figure 4.45), while DIF 
microscopy revealed lack of binding of IgG antibodies to both palatinal (Figure 4.46a) and tongue 
(Figure 4.46b) mucosa. Comparative analysis of mouse and human Dsg3 amino acid sequences 
yielded an overall homology of 85.6%, indicating a relatively high level of conservation. 
Particularly, the proportion of identical sequences between the ectodomains of Dsg3 rises from 
the carboxy-terminal EC5 domain (56%) to the amino-terminal EC1 and EC2 domains (86–89%) 
(Ishikawa et al. 2000). Of note, the amino-terminal adhesive surface of Dsg3 was identified to 
provide the dominant pathogenic auto-ab epitopes in PV patients (Sekiguchi et al. 2001; Futei et 
al. 2000; Yokouchi et al. 2009). However, anti-human Dsg3-reactive IgG failed to efficiently bind 
to epithelial Dsg3 in vivo, which might explain the absence of a blistering phenotype in our HLA-
DRB1*04:02–tg mouse model of PV. A possible explanation may be the amino acid sequences 
of human and mouse Dsg3 significantly differing at the sites critical for CD4+ T cell activation. 
Insufficient activation of Dsg3-reactive CD4+ T cells may critically hamper activation of 
autoreactive B cells being responsible for the production of pathogenic antibodies (Eming et al. 
2014). 
 
To summarize, because of a missing clinical phenotype in HLA-DRB1*04:02–tg mice due to 
limited cross-reactivity of human Dsg3-specific antibodies against murine Dsg3, this model does 
not comprehensively reproduce human PV. Yet, this model efficiently displays 
immunopathological mechanisms on both the CD4+ T cell and B cell level of PV considering the 
important restriction by HLA-DRB1*04:02. Thus, our HLA-DRB1*04:02–tg mouse model 
represents a promising tool for further investigations of pathoimmunological mechanisms. 
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5.2.4 Summary 
In our HLA-DRB1*04:02–tg mouse model of PV we investigated Dsg3-specific cellular and 
humoral immune responses under the immunogenetic restriction by HLA-DRB1*04:02 based on 
the prevalence of PV being associated with distinct HLA class II alleles, including HLA-
DRB1*04:02, –DRB1*14:01, and –DQB1*05:03. Our model convincingly confirmed the basic 
mechanisms of HLA-dependent and Dsg3-specific induction of CD4+ T and B cell responses 
observed in PV patients. Accordingly, the generation of human Dsg3-reactive IgG antibody 
responses highly depended on prior activation of Dsg3-reactive CD4+ T cells. In addition, APC-
mediated activation of T cells critically relied on the recognition of epitopes of the Dsg3 
ectodomain displaying strong binding affinity to the PV-linked HLA class II allele HLA-
DRB1*04:02. 
A limitation of this PV model is the found restricted cross-reactivity of Dsg3-specific IgG antibodies 
against the mouse analogue protein explaining lack of a clinical PV phenotype upon immunization 
of HLA-DRB1*04:02–tg mice with human Dsg3 protein. Yet, this model accurately reproduces 
that polymorphisms of peptide-binding motifs of specific PV-related HLA-class II alleles tightly 
regulate CD4+ T cell-mediated induction of Dsg3-reactive IgG antibodies. Consequently, our 
novel mouse model represents a promising tool for further studies of PV pathoimmunological 
mechanisms in vivo considering the strong HLA class II association of the disease. 
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